[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Medline Industries Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":398},{"warningLetters":4,"total":397},[5,31,51,73,95,120,142,163,180,197,216,233,252,271,292,312,332,348,360,378],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},244,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-04-07T04:00:00Z\">04\u002F07\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-25T04:00:00Z\">03\u002F25\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedline-industries-lp-723866-03252026\">Medline Industries, LP \u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jim Boyle\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Medline Industries, LP \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3 Lakes Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Northfield\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60093\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:JBoyle@medline.com\"> JBoyle@medline.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 723866\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 25, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Boyle:\u003C\u002Fp>\u003Cp>During an inspection of your firm, Medline Industries, LP (NAMIC Division), located at 10 Glens Falls Tech Park, Glen Falls, NY 12801, from December 1, 2025 through December 12, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures and assembles numerous medical devices into Cardiovascular Procedure Kits to include (but not limited to) NAMIC brand Angiographic Control Syringes and manifolds intended to be used for the intra-arterial or intravenous administration of radiographic contrast media. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Mr. Richard Kalita, Senior Manager of Quality Assurance, dated January 13, 2026, and February 27, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>Specifically:\u003C\u002Fp>\u003Cp>A. Your firm failed to implement section 5.8.4 of your “Internal Corrective-Preventive Action Procedure (CAPA)” (SOP-00022; Rev. 40), which states “***\u003Cem>[the] degree of corrective and preventive action taken to eliminate or minimize actual or potential nonconformities must be appropriate to the magnitude of the problem and commensurate with the risks encountered\u003C\u002Fem>***”, in that your firm did not take actions commensurate with risk for NAMIC Angiographic Control Syringes in the field for which CAPA-01872 was opened due to an increase in complaints in June 2023 regarding disconnection from manifolds you attributed to the presence of excess silicone. Your Health Hazard Evaluation (HHE) Qual-124366 dated June 11, 2024, determined the risk was low, which is inconsistent with your design failure modes and effectiveness analysis (dFMEA) (RA2022047; Rev. 4) which identified \"air embolism\" as the highest severity issue for loose connections. Your firm’s corrective actions only included scrapping devices in inventory and increasing the cleaning frequency of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine to prevent excess silicone from migrating to the luer connector, despite receiving 221 complaints and filing 177 MDRs for the disconnection of the NAMIC Angiographic Control Syringes from manifolds which impact patients and clinicians, including one (1) MDR # 3015910259-2025-00109 involving the injection of air into a patient (Complaint # \u003Cstrong>(b)(4)\u003C\u002Fstrong> dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and one (1) MDR # 3015910259-2024-00045 involving biohazard exposure of a clinician (Complaint # \u003Cstrong>(b)(4)\u003C\u002Fstrong> dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\u003Cp>B. Your firm failed to implement section 5.19 of your “Internal Corrective-Preventive Action Procedure (CAPA)” (SOP-00022; Rev. 47; Effective: 11\u002F1\u002F25), in that “***\u003Cem>while in the effectiveness check stage and either the effectiveness check failed or additional root causes or problems are identified; the CAPA may be routed back to a previous phase or an additional CAPA may be opened at the discretion of the CRB [CAPA Review Board]. Risk and containment activities must be considered when moving the CAPA to a previous phase\u003C\u002Fem>***”. Your firm did not execute any of the above actions for CAPA-01872 when trending data revealed, as early as Quarter 1 of 2025, that the complaints per million (CPM) of NAMIC Angiographic Control Syringes manufactured post-corrective action was at 16.90 CPM followed by 16.44 CPM in Quarter 2 and 26.81 CPM in Quarter 3, all of which was above the 15.98 CPM threshold for complaints received for disconnections established in the verification of effectiveness plan (VOE AI# \u003Cstrong>(b)(4)\u003C\u002Fstrong> to start 1\u002F15\u002F25; Updated 8\u002F1\u002F25). Moreover, the total rate of complaints, including devices manufactured before and after the implementation of the corrective action (starting January 15, 2025) and for product where the manufacturing date is unknown, was 39.95 CPM, 31.62 CPM, and 59.27 CPM for Quarters 1, 2 and 3 of 2025, respectively.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. In your January 13, 2026, response, your firm acknowledged that the corrective action was not effective, closed CAPA-01872, and opened a new CAPA-02612 to further investigate the issue. You also communicate a plan to issue a field correction with a safety notice to all customers who have received or will receive NAMIC Angiographic Control Syringes, based on a HHE (Qual-156459) of post-market data from June 2023 to December 2025, to alert them about the unwinding issue and provide reinforced instructions and additional guidance. You further state that you plan to develop \u003Cstrong>(b)(4)\u003C\u002Fstrong> syringe solution currently undergoing verification with production targeted to begin in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and proposed that a field notice rather than a full product removal was appropriate given the effectiveness of prior communications, the upcoming alternative solution, and prevention of a market shortage.\u003C\u002Fp>\u003Cp>In your latest response on February 27, 2026, you state that you updated your HHE (Qual-156459; Approved 2\u002F26\u002F26) to reflect your revised plan to conduct a removal of NAMIC Angiographic Control Syringes based on multiple discussions with the agency regarding your recall strategy. This HHE reports a total CPM for the syringe\u002F manifold disconnection issue from June 2023 to February 19, 2026, as 62.62 CPM (250 complaints out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> syringes manufactured ending \u003Cstrong>(b)(4)\u003C\u002Fstrong>). On March 13, 2026, an 806 Report was submitted to the agency for the removal of these devices (\u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\u003Cp>You also indicate that you initiated an additional CAPA-02627 under which you conducted a systemic review of all open CAPAs and trained personnel on an updated CAPA procedure (SOP-00022) which requires more frequent post-market data reviews per established guidance. The targeted completion date for CAPA-02627 is June 30, 2026.\u003C\u002Fp>\u003Cp>With regards to CAPA-02612, no information was provided on when you anticipate a new investigation will be completed to determine the cause(s) of the disconnections between the syringes and manifolds to assure your actions are timely and commensurate with risk of this issue. Furthermore, no assurance was provided that the scope of the product removal will include affected devices manufactured both before and after the corrective action (April 17, 2024) since the corrective action was found to be ineffective. Furthermore, the manufacturing quantities documented in your updated HHE fall short of the nearly \u003Cstrong>(b)(4)\u003C\u002Fstrong> syringes your Senior Director of Quality stated were manufactured (approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and nearly \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>) in that it states that only \u003Cstrong>(b)(4)\u003C\u002Fstrong> syringes were manufactured through \u003Cstrong>(b)(4)\u003C\u002Fstrong>, resulting in 62.62 CPM (250 complaints), without defining the manufacturing start date of affected products. The HHE also incorrectly specifies a corrective action start date of June 2024 instead of April 16, 2024, as specified in CAPA-01872.\u003C\u002Fp>\u003Cp>With regards to CAPA-02627, you did not identify actions that assure that employees will follow your corrective action procedure to route the CAPA back to a previous phase or open an additional CAPA as soon as it is evident that corrective actions are not effective, as was the case in \u003Cstrong>(b)(4)\u003C\u002Fstrong> of 2025 when your complaint analysis data showed that the CPM for syringe and manifold disconnections was above the established CPM thresholds.\u003C\u002Fp>\u003Cp>Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain schedules for the adjustment, cleaning, and other maintenance of equipment to ensure that manufacturing specifications are met, as required by 21 CFR 820.70(g)(1).\u003C\u002Fp>\u003Cp>Specifically, your firm failed to implement sections 6.2.2 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning) and 6.3 (General Requirements) of your “GN 010 - Manufacturing Cleaning Procedure” (NMC-00228; Rev. 7; Effective: 5\u002F2\u002F25) which state “\u003Cem>a top-to-bottom cleaning of the controlled environments will be conducted, at minimum, \u003Cstrong>(b)(4)\u003C\u002Fstrong>***The cleaning shall also include all equipment not routinely cleaned by operators***” and “***Always clean the \u003Cstrong>(b)(4)\u003C\u002Fstrong> first and work toward the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of cleaning with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> being last\u003C\u002Fem>***,” respectively, of controlled environments such as the clean rooms where you manufacture various Angiographic and Radiology Syringes. In addition, the corresponding forms titled “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Schedule and Sign-off Sheet” form (NMC-00228-F-00001; Rev. 2) and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Schedule and Sign-off Sheet” (NMC-00228-F-00002; Rev.1) are inadequate because they fail to ensure consistent implementation of sections 6.2.2 and 6.3 of NMC-00228 due to absence of specific instructions requiring the cleaning of top of manufacturing equipment as is included for the cleaning of vents, ceiling lights, walls, benches, cabinets, fixtures, etc. For example, on December 1, 2025, the investigator observed a visible accumulation of particulate on the top of manufacturing equipment in cleanrooms including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> syringe manufacturing machine (ID # 90303527), \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine (ID # 90306846), \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing machine (ID # 90308616), and \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine (Asset # 8974). There have been approximately 114 complaints regarding foreign matter or hair in the package or device from December 2023 to at least December 1, 2025.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. In your January 13, 2026, response, you state you performed immediate ad-hoc cleaning of all equipment to remove observed particulate matter, established preventative maintenance schedules based on \u003Cstrong>(b)(4)\u003C\u002Fstrong> of monitoring data, and updated the cleaning and preventative maintenance procedures (NMC-00228 and NMC-00171) to formalize these requirements followed by training under CAPA-02518. Additionally, you state you developed an ad-hoc cleaning procedure (NMC-01120) and addressed air filtration concerns by installing \u003Cstrong>(b)(4)\u003C\u002Fstrong> indicators around all cleanroom \u003Cstrong>(b)(4)\u003C\u002Fstrong> vents to ensure proper clearance, repaired damaged vents, and updated your environmental control procedure (NMC-00233) to include inspection and clearance requirements. You also determined that validation of the cleaning process was not required.\u003C\u002Fp>\u003Cp>In your latest response on February 27, 2026, you state you conducted a comprehensive review of the cleanroom manufacturing environments and identified improvement opportunities but not any risks. The target completion for these additional actions is April 30, 2026, and the target completion date of CAPA-02518 is July 17, 2026.\u003C\u002Fp>\u003Cp>However, there were no corrective actions identified to assess the impact of products in the field and inventory for products which have been manufactured in these cleanrooms since the last documented cleaning of equipment tops on November 26, 2023, including review of the manufacturing dates of products referenced in the 114 complaints received for foreign matter or hair since this date as a part of the respective complaint investigations. Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures for verifying the device design. Design verification shall confirm that the design output meets the design input requirements, as required by 21 CFR 820.30(f).\u003C\u002Fp>\u003Cp>Specifically, your firm’s design verification conducted under “Design Verification Protocol Polycarbonate Female Luer ISO 80369-7” (P017333; Rev. B; Approved: 10\u002F7\u002F20) with resulting “Design Verification Report Polycarbonate Female Luer ISO 80369-7” (P017334; Rev. A; Approved: 6\u002F30\u002F20) fails to demonstrate that the polycarbonate female luer connector components of your Fluid Management product lines (e.g., stopcock product family, manifold product family, disposable transducer product family, Y adaptor, etc.), which underwent changes to their threads and taper dimensions to become BS EN ISO 80369-7 compliant, meet the dimensional and functional testing requirements specified in this standard. For example, there was no documentation in the protocol (or elsewhere) on why design verification testing was only performed on a single female luer connector (Part # 24644210) and not any of the other \u003Cstrong>(b)(4)\u003C\u002Fstrong> connectors listed in the “Scope” section of this protocol which were also impacted by this design change. Moreover, this solely tested connector is not included in the final version of your “Design Change Analysis Form (DCAF) for ISO 80369-7 Compliance for Male and Female Luer Connectors (P017104) QUAL-66717 Rev. 4” (Approved: 9\u002F7\u002F22) which captures all luer connectors affected by this design change.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. In your January 13, 2026 response, you state you revised the design verification procedure (NMC-00155) to require documentation of part selection rationale, added product configuration tables and guidance for recording representative SKU selection and rationale for selection in the Design Verification Protocol Template (NMC-00155-F-00001), and amended design change file QUAL-66717 to include the missing justification for part selection under CAPA-02610.\u003C\u002Fp>\u003Cp>In your latest response on February 27, 2026, you state you conducted a comprehensive review of all design changes from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to present that required design verification testing and uncovered four (4) instances of insufficient documentation of part rationale which will require protocol updates with appropriate justification. The target completion of CAPA-02610 is June 1, 2026.\u003C\u002Fp>\u003Cp>However, review of the “Unit Rationale” provided revealed that it fails to explain how design verification testing of part number 41338202 covers anything beyond the manifold product family, such as the stopcock product family, disposable transducer product family, and Y adaptor of the Fluid Management product lines which were in the scope of the Design Verification. Moreover, this rationale does not explain why this part number was not listed in the final version of your “Design Change Analysis Form (DCAF) for ISO 80369-7 Compliance for Male and Female Luer Connectors (P017104) QUAL-66717 Rev. 4” (Approved: 9\u002F7\u002F22) meant to capture all the luer connectors affected by this design change. Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a \u003Cu>final rule\u003C\u002Fu> amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on December 1, 2025 to December 12, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 723866” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara A. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Bradley R. Pratt, Sr. Director of Manufacturing Operations, BPratt@medline.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJim Boyle\n\nRecipient Title\n\nCEO\n\nMedline Industries, LP\n\n3 Lakes Drive\n\nNorthfield, IL 60093\n\nUnited States\n\nJBoyle@medline.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 723866\nMarch 25, 2026\nDear Mr. Boyle:\nDuring an inspection of your firm, Medline Industries, LP (NAMIC Division), located at 10 Glens Falls Tech Park, Glen Falls, NY 12801, from December 1, 2025 through December 12, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures and assembles numerous medical devices into Cardiovascular Procedure Kits to include (but not limited to) NAMIC brand Angiographic Control Syringes and manifolds intended to be used for the intra-arterial or intravenous administration of radiographic contrast media. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Mr. Richard Kalita, Senior Manager of Quality Assurance, dated January 13, 2026, and February 27, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically:\nA. Your firm failed to implement section 5.8.4 of your “Internal Corrective-Preventive Action Procedure (CAPA)” (SOP-00022; Rev. 40), which states “***[the] degree of corrective and preventive action taken to eliminate or minimize actual or potential nonconformities must be appropriate to the magnitude of the problem and commensurate with the risks encountered***”, in that your firm did not take actions commensurate with risk for NAMIC Angiographic Control Syringes in the field for which CAPA-01872 was opened due to an increase in complaints in June 2023 regarding disconnection from manifolds you attributed to the presence of excess silicone. Your Health Hazard Evaluation (HHE) Qual-124366 dated June 11, 2024, determined the risk was low, which is inconsistent with your design failure modes and effectiveness analysis (dFMEA) (RA2022047; Rev. 4) which identified \"air embolism\" as the highest severity issue for loose connections. Your firm’s corrective actions only included scrapping devices in inventory and increasing the cleaning frequency of the (b)(4) machine to prevent excess silicone from migrating to the luer connector, despite receiving 221 complaints and filing 177 MDRs for the disconnection of the NAMIC Angiographic Control Syringes from manifolds which impact patients and clinicians, including one (1) MDR # 3015910259-2025-00109 involving the injection of air into a patient (Complaint # (b)(4) dated (b)(4)) and one (1) MDR # 3015910259-2024-00045 involving biohazard exposure of a clinician (Complaint # (b)(4) dated (b)(4)).\nB. Your firm failed to implement section 5.19 of your “Internal Corrective-Preventive Action Procedure (CAPA)” (SOP-00022; Rev. 47; Effective: 11\u002F1\u002F25), in that “***while in the effectiveness check stage and either the effectiveness check failed or additional root causes or problems are identified; the CAPA may be routed back to a previous phase or an additional CAPA may be opened at the discretion of the CRB [CAPA Review Board]. Risk and containment activities must be considered when moving the CAPA to a previous phase***”. Your firm did not execute any of the above actions for CAPA-01872 when trending data revealed, as early as Quarter 1 of 2025, that the complaints per million (CPM) of NAMIC Angiographic Control Syringes manufactured post-corrective action was at 16.90 CPM followed by 16.44 CPM in Quarter 2 and 26.81 CPM in Quarter 3, all of which was above the 15.98 CPM threshold for complaints received for disconnections established in the verification of effectiveness plan (VOE AI# (b)(4) to start 1\u002F15\u002F25; Updated 8\u002F1\u002F25). Moreover, the total rate of complaints, including devices manufactured before and after the implementation of the corrective action (starting January 15, 2025) and for product where the manufacturing date is unknown, was 39.95 CPM, 31.62 CPM, and 59.27 CPM for Quarters 1, 2 and 3 of 2025, respectively.\nWe reviewed your firm’s response and conclude that it is not adequate. In your January 13, 2026, response, your firm acknowledged that the corrective action was not effective, closed CAPA-01872, and opened a new CAPA-02612 to further investigate the issue. You also communicate a plan to issue a field correction with a safety notice to all customers who have received or will receive NAMIC Angiographic Control Syringes, based on a HHE (Qual-156459) of post-market data from June 2023 to December 2025, to alert them about the unwinding issue and provide reinforced instructions and additional guidance. You further state that you plan to develop (b)(4) syringe solution currently undergoing verification with production targeted to begin in (b)(4) and proposed that a field notice rather than a full product removal was appropriate given the effectiveness of prior communications, the upcoming alternative solution, and prevention of a market shortage.\nIn your latest response on February 27, 2026, you state that you updated your HHE (Qual-156459; Approved 2\u002F26\u002F26) to reflect your revised plan to conduct a removal of NAMIC Angiographic Control Syringes based on multiple discussions with the agency regarding your recall strategy. This HHE reports a total CPM for the syringe\u002F manifold disconnection issue from June 2023 to February 19, 2026, as 62.62 CPM (250 complaints out of (b)(4) syringes manufactured ending (b)(4)). On March 13, 2026, an 806 Report was submitted to the agency for the removal of these devices ((b)(4)).\nYou also indicate that you initiated an additional CAPA-02627 under which you conducted a systemic review of all open CAPAs and trained personnel on an updated CAPA procedure (SOP-00022) which requires more frequent post-market data reviews per established guidance. The targeted completion date for CAPA-02627 is June 30, 2026.\nWith regards to CAPA-02612, no information was provided on when you anticipate a new investigation will be completed to determine the cause(s) of the disconnections between the syringes and manifolds to assure your actions are timely and commensurate with risk of this issue. Furthermore, no assurance was provided that the scope of the product removal will include affected devices manufactured both before and after the corrective action (April 17, 2024) since the corrective action was found to be ineffective. Furthermore, the manufacturing quantities documented in your updated HHE fall short of the nearly (b)(4) syringes your Senior Director of Quality stated were manufactured (approximately (b)(4) devices from (b)(4) to (b)(4) and nearly (b)(4) devices from (b)(4) to (b)(4)) in that it states that only (b)(4) syringes were manufactured through (b)(4), resulting in 62.62 CPM (250 complaints), without defining the manufacturing start date of affected products. The HHE also incorrectly specifies a corrective action start date of June 2024 instead of April 16, 2024, as specified in CAPA-01872.\nWith regards to CAPA-02627, you did not identify actions that assure that employees will follow your corrective action procedure to route the CAPA back to a previous phase or open an additional CAPA as soon as it is evident that corrective actions are not effective, as was the case in (b)(4) of 2025 when your complaint analysis data showed that the CPM for syringe and manifold disconnections was above the established CPM thresholds.\nPlease provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n2. Failure to establish and maintain schedules for the adjustment, cleaning, and other maintenance of equipment to ensure that manufacturing specifications are met, as required by 21 CFR 820.70(g)(1).\nSpecifically, your firm failed to implement sections 6.2.2 ((b)(4) Cleaning) and 6.3 (General Requirements) of your “GN 010 - Manufacturing Cleaning Procedure” (NMC-00228; Rev. 7; Effective: 5\u002F2\u002F25) which state “a top-to-bottom cleaning of the controlled environments will be conducted, at minimum, (b)(4)***The cleaning shall also include all equipment not routinely cleaned by operators***” and “***Always clean the (b)(4) first and work toward the (b)(4) of cleaning with the (b)(4) being last***,” respectively, of controlled environments such as the clean rooms where you manufacture various Angiographic and Radiology Syringes. In addition, the corresponding forms titled “(b)(4) Cleaning Schedule and Sign-off Sheet” form (NMC-00228-F-00001; Rev. 2) and “(b)(4) Cleaning Schedule and Sign-off Sheet” (NMC-00228-F-00002; Rev.1) are inadequate because they fail to ensure consistent implementation of sections 6.2.2 and 6.3 of NMC-00228 due to absence of specific instructions requiring the cleaning of top of manufacturing equipment as is included for the cleaning of vents, ceiling lights, walls, benches, cabinets, fixtures, etc. For example, on December 1, 2025, the investigator observed a visible accumulation of particulate on the top of manufacturing equipment in cleanrooms including the (b)(4) syringe manufacturing machine (ID # 90303527), (b)(4) machine (ID # 90306846), (b)(4) manufacturing machine (ID # 90308616), and (b)(4) machine (Asset # 8974). There have been approximately 114 complaints regarding foreign matter or hair in the package or device from December 2023 to at least December 1, 2025.\nWe reviewed your firm’s response and conclude that it is not adequate. In your January 13, 2026, response, you state you performed immediate ad-hoc cleaning of all equipment to remove observed particulate matter, established preventative maintenance schedules based on (b)(4) of monitoring data, and updated the cleaning and preventative maintenance procedures (NMC-00228 and NMC-00171) to formalize these requirements followed by training under CAPA-02518. Additionally, you state you developed an ad-hoc cleaning procedure (NMC-01120) and addressed air filtration concerns by installing (b)(4) indicators around all cleanroom (b)(4) vents to ensure proper clearance, repaired damaged vents, and updated your environmental control procedure (NMC-00233) to include inspection and clearance requirements. You also determined that validation of the cleaning process was not required.\nIn your latest response on February 27, 2026, you state you conducted a comprehensive review of the cleanroom manufacturing environments and identified improvement opportunities but not any risks. The target completion for these additional actions is April 30, 2026, and the target completion date of CAPA-02518 is July 17, 2026.\nHowever, there were no corrective actions identified to assess the impact of products in the field and inventory for products which have been manufactured in these cleanrooms since the last documented cleaning of equipment tops on November 26, 2023, including review of the manufacturing dates of products referenced in the 114 complaints received for foreign matter or hair since this date as a part of the respective complaint investigations. Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n3. Failure to establish and maintain procedures for verifying the device design. Design verification shall confirm that the design output meets the design input requirements, as required by 21 CFR 820.30(f).\nSpecifically, your firm’s design verification conducted under “Design Verification Protocol Polycarbonate Female Luer ISO 80369-7” (P017333; Rev. B; Approved: 10\u002F7\u002F20) with resulting “Design Verification Report Polycarbonate Female Luer ISO 80369-7” (P017334; Rev. A; Approved: 6\u002F30\u002F20) fails to demonstrate that the polycarbonate female luer connector components of your Fluid Management product lines (e.g., stopcock product family, manifold product family, disposable transducer product family, Y adaptor, etc.), which underwent changes to their threads and taper dimensions to become BS EN ISO 80369-7 compliant, meet the dimensional and functional testing requirements specified in this standard. For example, there was no documentation in the protocol (or elsewhere) on why design verification testing was only performed on a single female luer connector (Part # 24644210) and not any of the other (b)(4) connectors listed in the “Scope” section of this protocol which were also impacted by this design change. Moreover, this solely tested connector is not included in the final version of your “Design Change Analysis Form (DCAF) for ISO 80369-7 Compliance for Male and Female Luer Connectors (P017104) QUAL-66717 Rev. 4” (Approved: 9\u002F7\u002F22) which captures all luer connectors affected by this design change.\nWe reviewed your firm’s response and conclude that it is not adequate. In your January 13, 2026 response, you state you revised the design verification procedure (NMC-00155) to require documentation of part selection rationale, added product configuration tables and guidance for recording representative SKU selection and rationale for selection in the Design Verification Protocol Template (NMC-00155-F-00001), and amended design change file QUAL-66717 to include the missing justification for part selection under CAPA-02610.\nIn your latest response on February 27, 2026, you state you conducted a comprehensive review of all design changes from (b)(4) to present that required design verification testing and uncovered four (4) instances of insufficient documentation of part rationale which will require protocol updates with appropriate justification. The target completion of CAPA-02610 is June 1, 2026.\nHowever, review of the “Unit Rationale” provided revealed that it fails to explain how design verification testing of part number 41338202 covers anything beyond the manifold product family, such as the stopcock product family, disposable transducer product family, and Y adaptor of the Fluid Management product lines which were in the scope of the Design Verification. Moreover, this rationale does not explain why this part number was not listed in the final version of your “Design Change Analysis Form (DCAF) for ISO 80369-7 Compliance for Male and Female Luer Connectors (P017104) QUAL-66717 Rev. 4” (Approved: 9\u002F7\u002F22) meant to capture all the luer connectors affected by this design change. Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on December 1, 2025 to December 12, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 723866” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara A. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Bradley R. Pratt, Sr. Director of Manufacturing Operations, BPratt@medline.com","Medline Industries, LP","medline-industries-lp-723866-03252026","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedline-industries-lp-723866-03252026","2026-10-26T08:09:23.493183+00:00","Warning Letter","Issued","2026-04-07","723866","Medical Devices","Jim Boyle","2026-08-19T04:49:13.251+00:00","VIA Electronic Mail","2026-03-25",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":16,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":47,"body_fetched_at":48,"delivery_method":49,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},1558,[34,35,36,11,37,13,13,13],"\u003Ctime datetime=\"2024-03-19T17:50:00Z\">03\u002F19\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-03-18T04:00:00Z\">03\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedline-industries-lp-677545-03182024\">Medline Industries, LP\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>James Boyle\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Medline Industries, LP\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3 Lakes Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Northfield\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60093-2753\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# (677545)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 18, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. Boyle:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at 3 Lakes Drive, Northfield, IL on December 11, 2023, through January 22, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer and complaint file establishment of sterile and bulk non-sterile syringes, needles for human and veterinary use under the Medline brand, and sterile convenience kits used in operating rooms. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>We received a response(s) from Joseph Zeman dated February 12, 2024, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved Device Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the \u003Cem>MEDLINE SYRINGES, MULTIPLE\u003C\u002Fem> and the Jiangsu Shenli Medical Production Co. Ltd. Piston syringes of the sizes and configurations listed in \u003Cstrong>Table 1\u003C\u002Fstrong>, which you include in convenience kits, are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring&nbsp;premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that you need to submit in order to obtain approval or clearance for the device is described on the Internet at&nbsp;http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that you submit and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cdiv>\n\u003Ctable>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Model #\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Item Description\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Model #\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Item Description\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83077\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 30ML L\u002FS\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91839\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL YELLOW\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83078\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 30ML L\u002FL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91840\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 3ML L\u002FL PURPLE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83079\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 60ML L\u002FS\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91841\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL PURPLE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83080\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 60ML L\u002FL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91842\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL PURPLE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83081\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FS\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91845\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL BLUE SALINE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83082\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91846\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL YELLOW CONT\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83083\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 3ML L\u002FS\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91847\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL BLUE LIDO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83084\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 3ML L\u002FL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91849\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL BLUE SALINE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83085\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FS\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91850\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL RED LIDO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83087\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FS\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91851\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL RED HEPARIN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83088\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91852\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL YELLOW NITRO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83089\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 1ML TB\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91854\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL YELLOW LIDO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91820\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 3ML L\u002FL RED\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91855\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL YELLOW HEP\u002FSALINE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91821\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 3ML L\u002FL GREEN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91856\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL RED CONT\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91822\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 3ML L\u002FL BLUE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91857\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL GREEN CONT\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91825\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL RED\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91858\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL WHITE SALINE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91826\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL GREEN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91859\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL PURPLE NITRO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91827\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL BLUE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91863\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL YELLOW LIDO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91828\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL WHITE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91866\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL RED NITRO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91829\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL YELLOW\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91867\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL BLUE HEPARIN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91830\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL RED\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91872\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FS BLUE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91831\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL GREEN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91873\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL WHITE LIDO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91832\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL BLUE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91874\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FS RED\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91833\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL WHITE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91876\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR CNTRL 10ML L\u002FL YEL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91834\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL YELLOW\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91877\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR CNTRL 10ML L\u002FIL YELLOW LIDO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91835\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL RED\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91878\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR CNTRL 10 ML L\u002FL RED\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91836\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL GREEN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91879\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR CNTRL 10ML L\u002FL GRN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91837\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL BLUE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91880\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR CNTRL 10ML L\u002FL BLUE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91838\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL WHITE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91881\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL CONTROL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>&nbsp;\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003C\u002Fdiv>\n\n\u003Cp>\u003Cstrong>Table 1.\u003C\u002Fstrong> List of Jiangsu Shenli Medical Production Co. Ltd. Piston syringe configurations implicated in this Warning Letter.\u003C\u002Fp>\n\n\u003Cp>Specifically, during our inspection:\u003C\u002Fp>\n\n\u003Cp>1. The Jiangsu Shenli Medical Production Co. Ltd. Piston Syringe (5cc Luer Lock) was cleared under K103830. The intended use of the Jiangsu Shenli Medical Production Co., Ltd. 5cc luer lock piston syringe is to inject fluids into or withdraw fluids from the body. Based on FDA's evaluation of your firm's activities, there is evidence that your firm is engaged in the distribution of these Jiangsu Shenli syringes for use within the United States, including as part of convenience kits, with substantially different technological characteristics, namely sizes other than 5 mL, luer slip instead of luer lock tips, syringes intended for specific drugs, different colors (i.e., colorants), and control syringes, each of which constitute a significant change or modification in design that could significantly alter the safety or effectiveness of the device. For further explanation on the need for a new premarket notification, or “510(k),” for changes to the intended use or design affecting safety and effectiveness, it is recommended that you consult the guidance document “Deciding When to Submit a 510(k) for a Change to an Existing Device – Guidance for Industry and Food and Drug Administration Staff (fda.gov).” In the guidance at Figure 3 – Flowchart B: Technology, Engineering, and Performance Changes, FDA explains why changes in size, color, specific drug indications and connector type all constitute a major change or modification to the device’s intended use, for which there is not clearance or approval.\u003C\u002Fp>\n\n\u003Cp>As discussed above the products listed in \u003Cstrong>Table 1\u003C\u002Fstrong> are misbranded because there are one or more change(s) or modification(s) to each device that could significantly affect the safety or effectiveness of the devices you have purchased from the manufacturer, Jiangsu Shenli, despite the manufacturer not submitting a 510(k) to FDA. Specifically, changing the volume of the syringe, switching from a luer lock to a luer slip syringe tip, and changing from a traditional syringe to a control syringe could result in the risk of patient harm such as inaccurate dosing, a leaking device, a higher risk of inappropriate needle detachment, and incorrect device handling. Furthermore, the addition of color additives to the syringe could result in adverse health effects such as allergic reactions, skin irritation or inflammation, pain, fever, red blood cell damage that induces organ stress, and toxicity that leads to loss of organ function or failure. Labeling the syringe for a specific drug can also cause harm because differences in drug viscosities impact the function of the syringe and can result in patient harm such as inaccurate dosing or incorrect drug usage.\u003C\u002Fp>\n\n\u003Cp>Your firm’s failure to ensure the syringes you are including in convenience kits, importing, and commercially distributing in the United States have 510(k) clearance has prevented FDA from evaluating the risks posed by these substantially different technological characteristics or from determining that there is reasonable assurance of the safety and effectiveness of these modified devices such that they may be legally marketed syringes. Further, FDA has observed evidence of postmarket safety signals indicating product quality issues that have the potential to cause serious patient harm. Our inspection revealed multiple customer complaints regarding quality issues (e.g. cracks, breakage during use) for syringes in your surgical kits that include syringes supplied by Jiangsu Shenli Medical Production Co. Ltd that you failed to properly investigate.\u003C\u002Fp>\n\n\u003Cp>Your response dated February 12, 2024, is not adequate. The response indicates you plan to implement further supplier agreements and that you completed a vendor audit for Jiangsu Shenli on February 5, 2024. The findings and outcome of the vendor audit are unclear because you did not provide the complete report. The proposed procedural changes to your vendor evaluation procedure are insufficient because they continue to place all responsibility on the suppliers to claim premarket clearance without you confirming that such clearance exists and is appropriate for device(s) provided by the vendor. It also unclear when these procedures would be implemented and which suppliers they would apply to. Moreover, these procedures would not have detected that K103830 does not permit marketing of syringes other than what was cleared (i.e., 5 mL luer lock syringes). Your response also states you have ceased purchasing syringes from Jiangsu Shenli until they receive appropriate marketing clearance (i.e., a new 510(k)); however, you have not taken action sufficient to mitigate the risks for US consumers related to these violative syringes. For example, you have not committed to recalling and\u002For removing these violative syringes on the US market, not using any violative syringes already in transit from Jiangsu Shenli to Medline, and not using any violative syringes already received by Medline (e.g., in Mexico for inclusion into Medline convenience kits) but yet to be distributed to US customers. Therefore, the proposed corrections are inadequate.\u003C\u002Fp>\n\n\u003Cp>2. During our inspection, we collected documents used to support changes you made to your 510(k) \u003Cem>\u003Cstrong>MEDLINE SYRINGES, MULTIPLE (K061275)\u003C\u002Fstrong>\u003C\u002Fem>, such as the Regulatory Assessment of Change (RAC) K061275-03. The RAC K061275-03 document approved Jiangsu Caina Medical Co Ltd (“Jiangsu Caina”) “as an additional contract manufacturer and contract sterilizer” in China for Medline’s 1 mL luer lock and 1 mL luer slip syringes. In your FDA 483 response to Observation 5 from February 12, 2024, you referenced the flowcharts in FDA guidance, “Deciding When to Submit a 510(k) for a Change to an Existing Device” (available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F99812\u002Fdownload) for this change. In decision point B5.4 “Do design verification and\u002For validation activities produce any unexpected issues of safety or effectiveness?”, you indicated “No.” However, review of your RAC K061275-03 documents demonstrates that this decision was incorrect because the testing had unexpected and unexplained failures.\u003C\u002Fp>\n\n\u003Cp>Specifically, you conducted assessments of the Jiangsu Caina 1mL luer lock and luer slip syringes according to ISO 7886-1 in report “L18-215 Final Report” (dated October 3, 2018) titled “Performance Evaluation of Caina SYR101010 1 mL Luer Lock Syringes per ISO 7886-1” and report “L18-216 Final Report” (dated October 3, 2018) titled “Performance Evaluation of Caina SYR101020 1 mL Luer Slip Syringes per ISO 7886-1.” You noted that 55% and 75% of test samples respectively failed when testing the “Tolerance on Graduated Capacity” for delivering 0.2 mL of fluid. You opened an investigation, TOOS18-014, but no further documentation describing the outcome of the investigation was provided. In report “L18-215 – Addendum – 01 Final Report” (dated March 7, 2019) titled “Performance Evaluation of Caina SYR101010 1 mL Luer Lock Syringes per ISO 7886-1”, you stated for the “Tolerance on Graduated Capacity” testing that “the original method did not account for the dead space of the syringe. Therefore, specimens needed to be retested with the correct procedure.” However, “Tolerance on Capacity Testing” per ISO 7886-1:2017 (and as described in section 9.2 of your procedure LAB-00107 Rev. 10) already accounts for dead space, and you still observed a failure rate of 5% among test samples for delivering 0.2 mL of fluid in “L18-215 – Addendum – 01 Final Report” for the 1 mL luer lock syringes. In “MGT - Study Inspection and Status Report”, the “Findings” and “Recommended Actions” sections of each report contain the same handwritten notes saying, “Testing completed as expected” and “None,” respectively, despite seeing failures in the testing. These reports were signed and approved prior to conducting the testing. You then repeated only the “Tolerance on Graduated Capacity” testing in “L21-002 Final Report” (dated January 25, 2021) and reported passing results for all test samples. Your documentation does not contain details of a root cause analysis for the failures observed in the “Tolerance on Graduated Capacity” testing in 2018 and 2019 nor an acceptable rationale for invalidating these test results, whether any changes were made to improve the performance of the syringes between 2019 and 2021 as a result of a root cause analysis, and it does not contain a justification why the testing completed in 2018 and 2019 could be leveraged to support the performance of the syringes tested in 2021. Despite these observations, on January 28, 2021 and January 29, 2021, you finalized RAC K061275-03 document noting, “results from test reports did not produce any unexpected issues of safety or effectiveness.” This statement is incorrect since your performance testing showed unexpected and unexplained failures. Your testing documentation does not support that the modified syringes can successfully deliver accurate volumes across the full range of their claimed graduated capacity. The inability of these syringes to deliver the intended dose could lead to administering syringe content in excess of the intended dose and thus lead to harm to patients. Therefore, your change in manufacturing process (i.e., approving Jiangsu Caina as a manufacturer and sterilizer) could significantly affect the safety or effectiveness of the device. Per 21 CFR 807.81(a)(3)(i) a premarket notification was required before introducing the device into commercial distribution.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality System Regulation Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at 21 CFR Part 820.\u003C\u002Fp>\n\n\u003Cp>These violations include, but are not limited to, the following:\u003Cbr>\n\u003Cbr>\n1. Failure to adequately establish and maintain procedures for the identification, documentation, validation, or where appropriate verification, review, and approval of design changes, as required by part 21 CFR 820.30(i). Specifically,\u003C\u002Fp>\n\n\u003Cp>A. Your firm has not adequately implemented “Corporate Design Control Procedure”, SOP-00050, Rev.13 which states:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. in step 11.3 that “All design changes must be verified and\u002For validated unless proper justification is given as to why verification or validation is unnecessary.” On or about January 31, 2018, Medline approved a Regulatory Assessment Change (RAC), K061275-01 to allow dimensional changes to the Medline Piston Syringes to improve the user experience by reducing the chance for cracked syringes and plunger pullout. However, your firm’s risk assessment for the dimensional changes to the syringes does not adequately address identified hazards (i.e., cracked syringes or plunger pullout) or support that the changes would mitigate the risk by reducing the probability of the hazard occurring and would not significantly affect the safety or effectiveness of the piston syringes. A user validation was not performed to confirm the dimensional changes did not adversely affect use of the piston syringes. Your firm’s RAC notes that this is not considered a major change and that verification performance\u002Fbench testing was sufficient to support your firm’s assessment that a new 510(k) was not required as it did not impact safety and effectiveness of syringes.\u003C\u002Fp>\n\n\u003Cp>ii. in step 6.1 “Design reviews may be held at other times throughout the design and development process, including addressing ambiguous data (e.g., inputs, validation activities etc.)”. For example, the Revised Specifications of piston syringes for K061275, as they relate to Design transfer agreement and current contract manufacturing specifications for the manufacturing of these piston syringes include conflicting or ambiguous dimensional specification requirements. The manufacturing dimensional specifications used by your contract manufacturers do not correspond with dimensional changes approved in Regulatory Assessment Change (RAC), K061275. This may adversely impact product quality based on variations from the approved specification and the current contract manufacturing specifications.\u003C\u002Fp>\n\n\u003Cp>B. You firm was unable to provide our investigators with a completed “Product Change Notice and QA Approval Form” for RAC 061275-01 as required by “Corporate Design Control Procedure”, SOP-00050 step 11.2. According to the procedure, design changes are to be documented on a Product Change Notice and QA Approval Form which are also design control requirements set forth under 21 CFR 820.30(i) and (j). The RAC K061275-01 was initiated for “…dimensional changes to increase the wall thickness, edit the taper of the barrel and the retention ring to improve the user experience by reducing&nbsp;the chance for cracked syringes and plunger pullout.” Your firm did not include an assessment of any new risks as part of the dimensional changes as required by the Product Change Notice and QA Approval Form. In addition, section 11.7.1 of the procedure notes that the Change Verification and Validation section of the Product Change and QA Approval Form should be utilized to determine whether or not verification and\u002For validation are required for approval of the proposed change(s). The procedure further states “Should verification and\u002For validation be required, divisional QA must make sure that all supporting documentation, results, justification, etc. are available and attached with form”.\u003C\u002Fp>\n\n\u003Cp>Validation of the design change to support a reduction in cracked syringes and plunger pullout was not performed prior to the implementation and release of product into distribution. In addition, you did not update the design failure mode and effects analysis (DFMEA), SOP-00099-F-00004 and application failures mode and effects analysis (aFMEA) SOP-00099-F-00005 for barrel breakage for the Medline piston syringe (K061275). Your firm continues to receive complaints related to cracked syringes or plunger issues in addition to leaks and breakage during use.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated February 12, 2024, cannot be determined at this time. The response notes that you have undertaken corrective actions to address the issue with Design Control procedures (design change, design transfer, design change forms), design change form to support the K061275-01 design change and perform an evaluation of design changes to K061275 syringes. These actions encompass conducting a retrospective review of design changes of non-syringe design history files to assure no similar deficiencies exist, updating risk management files, revising procedures, and training staff members. Additionally, corrective actions are being created within the CAPA system for each respective observation to decide if further remediation actions are necessary. However, the response does not furnish specific information regarding the results or outcomes of these corrective actions as they are still ongoing.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, the “Complaint Handling and Evaluation” procedure, CHP-00001 has not been adequately implemented to ensure:\u003C\u002Fp>\n\n\u003Cp>A. Complaints are evaluated to determine whether they are events that are required to be reported to FDA. For example,\u003C\u002Fp>\n\n\u003Cp>i. the complaint handling procedure states that a regulatory investigation is required for Medline labeled or branded product complaints that occur during patient use and\u002For cause an adverse reaction or injury. Our investigator noted 16 of 20 complaints did not have a regulatory investigation as required:\u003C\u002Fp>\n\n\u003Ctable>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Complaint Number\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Notification Date\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Complaint Description\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200391920\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>06\u002F24\u002F2020\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Shattered syringe, piece almost went into surgeon’s hand\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200430173\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>02\u002F23\u002F2021\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Syringe broke off inside stent connector\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200439795\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>04\u002F21\u002F2021\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91881 syringe broke when surgeon started to push in medication; ring on plunger broke off, small plastic piece broke off; very sharp piece and if it went into the abdomen, it would not be found by x-ray. Very dangerous; other syringes have broken, too.\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200446540\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>06\u002F04\u002F2021\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Syringes crack and squirt fluids in the CCL during procedures; one exploded with blood in it.\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200477084\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>01\u002F12\u002F2022\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Particles found in packaging…can ruin patient’s one chance at treatment\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200558997\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>05\u002F16\u002F2023\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Syringes broke during use\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200546695\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>03\u002F03\u002F2023 \u002F [02\u002F15\u002F2023 email sent by customer]\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91881C seems very cheap, breaking or not working when trying to use\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200441924\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>05\u002F04\u002F2021\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Syringes cracked, medicine going everywhere\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200438138\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>04\u002F09\u002F2021\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Surgery has found syringes leaking during use\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200392513\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>06\u002F26\u002F2020\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Tabs have been breaking off causing surgeon’s gloves to tear\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200488141\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>03\u002F22\u002F2022\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Needles not locking with syringe and leaking Botox out\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200507995\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>07\u002F18\u002F2022\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Particles found in syringe\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200530846\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>11\u002F28\u002F2022\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Syringe cracked down the middle when using.\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200546698\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>02\u002F08\u002F2023\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Control syringe is unsafe and comes apart.\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200550282\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>03\u002F27\u002F2023\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>“We have been having issues with these syringes. The needle is not well attached and as we draw up sedation with it, we have been losing the sedation and having to waste the meds. It is possible to have the needle on tight so that it does not have to be checked every time. It could also lead to a needle stick if not careful.”\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200361247\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>01\u002F03\u002F2020\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>[customer] found a hair wrapped around the Syringe Control 10ML product inside this pack.\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\n\u003Cp>ii. complaint handling procedure Step 5.4.2 states that “…various “key words” and phrases are used to help determine if complaint is a potentially reportable event. The procedure provides key words and phrases that include but are not limited to… Bleeding, Broken components used on a patient, Cut, Exploded, Needle stick, Severe reaction (requiring a medical intervention), Surgery…”. However, 13 of 16 complaints reviewed by our investigator included these key words or phrases and were not evaluated to determine whether the event was reportable to the FDA.\u003C\u002Fp>\n\n\u003Cp>iii. complaints of medical device malfunctions which if they were to recur would likely cause or contribute to a death or serious injury are not evaluated to determine if such event are required to be reported to FDA as a medical device report as required by 21 CFR 820.198(a)(3). In cases where you specified that a clinical review was not required an adequate justification for not performing was included.\u003C\u002Fp>\n\n\u003Cp>B. All complaints are reviewed and evaluated to determine if investigation is necessary and complaints not needing an investigation shall be maintained with the reason for no investigation along with the name of the individual responsible for the decision.\u003C\u002Fp>\n\n\u003Cp>i. There is no written procedure to define the coding that is selected by the complaint handling personnel. Inaccurate coding of the failure or defect will affect the quality data source analysis and may prevent action(s) being taken when necessary.\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; a. 15 of 20 complaints reviewed by our investigator during the inspection were incorrectly coded as needle defects or parts\u002Fcomponents instead of syringe.\u003Cbr>\n&nbsp; &nbsp; b. Complaints listing multiple failed units are counted as one complaint, for trending and analysis.\u003Cbr>\n&nbsp; &nbsp; c. The procedure is lacking other common key words to help determine reportability such as\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Cracks\u003C\u002Fli>\n\t\u003Cli>Dislodgement of the needle from the syringe\u003C\u002Fli>\n\t\u003Cli>Contamination\u003C\u002Fli>\n\t\u003Cli>Particulates\u003C\u002Fli>\n\t\u003Cli>Out of specification syringes (markings dead space, not fitting, deformation)\u003C\u002Fli>\n\t\u003Cli>Leaks\u003C\u002Fli>\n\t\u003Cli>Blockage, foreign material stuck in the syringe.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>ii. Our investigator noted that 16 of 20 complaints reviewed for syringe malfunctions or failures complaints were not evaluated or investigated in accordance with your firm’s written procedure “Finished Device Alleged Failure Investigation”, SOP-00031. According to step 3.2.1.3, the following methods are to be used when completing complaint investigations:\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; a. DHR reviews\u003Cbr>\n&nbsp; &nbsp; b. Review of product change notifications\u003Cbr>\n&nbsp; &nbsp; c. Label and or instructions for use review to ensure necessary instructions\u002Fcomplications are complete.\u003Cbr>\n&nbsp; &nbsp; d. Review of inspection reports\u003Cbr>\n&nbsp; &nbsp; e. BOM review\u003C\u002Fp>\n\n\u003Cp>Finished Device Alleged Failure Investigation Procedure SOP-00031 Rev. 21 (the version reviewed during the inspection) required that: “During the complaint investigation process, any\u002Fall applicable investigation methods listed above should be used until the complaint is confirmed.” The result of the investigation methods should be documented within the complaint. If none of the methods can be utilized, a justification\u002Frationale shall be documented in the investigation. A detailed conclusion must be provided.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated February 12, 2024, cannot be determined at this time. The response notes that your firm has undertaken corrective actions to address the issue of complaint handling, MDR evaluation and determination, complaint coding, and investigations. These actions encompass conducting a retrospective review of complaints (syringe and non-syringe), revising procedures, and training staff members. Additionally, corrective actions are being created within the CAPA system for each respective observation to decide if further remediation actions are necessary. Your firm’s response does not address the multiple complaints contained within each complaint as this can adversely affect their trending and analysis. Further, the response does not furnish specific information regarding the results or outcomes of these corrective actions as they are still ongoing.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately establish and maintain procedures for implementing corrective and preventative actions, as required by part 21 CFR 820.100.\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not adequately implemented your written procedure “Internal Corrective-Preventive Action Procedure”, SOP-00022, to analyze quality data such as customer complaints in order to identify existing and potential causes of nonconforming product or other quality problems in order to correct and prevent their recurrence. A review of quality data by our investigator noted approximately 2300 syringe complaints between 2020 and 2023 that were either confirmed or not confirmed, for all syringe types (e.g., bulb syringes, feeding syringes, flush syringes, piston syringes etc.) and other OEM syringes. Your firm’s procedure states in step 5.2, that Medline assesses “…quality data on an on-going basis from both a risk and systemic standpoint using appropriate statistical methodology and analysis.” No trend has been identified for piston syringes by defect group\u002Ffailure code as defined by your firm for any of the following:\u003C\u002Fp>\n\n\u003Ctable>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Defect Group\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Number of Complaints\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Needles\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>122\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Particulate\u002FContamination\u002FStains\u002FSpots\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>148\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Parts and Components Issues\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>333\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Syringe\u002FSyringe Damaged\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>129\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Assembly Issue\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>225\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\n\u003Ctable>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Short Text for Cause Code\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Ctable>\n\t\t\t\t\u003Ctbody>\n\t\t\t\t\t\u003Ctr>\n\t\t\t\t\t\t\u003Ctd>\n\t\t\t\t\t\t\u003Cp>MFG: Environmental controls\u003Cbr>\n\t\t\t\t\t\t&nbsp;\u003C\u002Fp>\n\t\t\t\t\t\t\u003C\u002Ftd>\n\t\t\t\t\t\t\u003Ctd>\n\t\t\t\t\t\t\u003Cp>127\u003C\u002Fp>\n\t\t\t\t\t\t\u003C\u002Ftd>\n\t\t\t\t\t\u003C\u002Ftr>\n\t\t\t\t\t\u003Ctr>\n\t\t\t\t\t\t\u003Ctd>\n\t\t\t\t\t\t\u003Cp>MFG: Assembly\u002FHuman Error\u003C\u002Fp>\n\t\t\t\t\t\t\u003C\u002Ftd>\n\t\t\t\t\t\t\u003Ctd>\n\t\t\t\t\t\t\u003Cp>213\u003C\u002Fp>\n\t\t\t\t\t\t\u003C\u002Ftd>\n\t\t\t\t\t\u003C\u002Ftr>\n\t\t\t\t\t\u003Ctr>\n\t\t\t\t\t\t\u003Ctd>\n\t\t\t\t\t\t\u003Cp>Customer: Knowledge (Use Error)\u003C\u002Fp>\n\t\t\t\t\t\t\u003C\u002Ftd>\n\t\t\t\t\t\t\u003Ctd>\n\t\t\t\t\t\t\u003Cp>71\u003C\u002Fp>\n\t\t\t\t\t\t\u003C\u002Ftd>\n\t\t\t\t\t\u003C\u002Ftr>\n\t\t\t\t\u003C\u002Ftbody>\n\t\t\t\u003C\u002Ftable>\n\n\t\t\t\u003Cp>&nbsp;\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\n\u003Cp>In addition, your firm’s procedure states in section 5.3 that “there may be a scenario where it is appropriate to initiate a CAPA based on one quality event (e.g. one complaint, one MDR, one recall, one external audit observation, etc.) …. decisions should be commensurate with risk, including the extent of action required to address the quality event.”. Your firm’s management stated that there has not been one quality event in the three years of data reviewed for piston syringes that has resulted in CAPA.\u003C\u002Fp>\n\n\u003Cp>During the inspection our investigator noted that you initiated a Regulatory Assessment Change (RAC), K061275-01 to allow dimensional changes to the Medline Piston Syringes to improve the user experience by reducing the chance for cracked syringes and plunger pullout. Your firm’s management explained to our investigator that the RAC was an improvement and enhancement and not done to improve clinical outcomes, mitigate a known risk, or in response to an adverse event. Your firm’s design failure mode and effects analysis (DFMEA), SOP-00099-F-00004 for Medline piston syringe (K061275) lists among other things, piston syringes dimensions and fit as having an impact on product quality and functionality.\u003C\u002Fp>\n\n\u003Cp>The DFMEA indicates that performance testing and finished product testing have reduced the risk as low as possible however your firm continues to receive complaints for loss of primary function among others. All complaints cannot be attributed to application user failures described in your firm’s application failure mode and effects analysis (aFMEA) SOP-00099-F-00005 for Medline piston syringe (K061275).\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated February 12, 2024, cannot be determined at this time. The response notes that your firm has undertaken corrective actions to address the issue with CAPA procedures. These actions encompass conducting a retrospective review of complaints, a reanalysis of complaints, revising procedures, and training staff members. Additionally, corrective actions are being created within the CAPA system for each respective observation to decide if further remediation actions are necessary. However, the response does not furnish specific information regarding the results or outcomes of these corrective actions as they are still ongoing.\u003C\u002Fp>\n\n\u003Cp>4. Failure to adequately establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50.\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm’s Vendor Evaluation Procedure SOP-00003 has not been adequately established or maintained to ensure requirements, including quality requirements have been met by suppliers and contractors. For example, the Vendor Evaluation - Supplier Disposition Form for supplier “S” lacks a documented review of marketing clearance for products you distribute and\u002For further manufacture. There is no objective evidence to support the quality agreement requirement “Supplier shall only supply product to Medline that has the appropriate marketing clearance.”\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated February 12, 2024, cannot be determined at this time. The response notes that your firm has undertaken corrective actions to address the issue with purchasing controls to include revisions to purchasing control procedures, employee training, retrospective review of all Medline-branded syringes and syringe kit components, performing a review of active Medline-branded medical devices (non-syringes) and submitting a new 510(k) Premarket Notification for all sizes\u002Fmodels of Medline Piston Syringes. Additionally, corrective actions are being created within the CAPA system for the observation to decide if further remediation actions are necessary. However, the response does not furnish specific information regarding the results or outcomes of these corrective actions as they are still ongoing.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. Refer to CMS # 677545 when replying. If you have any questions about the contents of this letter, please contact: Compliance Officer, Rafael Padilla at 312-596-4212 or Rafael.padilla@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Blake Bevill\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medial Device and Radiological Health\u003Cbr>\nOperations (OMDRHO) Division 2 Central\u003C\u002Fp>\n\n\u003Cp>And\u003Cbr>\n\u003Cbr>\nKellie B. Kelm, Ph.D.\u003Cbr>\nActing Director\u003Cbr>\nOHT3: Office of Gastrorenal, ObGyn, General Hospital, and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJames Boyle\n\nRecipient Title\n\nCEO\n\nMedline Industries, LP\n\n3 Lakes Drive\n\nNorthfield, IL 60093-2753\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nCMS# (677545)\n\nMarch 18, 2024\n\nDear Mr. Boyle:\n\nDuring an inspection of your firm located at 3 Lakes Drive, Northfield, IL on December 11, 2023, through January 22, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer and complaint file establishment of sterile and bulk non-sterile syringes, needles for human and veterinary use under the Medline brand, and sterile convenience kits used in operating rooms. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nWe received a response(s) from Joseph Zeman dated February 12, 2024, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations.\n\nUnapproved Device Violations\n\nOur inspection revealed that the MEDLINE SYRINGES, MULTIPLE and the Jiangsu Shenli Medical Production Co. Ltd. Piston syringes of the sizes and configurations listed in Table 1, which you include in convenience kits, are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that you need to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that you submit and decide whether the product may be legally marketed.\n\nModel #\n\nItem Description\n\nModel #\n\nItem Description\n\n83077\n\nSYR 30ML L\u002FS\n\n91839\n\nSYR 20ML L\u002FL YELLOW\n\n83078\n\nSYR 30ML L\u002FL\n\n91840\n\nSYR 3ML L\u002FL PURPLE\n\n83079\n\nSYR 60ML L\u002FS\n\n91841\n\nSYR 5ML L\u002FL PURPLE\n\n83080\n\nSYR 60ML L\u002FL\n\n91842\n\nSYR 10ML L\u002FL PURPLE\n\n83081\n\nSYR 10ML L\u002FS\n\n91845\n\nSYR 20ML L\u002FL BLUE SALINE\n\n83082\n\nSYR 10ML L\u002FL\n\n91846\n\nSYR 10ML L\u002FL YELLOW CONT\n\n83083\n\nSYR 3ML L\u002FS\n\n91847\n\nSYR 10ML L\u002FL BLUE LIDO\n\n83084\n\nSYR 3ML L\u002FL\n\n91849\n\nSYR 10ML L\u002FL BLUE SALINE\n\n83085\n\nSYR 5ML L\u002FS\n\n91850\n\nSYR 10ML L\u002FL RED LIDO\n\n83087\n\nSYR 20ML L\u002FS\n\n91851\n\nSYR 10ML L\u002FL RED HEPARIN\n\n83088\n\nSYR 20ML L\u002FL\n\n91852\n\nSYR 5ML L\u002FL YELLOW NITRO\n\n83089\n\nSYR 1ML TB\n\n91854\n\nSYR 10ML L\u002FL YELLOW LIDO\n\n91820\n\nSYR 3ML L\u002FL RED\n\n91855\n\nSYR 10ML L\u002FL YELLOW HEP\u002FSALINE\n\n91821\n\nSYR 3ML L\u002FL GREEN\n\n91856\n\nSYR 10ML L\u002FL RED CONT\n\n91822\n\nSYR 3ML L\u002FL BLUE\n\n91857\n\nSYR 10ML L\u002FL GREEN CONT\n\n91825\n\nSYR 5ML L\u002FL RED\n\n91858\n\nSYR 20ML L\u002FL WHITE SALINE\n\n91826\n\nSYR 5ML L\u002FL GREEN\n\n91859\n\nSYR 5ML L\u002FL PURPLE NITRO\n\n91827\n\nSYR 5ML L\u002FL BLUE\n\n91863\n\nSYR 20ML L\u002FL YELLOW LIDO\n\n91828\n\nSYR 5ML L\u002FL WHITE\n\n91866\n\nSYR 5ML L\u002FL RED NITRO\n\n91829\n\nSYR 5ML L\u002FL YELLOW\n\n91867\n\nSYR 5ML L\u002FL BLUE HEPARIN\n\n91830\n\nSYR 10ML L\u002FL RED\n\n91872\n\nSYR 10ML L\u002FS BLUE\n\n91831\n\nSYR 10ML L\u002FL GREEN\n\n91873\n\nSYR 10ML L\u002FL WHITE LIDO\n\n91832\n\nSYR 10ML L\u002FL BLUE\n\n91874\n\nSYR 10ML L\u002FS RED\n\n91833\n\nSYR 10ML L\u002FL WHITE\n\n91876\n\nSYR CNTRL 10ML L\u002FL YEL\n\n91834\n\nSYR 10ML L\u002FL YELLOW\n\n91877\n\nSYR CNTRL 10ML L\u002FIL YELLOW LIDO\n\n91835\n\nSYR 20ML L\u002FL RED\n\n91878\n\nSYR CNTRL 10 ML L\u002FL RED\n\n91836\n\nSYR 20ML L\u002FL GREEN\n\n91879\n\nSYR CNTRL 10ML L\u002FL GRN\n\n91837\n\nSYR 20ML L\u002FL BLUE\n\n91880\n\nSYR CNTRL 10ML L\u002FL BLUE\n\n91838\n\nSYR 20ML L\u002FL WHITE\n\n91881\n\nSYR 10ML L\u002FL CONTROL\n\nTable 1. List of Jiangsu Shenli Medical Production Co. Ltd. Piston syringe configurations implicated in this Warning Letter.\n\nSpecifically, during our inspection:\n\n1. The Jiangsu Shenli Medical Production Co. Ltd. Piston Syringe (5cc Luer Lock) was cleared under K103830. The intended use of the Jiangsu Shenli Medical Production Co., Ltd. 5cc luer lock piston syringe is to inject fluids into or withdraw fluids from the body. Based on FDA's evaluation of your firm's activities, there is evidence that your firm is engaged in the distribution of these Jiangsu Shenli syringes for use within the United States, including as part of convenience kits, with substantially different technological characteristics, namely sizes other than 5 mL, luer slip instead of luer lock tips, syringes intended for specific drugs, different colors (i.e., colorants), and control syringes, each of which constitute a significant change or modification in design that could significantly alter the safety or effectiveness of the device. For further explanation on the need for a new premarket notification, or “510(k),” for changes to the intended use or design affecting safety and effectiveness, it is recommended that you consult the guidance document “Deciding When to Submit a 510(k) for a Change to an Existing Device – Guidance for Industry and Food and Drug Administration Staff (fda.gov).” In the guidance at Figure 3 – Flowchart B: Technology, Engineering, and Performance Changes, FDA explains why changes in size, color, specific drug indications and connector type all constitute a major change or modification to the device’s intended use, for which there is not clearance or approval.\n\nAs discussed above the products listed in Table 1 are misbranded because there are one or more change(s) or modification(s) to each device that could significantly affect the safety or effectiveness of the devices you have purchased from the manufacturer, Jiangsu Shenli, despite the manufacturer not submitting a 510(k) to FDA. Specifically, changing the volume of the syringe, switching from a luer lock to a luer slip syringe tip, and changing from a traditional syringe to a control syringe could result in the risk of patient harm such as inaccurate dosing, a leaking device, a higher risk of inappropriate needle detachment, and incorrect device handling. Furthermore, the addition of color additives to the syringe could result in adverse health effects such as allergic reactions, skin irritation or inflammation, pain, fever, red blood cell damage that induces organ stress, and toxicity that leads to loss of organ function or failure. Labeling the syringe for a specific drug can also cause harm because differences in drug viscosities impact the function of the syringe and can result in patient harm such as inaccurate dosing or incorrect drug usage.\n\nYour firm’s failure to ensure the syringes you are including in convenience kits, importing, and commercially distributing in the United States have 510(k) clearance has prevented FDA from evaluating the risks posed by these substantially different technological characteristics or from determining that there is reasonable assurance of the safety and effectiveness of these modified devices such that they may be legally marketed syringes. Further, FDA has observed evidence of postmarket safety signals indicating product quality issues that have the potential to cause serious patient harm. Our inspection revealed multiple customer complaints regarding quality issues (e.g. cracks, breakage during use) for syringes in your surgical kits that include syringes supplied by Jiangsu Shenli Medical Production Co. Ltd that you failed to properly investigate.\n\nYour response dated February 12, 2024, is not adequate. The response indicates you plan to implement further supplier agreements and that you completed a vendor audit for Jiangsu Shenli on February 5, 2024. The findings and outcome of the vendor audit are unclear because you did not provide the complete report. The proposed procedural changes to your vendor evaluation procedure are insufficient because they continue to place all responsibility on the suppliers to claim premarket clearance without you confirming that such clearance exists and is appropriate for device(s) provided by the vendor. It also unclear when these procedures would be implemented and which suppliers they would apply to. Moreover, these procedures would not have detected that K103830 does not permit marketing of syringes other than what was cleared (i.e., 5 mL luer lock syringes). Your response also states you have ceased purchasing syringes from Jiangsu Shenli until they receive appropriate marketing clearance (i.e., a new 510(k)); however, you have not taken action sufficient to mitigate the risks for US consumers related to these violative syringes. For example, you have not committed to recalling and\u002For removing these violative syringes on the US market, not using any violative syringes already in transit from Jiangsu Shenli to Medline, and not using any violative syringes already received by Medline (e.g., in Mexico for inclusion into Medline convenience kits) but yet to be distributed to US customers. Therefore, the proposed corrections are inadequate.\n\n2. During our inspection, we collected documents used to support changes you made to your 510(k) MEDLINE SYRINGES, MULTIPLE (K061275), such as the Regulatory Assessment of Change (RAC) K061275-03. The RAC K061275-03 document approved Jiangsu Caina Medical Co Ltd (“Jiangsu Caina”) “as an additional contract manufacturer and contract sterilizer” in China for Medline’s 1 mL luer lock and 1 mL luer slip syringes. In your FDA 483 response to Observation 5 from February 12, 2024, you referenced the flowcharts in FDA guidance, “Deciding When to Submit a 510(k) for a Change to an Existing Device” (available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F99812\u002Fdownload) for this change. In decision point B5.4 “Do design verification and\u002For validation activities produce any unexpected issues of safety or effectiveness?”, you indicated “No.” However, review of your RAC K061275-03 documents demonstrates that this decision was incorrect because the testing had unexpected and unexplained failures.\n\nSpecifically, you conducted assessments of the Jiangsu Caina 1mL luer lock and luer slip syringes according to ISO 7886-1 in report “L18-215 Final Report” (dated October 3, 2018) titled “Performance Evaluation of Caina SYR101010 1 mL Luer Lock Syringes per ISO 7886-1” and report “L18-216 Final Report” (dated October 3, 2018) titled “Performance Evaluation of Caina SYR101020 1 mL Luer Slip Syringes per ISO 7886-1.” You noted that 55% and 75% of test samples respectively failed when testing the “Tolerance on Graduated Capacity” for delivering 0.2 mL of fluid. You opened an investigation, TOOS18-014, but no further documentation describing the outcome of the investigation was provided. In report “L18-215 – Addendum – 01 Final Report” (dated March 7, 2019) titled “Performance Evaluation of Caina SYR101010 1 mL Luer Lock Syringes per ISO 7886-1”, you stated for the “Tolerance on Graduated Capacity” testing that “the original method did not account for the dead space of the syringe. Therefore, specimens needed to be retested with the correct procedure.” However, “Tolerance on Capacity Testing” per ISO 7886-1:2017 (and as described in section 9.2 of your procedure LAB-00107 Rev. 10) already accounts for dead space, and you still observed a failure rate of 5% among test samples for delivering 0.2 mL of fluid in “L18-215 – Addendum – 01 Final Report” for the 1 mL luer lock syringes. In “MGT - Study Inspection and Status Report”, the “Findings” and “Recommended Actions” sections of each report contain the same handwritten notes saying, “Testing completed as expected” and “None,” respectively, despite seeing failures in the testing. These reports were signed and approved prior to conducting the testing. You then repeated only the “Tolerance on Graduated Capacity” testing in “L21-002 Final Report” (dated January 25, 2021) and reported passing results for all test samples. Your documentation does not contain details of a root cause analysis for the failures observed in the “Tolerance on Graduated Capacity” testing in 2018 and 2019 nor an acceptable rationale for invalidating these test results, whether any changes were made to improve the performance of the syringes between 2019 and 2021 as a result of a root cause analysis, and it does not contain a justification why the testing completed in 2018 and 2019 could be leveraged to support the performance of the syringes tested in 2021. Despite these observations, on January 28, 2021 and January 29, 2021, you finalized RAC K061275-03 document noting, “results from test reports did not produce any unexpected issues of safety or effectiveness.” This statement is incorrect since your performance testing showed unexpected and unexplained failures. Your testing documentation does not support that the modified syringes can successfully deliver accurate volumes across the full range of their claimed graduated capacity. The inability of these syringes to deliver the intended dose could lead to administering syringe content in excess of the intended dose and thus lead to harm to patients. Therefore, your change in manufacturing process (i.e., approving Jiangsu Caina as a manufacturer and sterilizer) could significantly affect the safety or effectiveness of the device. Per 21 CFR 807.81(a)(3)(i) a premarket notification was required before introducing the device into commercial distribution.\n\nQuality System Regulation Violations\n\nOur inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at 21 CFR Part 820.\n\nThese violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures for the identification, documentation, validation, or where appropriate verification, review, and approval of design changes, as required by part 21 CFR 820.30(i). Specifically,\n\nA. Your firm has not adequately implemented “Corporate Design Control Procedure”, SOP-00050, Rev.13 which states:\n\ni. in step 11.3 that “All design changes must be verified and\u002For validated unless proper justification is given as to why verification or validation is unnecessary.” On or about January 31, 2018, Medline approved a Regulatory Assessment Change (RAC), K061275-01 to allow dimensional changes to the Medline Piston Syringes to improve the user experience by reducing the chance for cracked syringes and plunger pullout. However, your firm’s risk assessment for the dimensional changes to the syringes does not adequately address identified hazards (i.e., cracked syringes or plunger pullout) or support that the changes would mitigate the risk by reducing the probability of the hazard occurring and would not significantly affect the safety or effectiveness of the piston syringes. A user validation was not performed to confirm the dimensional changes did not adversely affect use of the piston syringes. Your firm’s RAC notes that this is not considered a major change and that verification performance\u002Fbench testing was sufficient to support your firm’s assessment that a new 510(k) was not required as it did not impact safety and effectiveness of syringes.\n\nii. in step 6.1 “Design reviews may be held at other times throughout the design and development process, including addressing ambiguous data (e.g., inputs, validation activities etc.)”. For example, the Revised Specifications of piston syringes for K061275, as they relate to Design transfer agreement and current contract manufacturing specifications for the manufacturing of these piston syringes include conflicting or ambiguous dimensional specification requirements. The manufacturing dimensional specifications used by your contract manufacturers do not correspond with dimensional changes approved in Regulatory Assessment Change (RAC), K061275. This may adversely impact product quality based on variations from the approved specification and the current contract manufacturing specifications.\n\nB. You firm was unable to provide our investigators with a completed “Product Change Notice and QA Approval Form” for RAC 061275-01 as required by “Corporate Design Control Procedure”, SOP-00050 step 11.2. According to the procedure, design changes are to be documented on a Product Change Notice and QA Approval Form which are also design control requirements set forth under 21 CFR 820.30(i) and (j). The RAC K061275-01 was initiated for “…dimensional changes to increase the wall thickness, edit the taper of the barrel and the retention ring to improve the user experience by reducing the chance for cracked syringes and plunger pullout.” Your firm did not include an assessment of any new risks as part of the dimensional changes as required by the Product Change Notice and QA Approval Form. In addition, section 11.7.1 of the procedure notes that the Change Verification and Validation section of the Product Change and QA Approval Form should be utilized to determine whether or not verification and\u002For validation are required for approval of the proposed change(s). The procedure further states “Should verification and\u002For validation be required, divisional QA must make sure that all supporting documentation, results, justification, etc. are available and attached with form”.\n\nValidation of the design change to support a reduction in cracked syringes and plunger pullout was not performed prior to the implementation and release of product into distribution. In addition, you did not update the design failure mode and effects analysis (DFMEA), SOP-00099-F-00004 and application failures mode and effects analysis (aFMEA) SOP-00099-F-00005 for barrel breakage for the Medline piston syringe (K061275). Your firm continues to receive complaints related to cracked syringes or plunger issues in addition to leaks and breakage during use.\n\nThe adequacy of your firm’s response dated February 12, 2024, cannot be determined at this time. The response notes that you have undertaken corrective actions to address the issue with Design Control procedures (design change, design transfer, design change forms), design change form to support the K061275-01 design change and perform an evaluation of design changes to K061275 syringes. These actions encompass conducting a retrospective review of design changes of non-syringe design history files to assure no similar deficiencies exist, updating risk management files, revising procedures, and training staff members. Additionally, corrective actions are being created within the CAPA system for each respective observation to decide if further remediation actions are necessary. However, the response does not furnish specific information regarding the results or outcomes of these corrective actions as they are still ongoing.\n\n2. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, the “Complaint Handling and Evaluation” procedure, CHP-00001 has not been adequately implemented to ensure:\n\nA. Complaints are evaluated to determine whether they are events that are required to be reported to FDA. For example,\n\ni. the complaint handling procedure states that a regulatory investigation is required for Medline labeled or branded product complaints that occur during patient use and\u002For cause an adverse reaction or injury. Our investigator noted 16 of 20 complaints did not have a regulatory investigation as required:\n\nComplaint Number\n\nNotification Date\n\nComplaint Description\n\n200391920\n\n06\u002F24\u002F2020\n\nShattered syringe, piece almost went into surgeon’s hand\n\n200430173\n\n02\u002F23\u002F2021\n\nSyringe broke off inside stent connector\n\n200439795\n\n04\u002F21\u002F2021\n\n91881 syringe broke when surgeon started to push in medication; ring on plunger broke off, small plastic piece broke off; very sharp piece and if it went into the abdomen, it would not be found by x-ray. Very dangerous; other syringes have broken, too.\n\n200446540\n\n06\u002F04\u002F2021\n\nSyringes crack and squirt fluids in the CCL during procedures; one exploded with blood in it.\n\n200477084\n\n01\u002F12\u002F2022\n\nParticles found in packaging…can ruin patient’s one chance at treatment\n\n200558997\n\n05\u002F16\u002F2023\n\nSyringes broke during use\n\n200546695\n\n03\u002F03\u002F2023 \u002F [02\u002F15\u002F2023 email sent by customer]\n\n91881C seems very cheap, breaking or not working when trying to use\n\n200441924\n\n05\u002F04\u002F2021\n\nSyringes cracked, medicine going everywhere\n\n200438138\n\n04\u002F09\u002F2021\n\nSurgery has found syringes leaking during use\n\n200392513\n\n06\u002F26\u002F2020\n\nTabs have been breaking off causing surgeon’s gloves to tear\n\n200488141\n\n03\u002F22\u002F2022\n\nNeedles not locking with syringe and leaking Botox out\n\n200507995\n\n07\u002F18\u002F2022\n\nParticles found in syringe\n\n200530846\n\n11\u002F28\u002F2022\n\nSyringe cracked down the middle when using.\n\n200546698\n\n02\u002F08\u002F2023\n\nControl syringe is unsafe and comes apart.\n\n200550282\n\n03\u002F27\u002F2023\n\n“We have been having issues with these syringes. The needle is not well attached and as we draw up sedation with it, we have been losing the sedation and having to waste the meds. It is possible to have the needle on tight so that it does not have to be checked every time. It could also lead to a needle stick if not careful.”\n\n200361247\n\n01\u002F03\u002F2020\n\n[customer] found a hair wrapped around the Syringe Control 10ML product inside this pack.\n\nii. complaint handling procedure Step 5.4.2 states that “…various “key words” and phrases are used to help determine if complaint is a potentially reportable event. The procedure provides key words and phrases that include but are not limited to… Bleeding, Broken components used on a patient, Cut, Exploded, Needle stick, Severe reaction (requiring a medical intervention), Surgery…”. However, 13 of 16 complaints reviewed by our investigator included these key words or phrases and were not evaluated to determine whether the event was reportable to the FDA.\n\niii. complaints of medical device malfunctions which if they were to recur would likely cause or contribute to a death or serious injury are not evaluated to determine if such event are required to be reported to FDA as a medical device report as required by 21 CFR 820.198(a)(3). In cases where you specified that a clinical review was not required an adequate justification for not performing was included.\n\nB. All complaints are reviewed and evaluated to determine if investigation is necessary and complaints not needing an investigation shall be maintained with the reason for no investigation along with the name of the individual responsible for the decision.\n\ni. There is no written procedure to define the coding that is selected by the complaint handling personnel. Inaccurate coding of the failure or defect will affect the quality data source analysis and may prevent action(s) being taken when necessary.\n\na. 15 of 20 complaints reviewed by our investigator during the inspection were incorrectly coded as needle defects or parts\u002Fcomponents instead of syringe.\n\nb. Complaints listing multiple failed units are counted as one complaint, for trending and analysis.\n\nc. The procedure is lacking other common key words to help determine reportability such as\n\nCracks\n\nDislodgement of the needle from the syringe\n\nContamination\n\nParticulates\n\nOut of specification syringes (markings dead space, not fitting, deformation)\n\nLeaks\n\nBlockage, foreign material stuck in the syringe.\n\nii. Our investigator noted that 16 of 20 complaints reviewed for syringe malfunctions or failures complaints were not evaluated or investigated in accordance with your firm’s written procedure “Finished Device Alleged Failure Investigation”, SOP-00031. According to step 3.2.1.3, the following methods are to be used when completing complaint investigations:\n\na. DHR reviews\n\nb. Review of product change notifications\n\nc. Label and or instructions for use review to ensure necessary instructions\u002Fcomplications are complete.\n\nd. Review of inspection reports\n\ne. BOM review\n\nFinished Device Alleged Failure Investigation Procedure SOP-00031 Rev. 21 (the version reviewed during the inspection) required that: “During the complaint investigation process, any\u002Fall applicable investigation methods listed above should be used until the complaint is confirmed.” The result of the investigation methods should be documented within the complaint. If none of the methods can be utilized, a justification\u002Frationale shall be documented in the investigation. A detailed conclusion must be provided.\n\nThe adequacy of your firm’s response dated February 12, 2024, cannot be determined at this time. The response notes that your firm has undertaken corrective actions to address the issue of complaint handling, MDR evaluation and determination, complaint coding, and investigations. These actions encompass conducting a retrospective review of complaints (syringe and non-syringe), revising procedures, and training staff members. Additionally, corrective actions are being created within the CAPA system for each respective observation to decide if further remediation actions are necessary. Your firm’s response does not address the multiple complaints contained within each complaint as this can adversely affect their trending and analysis. Further, the response does not furnish specific information regarding the results or outcomes of these corrective actions as they are still ongoing.\n\n3. Failure to adequately establish and maintain procedures for implementing corrective and preventative actions, as required by part 21 CFR 820.100.\n\nSpecifically, your firm has not adequately implemented your written procedure “Internal Corrective-Preventive Action Procedure”, SOP-00022, to analyze quality data such as customer complaints in order to identify existing and potential causes of nonconforming product or other quality problems in order to correct and prevent their recurrence. A review of quality data by our investigator noted approximately 2300 syringe complaints between 2020 and 2023 that were either confirmed or not confirmed, for all syringe types (e.g., bulb syringes, feeding syringes, flush syringes, piston syringes etc.) and other OEM syringes. Your firm’s procedure states in step 5.2, that Medline assesses “…quality data on an on-going basis from both a risk and systemic standpoint using appropriate statistical methodology and analysis.” No trend has been identified for piston syringes by defect group\u002Ffailure code as defined by your firm for any of the following:\n\nDefect Group\n\nNumber of Complaints\n\nNeedles\n\n122\n\nParticulate\u002FContamination\u002FStains\u002FSpots\n\n148\n\nParts and Components Issues\n\n333\n\nSyringe\u002FSyringe Damaged\n\n129\n\nAssembly Issue\n\n225\n\nShort Text for Cause Code\n\nMFG: Environmental controls\n\n127\n\nMFG: Assembly\u002FHuman Error\n\n213\n\nCustomer: Knowledge (Use Error)\n\n71\n\nIn addition, your firm’s procedure states in section 5.3 that “there may be a scenario where it is appropriate to initiate a CAPA based on one quality event (e.g. one complaint, one MDR, one recall, one external audit observation, etc.) …. decisions should be commensurate with risk, including the extent of action required to address the quality event.”. Your firm’s management stated that there has not been one quality event in the three years of data reviewed for piston syringes that has resulted in CAPA.\n\nDuring the inspection our investigator noted that you initiated a Regulatory Assessment Change (RAC), K061275-01 to allow dimensional changes to the Medline Piston Syringes to improve the user experience by reducing the chance for cracked syringes and plunger pullout. Your firm’s management explained to our investigator that the RAC was an improvement and enhancement and not done to improve clinical outcomes, mitigate a known risk, or in response to an adverse event. Your firm’s design failure mode and effects analysis (DFMEA), SOP-00099-F-00004 for Medline piston syringe (K061275) lists among other things, piston syringes dimensions and fit as having an impact on product quality and functionality.\n\nThe DFMEA indicates that performance testing and finished product testing have reduced the risk as low as possible however your firm continues to receive complaints for loss of primary function among others. All complaints cannot be attributed to application user failures described in your firm’s application failure mode and effects analysis (aFMEA) SOP-00099-F-00005 for Medline piston syringe (K061275).\n\nThe adequacy of your firm’s response dated February 12, 2024, cannot be determined at this time. The response notes that your firm has undertaken corrective actions to address the issue with CAPA procedures. These actions encompass conducting a retrospective review of complaints, a reanalysis of complaints, revising procedures, and training staff members. Additionally, corrective actions are being created within the CAPA system for each respective observation to decide if further remediation actions are necessary. However, the response does not furnish specific information regarding the results or outcomes of these corrective actions as they are still ongoing.\n\n4. Failure to adequately establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50.\n\nSpecifically, your firm’s Vendor Evaluation Procedure SOP-00003 has not been adequately established or maintained to ensure requirements, including quality requirements have been met by suppliers and contractors. For example, the Vendor Evaluation - Supplier Disposition Form for supplier “S” lacks a documented review of marketing clearance for products you distribute and\u002For further manufacture. There is no objective evidence to support the quality agreement requirement “Supplier shall only supply product to Medline that has the appropriate marketing clearance.”\n\nThe adequacy of your firm’s response dated February 12, 2024, cannot be determined at this time. The response notes that your firm has undertaken corrective actions to address the issue with purchasing controls to include revisions to purchasing control procedures, employee training, retrospective review of all Medline-branded syringes and syringe kit components, performing a review of active Medline-branded medical devices (non-syringes) and submitting a new 510(k) Premarket Notification for all sizes\u002Fmodels of Medline Piston Syringes. Additionally, corrective actions are being created within the CAPA system for the observation to decide if further remediation actions are necessary. However, the response does not furnish specific information regarding the results or outcomes of these corrective actions as they are still ongoing.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. Refer to CMS # 677545 when replying. If you have any questions about the contents of this letter, please contact: Compliance Officer, Rafael Padilla at 312-596-4212 or Rafael.padilla@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nBlake Bevill\n\nProgram Division Director\n\nOffice of Medial Device and Radiological Health\n\nOperations (OMDRHO) Division 2 Central\n\nAnd\n\nKellie B. Kelm, Ph.D.\n\nActing Director\n\nOHT3: Office of Gastrorenal, ObGyn, General Hospital, and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","medline-industries-lp-677545-03182024","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedline-industries-lp-677545-03182024","2026-10-26T08:09:23.450135+00:00","2024-03-19","677545","James Boyle","2026-08-20T00:14:01.484+00:00","VIA UNITED PARCEL SERVICE","2024-03-18",{"id":52,"raw":53,"subject":58,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":63,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":67,"product_type":68,"closeout_date":19,"issuing_office":57,"recipient_name":69,"body_fetched_at":70,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},627,[54,55,56,57,58,13,13,13],"\u003Ctime datetime=\"2025-09-16T04:00:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-17T04:00:00Z\">07\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmericon-industries-inc-692733-07172025\">Mericon Industries, Inc. \u003C\u002Fa>","Human Foods Program","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brian Connelly\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Mericon Industries, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8819 N Pioneer Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Peoria\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>61615-1519\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Brian.Connelly@mericonindustries.com\"> Brian.Connelly@mericonindustries.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 17, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS #692733\u003C\u002Fp>\u003Cp>Dear Mr. Connelly:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility, located at 8819 N Pioneer Rd, Peoria, IL, from August 12 through 21, 2024. Based on inspectional findings and review of product labels collected during the inspections, as well as review of your website, www.mericonindustries.com, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection on August 21, 2024, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your response dated September 5, 2024, and we address your response below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drugs\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA reviewed your website at the Internet address www.mericonindustries.com in February, 2025, and has determined that you take orders there for the products Florical 100 capsules, Florical 500 capsules, and Meribin 120 capsules. The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\u003C\u002Fp>\u003Cp>Examples of some of the claims on your website www.mericonindustries.com that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cu>Florical 100 Capsules\u003C\u002Fu>\u003Cbr>“Prevention and remediation of osteoporosis.”\u003C\u002Fli>\u003Cli>\u003Cu>Florical 500 Capsules\u003C\u002Fu>\u003Cbr>“Prevention and remediation of osteoporosis.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Drugs\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Your products Florical 100 Capsules and Florical 500 Capsules are intended for treatment or prevention of one or more diseases that are not amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Florical 100 Capsules and Florical 500 Capsules fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulterated Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection of your facility on August 12 through 21, 2024, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the dietary supplements manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. Thus, in addition to being unapproved new drugs and\u002For misbranded drugs, your Florical 100 capsules, Florical 500 capsules, and Meribin 120 capsules are also adulterated dietary supplements under section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)].\u003C\u002Fp>\u003Cp>Your significant violations of the CGMP requirements are as follows:\u003C\u002Fp>\u003Cp>1. You failed to establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contaminants that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, you have not established identity specifications for your finished Florical and Meribin products. The identification test described in your batch records for these products are not adequate because they only include visual examination. Visual examination of the encapsulated powder is not be an appropriate identity test due to decreased reliability in confirming the identity of the product, potentially resulting in misidentification.\u003C\u002Fp>\u003Cp>In your response to the FDA Form 483, you did not provide finished product specifications. You also stated that, due to increased costs, it is difficult to accommodate private laboratory testing of your finished dietary supplement products. As required by 21 CFR 111.75(c), you must verify that your finished batch of the dietary supplement meets product specifications for identity, purity, strength, composition, and for limits on those types of contaminants that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement. To date, you have not submitted any evidence of corrective action for this violation.\u003C\u002Fp>\u003Cp>2. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any reprocessing, as required by 21 CFR 111.103. Specifically, during the inspection, when our investigator requested your written procedures for quality control operations, you were not able to provide any written procedures for quality control operations that are used to ensure the quality of the dietary supplements. On 05\u002F28\u002F2024, you manufactured Florical Lot#240528A and distributed the finished product on 08\u002F08\u002F2024.\u003C\u002Fp>\u003Cp>In your response to the FDA Form 483, you stated that you have quality controls in the form of a manual of Standard Operating Procedures. You did not provide any documentation to demonstrate that you have established and follow written procedures for the responsibilities of the quality control operations. To date, you have not submitted any evidence of corrective action.\u003C\u002Fp>\u003Cp>3. Your batch production records failed to include complete information relating to the production and control of each batch, as required by 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, your batch production records for the Florical and Meribin dietary supplement products that you manufacture failed to include:\u003C\u002Fp>\u003Cul>\u003Cli>The identity of the equipment and processing lines used in producing the batch (21 CFR 111.260(b));\u003C\u002Fli>\u003Cli>Documentation that the finished dietary supplement meets specifications established in accordance with 21 CFR 111.70(e) and (g) (21 CFR 111.260(i));\u003C\u002Fli>\u003Cli>Documentation at the time of performance that quality control personnel reviewed the batch production record (21 CFR 111.260(l)(1)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response to the FDA Form 483, you stated that you plan to create an SOP to address the batch production record deficiencies. To date, you have not submitted any evidence of corrective action.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, we reviewed your product labels collected during the inspection and have determined the Florical 100 Capsules, Florical 500 Capsules, and Meribin 120 Capsules products you manufacture are misbranded under section 403 of the Act [21 U.S.C. 343] because they do not comply with the labeling requirements for dietary supplements. Thus, in addition to being unapproved new drugs and misbranded drugs, your Florical 100 Capsules, Florical 500 Capsules, and Meribin 120 Capsules are also misbranded dietary supplements under section 403 of the Act [21 U.S.C. 343].] Specifically, we identified the following:\u003C\u002Fp>\u003Cp>1. Your Florical 100 Capsules, Florical 500 Capsules, and Meribin 120 Capsules, dietary supplement products are misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of the nutrition information on the labeling of your products does not comply with 21 CFR 101.36 and 21 CFR 101.9, and 21 CFR 101.4. For example, the calculated % Daily Value for all (b)(2)-dietary ingredients must be the quantitative amount by weight per serving divided by the RDI for each respective nutrient established in 21 CFR 101.9(c)(8)(iv), and expressed to the nearest whole percent in accordance with 21 CFR 101.36(b)(2)(C).\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be directed to Rebecca Allen, Compliance Officer, via email at HFPOCE-DietarySupplements@fda.hhs.gov. Please reference CMS #692733 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCEDietarySupplements@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD, MBA\u003Cbr>Acting Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nBrian Connelly\n\nRecipient Title\n\nOwner\n\nMericon Industries, Inc.\n\n8819 N Pioneer Rd.\n\nPeoria, IL 61615-1519\n\nUnited States\n\nBrian.Connelly@mericonindustries.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nJuly 17, 2025\nWARNING LETTER\nCMS #692733\nDear Mr. Connelly:\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility, located at 8819 N Pioneer Rd, Peoria, IL, from August 12 through 21, 2024. Based on inspectional findings and review of product labels collected during the inspections, as well as review of your website, www.mericonindustries.com, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\nAt the conclusion of the inspection on August 21, 2024, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your response dated September 5, 2024, and we address your response below.\nUnapproved New Drugs\nFDA reviewed your website at the Internet address www.mericonindustries.com in February, 2025, and has determined that you take orders there for the products Florical 100 capsules, Florical 500 capsules, and Meribin 120 capsules. The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\nExamples of some of the claims on your website www.mericonindustries.com that provide evidence that your products are intended for use as drugs include:\nFlorical 100 Capsules\n“Prevention and remediation of osteoporosis.”\nFlorical 500 Capsules\n“Prevention and remediation of osteoporosis.”\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\nMisbranded Drugs\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\nYour products Florical 100 Capsules and Florical 500 Capsules are intended for treatment or prevention of one or more diseases that are not amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Florical 100 Capsules and Florical 500 Capsules fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\nAdulterated Dietary Supplements\nThe inspection of your facility on August 12 through 21, 2024, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the dietary supplements manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. Thus, in addition to being unapproved new drugs and\u002For misbranded drugs, your Florical 100 capsules, Florical 500 capsules, and Meribin 120 capsules are also adulterated dietary supplements under section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)].\nYour significant violations of the CGMP requirements are as follows:\n1. You failed to establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contaminants that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, you have not established identity specifications for your finished Florical and Meribin products. The identification test described in your batch records for these products are not adequate because they only include visual examination. Visual examination of the encapsulated powder is not be an appropriate identity test due to decreased reliability in confirming the identity of the product, potentially resulting in misidentification.\nIn your response to the FDA Form 483, you did not provide finished product specifications. You also stated that, due to increased costs, it is difficult to accommodate private laboratory testing of your finished dietary supplement products. As required by 21 CFR 111.75(c), you must verify that your finished batch of the dietary supplement meets product specifications for identity, purity, strength, composition, and for limits on those types of contaminants that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement. To date, you have not submitted any evidence of corrective action for this violation.\n2. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any reprocessing, as required by 21 CFR 111.103. Specifically, during the inspection, when our investigator requested your written procedures for quality control operations, you were not able to provide any written procedures for quality control operations that are used to ensure the quality of the dietary supplements. On 05\u002F28\u002F2024, you manufactured Florical Lot#240528A and distributed the finished product on 08\u002F08\u002F2024.\nIn your response to the FDA Form 483, you stated that you have quality controls in the form of a manual of Standard Operating Procedures. You did not provide any documentation to demonstrate that you have established and follow written procedures for the responsibilities of the quality control operations. To date, you have not submitted any evidence of corrective action.\n3. Your batch production records failed to include complete information relating to the production and control of each batch, as required by 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, your batch production records for the Florical and Meribin dietary supplement products that you manufacture failed to include:\nThe identity of the equipment and processing lines used in producing the batch (21 CFR 111.260(b));\nDocumentation that the finished dietary supplement meets specifications established in accordance with 21 CFR 111.70(e) and (g) (21 CFR 111.260(i));\nDocumentation at the time of performance that quality control personnel reviewed the batch production record (21 CFR 111.260(l)(1)).\nIn your response to the FDA Form 483, you stated that you plan to create an SOP to address the batch production record deficiencies. To date, you have not submitted any evidence of corrective action.\nMisbranded Dietary Supplements\nIn addition, we reviewed your product labels collected during the inspection and have determined the Florical 100 Capsules, Florical 500 Capsules, and Meribin 120 Capsules products you manufacture are misbranded under section 403 of the Act [21 U.S.C. 343] because they do not comply with the labeling requirements for dietary supplements. Thus, in addition to being unapproved new drugs and misbranded drugs, your Florical 100 Capsules, Florical 500 Capsules, and Meribin 120 Capsules are also misbranded dietary supplements under section 403 of the Act [21 U.S.C. 343].] Specifically, we identified the following:\n1. Your Florical 100 Capsules, Florical 500 Capsules, and Meribin 120 Capsules, dietary supplement products are misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of the nutrition information on the labeling of your products does not comply with 21 CFR 101.36 and 21 CFR 101.9, and 21 CFR 101.4. For example, the calculated % Daily Value for all (b)(2)-dietary ingredients must be the quantitative amount by weight per serving divided by the RDI for each respective nutrient established in 21 CFR 101.9(c)(8)(iv), and expressed to the nearest whole percent in accordance with 21 CFR 101.36(b)(2)(C).\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be directed to Rebecca Allen, Compliance Officer, via email at HFPOCE-DietarySupplements@fda.hhs.gov. Please reference CMS #692733 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCEDietarySupplements@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD, MBA\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Mericon Industries, Inc.","mericon-industries-inc-692733-07172025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmericon-industries-inc-692733-07172025","2026-10-26T08:09:24.060729+00:00","2025-09-16","692733","DrugsFood & Beverages","Brian Connelly","2026-08-19T16:23:51.686+00:00","Via Email","2025-07-17",{"id":74,"raw":75,"subject":80,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":85,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":23,"posted_date":88,"marcs_cms_no":89,"product_type":90,"closeout_date":19,"issuing_office":79,"recipient_name":91,"body_fetched_at":92,"delivery_method":93,"recipient_title":19,"reference_number":19,"action_taken_date":94,"medical_device_id":19,"response_letter_date":19},2474,[76,77,78,79,80,13,13,13],"\u003Ctime datetime=\"2022-09-06T13:20:00Z\">09\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-01T04:00:00Z\">09\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhp-industries-inc-640949-09012022\">HP Industries Inc.\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Benjamin H. Hickman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u002FSecretary of Treasury\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>HP Industries Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1303 West Potter Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kirksville\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>63501\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ben@hpind.com\"> ben@hpind.com \u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:steve@hpind.com\"> steve@hpind.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 1, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Hickman:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that HP Industries Inc. manufactures and distributes nicotine toothpick products for commercial distribution in the United States, and that nicotine toothpick products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including nicotine toothpick products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Cinnamon NicotinePicks.com Nicotine Toothpicks without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The introduction into interstate commerce of any tobacco product that is adulterated or misbranded is a prohibited act under section 301(a) of the FD&amp;C Act (21 U.S.C. § 331(a)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200656, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Benjamin H. Hickman\u003Cbr>\nOwner\u003Cbr>\nHP Industries Inc.\u003Cbr>\nP.O. Box 989\u003Cbr>\nKirksville, MO 63501\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nBenjamin H. Hickman\n\nRecipient Title\n\nOwner\u002FSecretary of Treasury\n\nHP Industries Inc.\n\n1303 West Potter Avenue\n\nKirksville, MO 63501\n\nUnited States\n\nben@hpind.com\n\nsteve@hpind.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nSeptember 1, 2022\n\nWARNING LETTER\n\nDear Mr. Hickman:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that HP Industries Inc. manufactures and distributes nicotine toothpick products for commercial distribution in the United States, and that nicotine toothpick products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including nicotine toothpick products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Cinnamon NicotinePicks.com Nicotine Toothpicks without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The introduction into interstate commerce of any tobacco product that is adulterated or misbranded is a prohibited act under section 301(a) of the FD&C Act (21 U.S.C. § 331(a)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nAll new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200656, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\ncc:\n\nBenjamin H. Hickman\n\nOwner\n\nHP Industries Inc.\n\nP.O. Box 989\n\nKirksville, MO 63501","HP Industries Inc.","hp-industries-inc-640949-09012022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhp-industries-inc-640949-09012022","2026-10-26T08:08:56.144513+00:00","2022-09-06","640949","Tobacco","Benjamin H. Hickman","2026-08-20T01:36:32.938+00:00","VIA UPS and Electronic Mail","2022-09-01",{"id":96,"raw":97,"subject":103,"body_html":104,"body_text":105,"firm_name":106,"letter_id":107,"created_at":108,"fei_number":19,"letter_url":109,"updated_at":110,"action_type":22,"case_status":111,"posted_date":112,"marcs_cms_no":113,"product_type":114,"closeout_date":115,"issuing_office":57,"recipient_name":116,"body_fetched_at":117,"delivery_method":118,"recipient_title":19,"reference_number":19,"action_taken_date":119,"medical_device_id":19,"response_letter_date":19},1159,[98,99,100,57,101,13,102,13],"\u003Ctime datetime=\"2024-11-26T14:20:00Z\">11\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-29T04:00:00Z\">10\u002F29\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftova-industries-llc-693241-10292024\">Tova Industries, LLC\u003C\u002Fa>","Acidified Foods\u002FEmergency Permit Control\u002FAdulterated\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftova-industries-llc-693241-11182024\">\u003Ctime datetime=\"2024-12-03T05:00:00Z\">12\u002F03\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","Acidified Foods\u002FEmergency Permit Control\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Zack Melzer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Tova Industries, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2902 Blankenbaker Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jeffersontown\u003C\u002Fspan>, \u003Cspan>KY\u003C\u002Fspan> \u003Cspan>40299-3841\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:zmelzer@tovaindustries.com\"> zmelzer@tovaindustries.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 29, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 693241\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Zachery Melzer:\u003C\u002Fp>\n\n\u003Cp>On August 5, 2024 through August 8, 2024, the United States Food and Drug Administration (FDA) conducted an inspection of your dry goods and ready to eat (RTE) foods facility, located at 2902 Blankenbaker Rd. Jeffersontown, KY 40299-3841. During our inspection of your facility, the FDA investigators found serious violations of the from the Emergency Permit Control regulation (Title 21, Code of Federal Regulations, Part 108 (21 CFR 108)) and Acidified Foods regulation (21 CFR Part 114).\u003C\u002Fp>\n\n\u003Cp>As an acidified food processor, you are required to comply with the Food, Drug and Cosmetic Act (the Act) and the federal regulations related to the processing of acidified foods and current good manufacturing practices. These regulations are described in 21 CFR Part 108, Emergency Permit Control and in 21 CFR Part 114, Acidified Foods. The Emergency Permit Control regulation was issued, in part, pursuant to section 404 of the Act (21 U.S.C. § 344). A temporary emergency permit may be required for acidified foods whenever a processor has failed to fulfill the requirements of 21 CFR Part 108, Subpart B, including registration and filing of process information, and the mandatory requirements of 21 CFR Part 114. In addition, based upon certain criteria in Part 114, acidified food products may be adulterated within the meaning of section 402(a)(4) of the Act (21 U.S.C. 342(a)(4)) in that it may have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or may have been rendered injurious to health. You can find the Act and the Acidified Food regulation through the links in FDA’s homepage at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Your significant violations were as follows:\u003C\u002Fp>\n\n\u003Cp>1. A scheduled process was not established by a qualified person who has expert knowledge acquired through appropriate training and expertise in acidification and processing of acidified foods to comply with 21 CFR 114.83 for your Pancake Syrup, Pancake Syrup Lite, Pancake Syrup Ultra Lite, Pancake Syrup Super Lite, Pancake Syrup Sugar Free, Vanilla Extract Imitation, Vanilla Flavoring, Low Sodium Soy Sauce, Soy Sauce Economy Liquid, and Soy Sauce products.\u003C\u002Fp>\n\n\u003Cp>2. As a commercial processor engaged in the thermal processing of acidified foods, you must provide the FDA information as to the scheduled process including conditions for heat processing and control of pH, salt, sugar and preservative level, and source and date of the establishment of the process for each acidified food in each container size as required by 21 CFR 108.25(c)(2).\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your response to the FDA-483 received by our office on August 21, 2024. Your response states \u003Cstrong>(b)(4)\u003C\u002Fstrong>. To date, your firm has not responded to the inquiry. Please note, that all filings marked as “Incomplete” renders them as “Not Filed”. Information on registration and filing can be found in the guidance document “Establishment Registration and Process Filing for Acidified and Low-Acid Canned Foods (LACF)”: Electronic Submissions available at: https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Festablishment-registration-process-filing-acidified-and-low-acid-canned-foodslacf\u002Festablishment-registration-and-process-filing-acidified-and-low-acid-canned-foods-lacf-electronic\u003C\u002Fp>\n\n\u003Cp>We may take further action if you do not promptly correct these violations. For instance, we may take further action to seize your product(s) and\u002For enjoin your firm from operating.\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific things you are doing to correct these violations. You should include in your response documentation such as product formulations related to your acidifed foods, process filing\u002FSID information, and verification records, or other useful information that would assist us in evaluating your corrections. If you cannot complete all corrections before you respond, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>This letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the Acidified Food regulation (21 CFR Part 114) and the current Good Manufacturing Practice Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117 Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Rosemary Sexton, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Rosemary Sexton via email at: rosemary.sexton@fda.hhs.gov. Please include reference #693241 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Maria S. Knirk, J.D.\u003Cbr>\nActing Director, Office of Enforcement\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nHuman Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Zack Melzer\n\nRecipient Title\n\nPresident\n\nTova Industries, LLC\n\n2902 Blankenbaker Rd.\n\nJeffersontown, KY 40299-3841\n\nUnited States\n\nzmelzer@tovaindustries.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nOctober 29, 2024\n\nWARNING LETTER\n\nRe: CMS # 693241\n\nDear Mr. Zachery Melzer:\n\nOn August 5, 2024 through August 8, 2024, the United States Food and Drug Administration (FDA) conducted an inspection of your dry goods and ready to eat (RTE) foods facility, located at 2902 Blankenbaker Rd. Jeffersontown, KY 40299-3841. During our inspection of your facility, the FDA investigators found serious violations of the from the Emergency Permit Control regulation (Title 21, Code of Federal Regulations, Part 108 (21 CFR 108)) and Acidified Foods regulation (21 CFR Part 114).\n\nAs an acidified food processor, you are required to comply with the Food, Drug and Cosmetic Act (the Act) and the federal regulations related to the processing of acidified foods and current good manufacturing practices. These regulations are described in 21 CFR Part 108, Emergency Permit Control and in 21 CFR Part 114, Acidified Foods. The Emergency Permit Control regulation was issued, in part, pursuant to section 404 of the Act (21 U.S.C. § 344). A temporary emergency permit may be required for acidified foods whenever a processor has failed to fulfill the requirements of 21 CFR Part 108, Subpart B, including registration and filing of process information, and the mandatory requirements of 21 CFR Part 114. In addition, based upon certain criteria in Part 114, acidified food products may be adulterated within the meaning of section 402(a)(4) of the Act (21 U.S.C. 342(a)(4)) in that it may have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or may have been rendered injurious to health. You can find the Act and the Acidified Food regulation through the links in FDA’s homepage at www.fda.gov.\n\nYour significant violations were as follows:\n\n1. A scheduled process was not established by a qualified person who has expert knowledge acquired through appropriate training and expertise in acidification and processing of acidified foods to comply with 21 CFR 114.83 for your Pancake Syrup, Pancake Syrup Lite, Pancake Syrup Ultra Lite, Pancake Syrup Super Lite, Pancake Syrup Sugar Free, Vanilla Extract Imitation, Vanilla Flavoring, Low Sodium Soy Sauce, Soy Sauce Economy Liquid, and Soy Sauce products.\n\n2. As a commercial processor engaged in the thermal processing of acidified foods, you must provide the FDA information as to the scheduled process including conditions for heat processing and control of pH, salt, sugar and preservative level, and source and date of the establishment of the process for each acidified food in each container size as required by 21 CFR 108.25(c)(2).\n\nWe acknowledge receipt of your response to the FDA-483 received by our office on August 21, 2024. Your response states (b)(4). To date, your firm has not responded to the inquiry. Please note, that all filings marked as “Incomplete” renders them as “Not Filed”. Information on registration and filing can be found in the guidance document “Establishment Registration and Process Filing for Acidified and Low-Acid Canned Foods (LACF)”: Electronic Submissions available at: https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Festablishment-registration-process-filing-acidified-and-low-acid-canned-foodslacf\u002Festablishment-registration-and-process-filing-acidified-and-low-acid-canned-foods-lacf-electronic\n\nWe may take further action if you do not promptly correct these violations. For instance, we may take further action to seize your product(s) and\u002For enjoin your firm from operating.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific things you are doing to correct these violations. You should include in your response documentation such as product formulations related to your acidifed foods, process filing\u002FSID information, and verification records, or other useful information that would assist us in evaluating your corrections. If you cannot complete all corrections before you respond, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nThis letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the Acidified Food regulation (21 CFR Part 114) and the current Good Manufacturing Practice Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117 Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\n\nPlease send your reply to the Food and Drug Administration, Attention: Rosemary Sexton, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Rosemary Sexton via email at: rosemary.sexton@fda.hhs.gov. Please include reference #693241 on any submissions and within the subject line of any email correspondence to the agency.\n\nSincerely,\n\n\u002FS\u002F\n\nMaria S. Knirk, J.D.\n\nActing Director, Office of Enforcement\n\nOffice of Compliance and Enforcement\n\nHuman Foods Program","Tova Industries, LLC","tova-industries-llc-693241-10292024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftova-industries-llc-693241-10292024","2026-10-26T08:10:14.063144+00:00","Closed Out","2024-11-26","693241","Food & Beverages","2024-12-03","Mr. Zack Melzer","2026-08-19T18:14:01.906+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2024-10-29",{"id":121,"raw":122,"subject":128,"body_html":129,"body_text":130,"firm_name":131,"letter_id":132,"created_at":108,"fei_number":19,"letter_url":133,"updated_at":134,"action_type":22,"case_status":23,"posted_date":135,"marcs_cms_no":136,"product_type":137,"closeout_date":19,"issuing_office":126,"recipient_name":138,"body_fetched_at":139,"delivery_method":71,"recipient_title":19,"reference_number":140,"action_taken_date":141,"medical_device_id":19,"response_letter_date":19},1055,[123,124,125,126,127,13,13,13],"\u003Ctime datetime=\"2025-02-18T05:00:00Z\">02\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-06T05:00:00Z\">02\u002F06\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftyche-industries-ltd-693081-02062025\">Tyche Industries Ltd\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated\u003Cbr \u002F>\r\n","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-41\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Sandeep Gokaraju\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner and Director \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Tyche Industries Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6-223, Sarpavaram (V)\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kakinada\u003C\u002Fspan> \u003Cspan>533005\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Andhra Pradesh\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sandeepraju@tycheindustries.net\"> sandeepraju@tycheindustries.net\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-41\u003C\u002Fp>\u003Cp>February 6, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Gokaraju:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Tyche Industries Ltd, FEI 3004790309, at 6-223, Sarpavaram (V), Kakinada, from August 12 to 16, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your September 4, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific deviations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to record all quality-related activities at the time they are performed.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) failed to ensure the integrity of CGMP records. For example, during the inspection, a member of your management stated that two of your operators admitted to falsifying temperature data for a drying oven that was not turned on during the manufacture of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch, which later failed to meet the residual solvents specification. In addition, an Assistant Manager in Production, an Assistant Manager in Quality Assurance, and a Quality Control Manager admitted to participating in the preparation of a “backdated calculation sheet” that was given to our investigator.\u003C\u002Fp>\u003Cp>Your documentation practices were not indicative of a facility that is in compliance with CGMP.\u003C\u002Fp>\u003Cp>Your response is inadequate. You state that you plan to hire a consultant to identify data integrity gaps and prepare and implement an action plan by June 30, 2025, approximately ten months from the conclusion of the inspection, which documented serious questionable data integrity practices. In addition, you state that you removed some of the employees involved in these incidents from CGMP-related activities, but you do not explain what was done to prevent the other employees involved in these activities from further data integrity deviations. Finally, you do not fully evaluate the scope of data integrity lapses at your firm, including by interviewing current and former employees and comprehensively reviewing data records.\u003C\u002Fp>\u003Cp>Significant findings in this letter indicate that your QU is not fully exercising its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: \u003Cem>Q8(R2) Pharmaceutical Development\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload, \u003Cem>Q9 Quality Risk Management \u003C\u002Fem>at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload and \u003Cem>Q10 Pharmaceutical Quality System\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Failure to clean equipment and utensils to prevent contamination or carry-over of a material that would alter the quality of the APIs beyond the official or other established specifications.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA documented rust-like residues inside \u003Cstrong>(b)(4)\u003C\u002Fstrong> non-dedicated \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the production of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, FDA documented bare footprints inside another \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the production of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Each \u003Cstrong>(b)(4)\u003C\u002Fstrong> was labeled that it had been cleaned and was ready for use.\u003C\u002Fp>\u003Cp>Inadequately cleaned and maintained manufacturing equipment can lead to potential cross- contamination that could compromise your API’s quality and safety.\u003C\u002Fp>\u003Cp>Your response is inadequate. You state that you reviewed the quality of the products manufactured in the impacted equipment since February 2024, but you do not describe how you conducted this review, nor the reason you limited your review to this timeframe. In addition, you do not adequately explain how you will prevent the failure to clean equipment after personnel enter inside it from recurring. Finally, you state that personnel entering inside equipment should “wear cloth shoe cover after removing shoe,” but failing to wear suitable clothing, including appropriate footwear, poses an unacceptable risk to the product.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\u003Cli>Your CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning for all products and equipment; and all other needed remediations.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Failure to test the identity of each batch of incoming production material.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your incoming raw material used to manufacture API intended for the U.S. market was not adequately tested. For example, you did not test the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used as a raw material in the production of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for identity.\u003C\u002Fp>\u003Cp>Your response is inadequate. You state that you “initiated the activity” to test \u003Cstrong>(b)(4)\u003C\u002Fstrong> for identity. However, you do not address whether all other raw materials are tested for identity or how you will prevent this deviation from recurring with new raw materials.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of raw materials, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable raw materials, containers, and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming batch of raw material for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each raw material batch for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificates of analysis (COAs) instead of testing each raw material batch for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming raw material batch.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all raw materials to evaluate the reliability of the COA from each raw material manufacturer. Include your standard operating procedure that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\u003Cp>FDA placed products offered for import into the United States from your firm on Import Alert 66-40 on January 2, 2025.\u003C\u002Fp>\u003Cp>Correct any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any deviations.\u003C\u002Fp>\u003Cp>Failure to address any deviations may also result in the FDA continuing to refuse admission of articles manufactured at Tyche Industries Ltd in Kakinada, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004790309 and ATTN: Russell Riley.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-41\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Sandeep Gokaraju\n\nRecipient Title\n\nOwner and Director\n\nTyche Industries Ltd\n\n6-223, Sarpavaram (V)\n\nKakinada 533005\n\nAndhra Pradesh\n\nIndia\n\nsandeepraju@tycheindustries.net\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-41\nFebruary 6, 2025\nDear Mr. Gokaraju:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Tyche Industries Ltd, FEI 3004790309, at 6-223, Sarpavaram (V), Kakinada, from August 12 to 16, 2024.\nThis warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your September 4, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific deviations including, but not limited to, the following.\n1. Failure to record all quality-related activities at the time they are performed.\nYour quality unit (QU) failed to ensure the integrity of CGMP records. For example, during the inspection, a member of your management stated that two of your operators admitted to falsifying temperature data for a drying oven that was not turned on during the manufacture of a (b)(4) batch, which later failed to meet the residual solvents specification. In addition, an Assistant Manager in Production, an Assistant Manager in Quality Assurance, and a Quality Control Manager admitted to participating in the preparation of a “backdated calculation sheet” that was given to our investigator.\nYour documentation practices were not indicative of a facility that is in compliance with CGMP.\nYour response is inadequate. You state that you plan to hire a consultant to identify data integrity gaps and prepare and implement an action plan by June 30, 2025, approximately ten months from the conclusion of the inspection, which documented serious questionable data integrity practices. In addition, you state that you removed some of the employees involved in these incidents from CGMP-related activities, but you do not explain what was done to prevent the other employees involved in these activities from further data integrity deviations. Finally, you do not fully evaluate the scope of data integrity lapses at your firm, including by interviewing current and former employees and comprehensively reviewing data records.\nSignificant findings in this letter indicate that your QU is not fully exercising its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: Q8(R2) Pharmaceutical Development at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload, Q9 Quality Risk Management at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload and Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\nIn your response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n2. Failure to clean equipment and utensils to prevent contamination or carry-over of a material that would alter the quality of the APIs beyond the official or other established specifications.\nFDA documented rust-like residues inside (b)(4) non-dedicated (b)(4) used in the production of (b)(4). In addition, FDA documented bare footprints inside another (b)(4) used in the production of (b)(4). Each (b)(4) was labeled that it had been cleaned and was ready for use.\nInadequately cleaned and maintained manufacturing equipment can lead to potential cross- contamination that could compromise your API’s quality and safety.\nYour response is inadequate. You state that you reviewed the quality of the products manufactured in the impacted equipment since February 2024, but you do not describe how you conducted this review, nor the reason you limited your review to this timeframe. In addition, you do not adequately explain how you will prevent the failure to clean equipment after personnel enter inside it from recurring. Finally, you state that personnel entering inside equipment should “wear cloth shoe cover after removing shoe,” but failing to wear suitable clothing, including appropriate footwear, poses an unacceptable risk to the product.\nIn your response to this letter, provide:\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\nYour CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning for all products and equipment; and all other needed remediations.\n3. Failure to test the identity of each batch of incoming production material.\nYour incoming raw material used to manufacture API intended for the U.S. market was not adequately tested. For example, you did not test the (b)(4) used as a raw material in the production of (b)(4) for identity.\nYour response is inadequate. You state that you “initiated the activity” to test (b)(4) for identity. However, you do not address whether all other raw materials are tested for identity or how you will prevent this deviation from recurring with new raw materials.\nIn your response to this letter, provide:\nA comprehensive, independent review of your material system to determine whether all suppliers of raw materials, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable raw materials, containers, and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming batch of raw material for use in manufacturing.\nA description of how you will test each raw material batch for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificates of analysis (COAs) instead of testing each raw material batch for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming raw material batch.\nA summary of results obtained from testing all raw materials to evaluate the reliability of the COA from each raw material manufacturer. Include your standard operating procedure that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\nData Integrity Remediation\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\nConclusion\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\nFDA placed products offered for import into the United States from your firm on Import Alert 66-40 on January 2, 2025.\nCorrect any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any deviations.\nFailure to address any deviations may also result in the FDA continuing to refuse admission of articles manufactured at Tyche Industries Ltd in Kakinada, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004790309 and ATTN: Russell Riley.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Tyche Industries Ltd","tyche-industries-ltd-693081-02062025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftyche-industries-ltd-693081-02062025","2026-10-26T08:10:16.529703+00:00","2025-02-18","693081","Drugs","Mr. Sandeep Gokaraju","2026-08-19T17:01:59.143+00:00","320-25-41","2025-02-06",{"id":143,"raw":144,"subject":149,"body_html":150,"body_text":151,"firm_name":152,"letter_id":153,"created_at":42,"fei_number":19,"letter_url":154,"updated_at":155,"action_type":22,"case_status":23,"posted_date":156,"marcs_cms_no":157,"product_type":137,"closeout_date":19,"issuing_office":158,"recipient_name":159,"body_fetched_at":160,"delivery_method":161,"recipient_title":19,"reference_number":19,"action_taken_date":162,"medical_device_id":19,"response_letter_date":19},1967,[145,146,147,148,149,13,13,13],"\u003Ctime datetime=\"2023-08-01T13:20:00Z\">08\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-18T04:00:00Z\">07\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Favlon-industries-inc-652903-07182023\">Avlon Industries, Inc.\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations III","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Next Day\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Ali N. Syed\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Co-President\u002FChairman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Avlon Industries, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1999 N. 15th Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Melrose Park\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60160\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 18, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nWL #652903\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Dr. Syed:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Avlon Industries, Inc., FEI 3007090726, at 1999 N. 15th Avenue, Melrose Park, from January 17 to 24, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your February 13, 2023 response and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to test your incoming components for identity prior to manufacturing your over-the-counter (OTC) drug products (e.g., active ingredients, glycerin, and water as a component). Additionally, you relied on certificates of analysis (COAs) from unqualified suppliers for specifications such as purity, strength, and quality. By not adequately analyzing your components for identity, purity, strength, and quality, you failed to ensure your incoming components meet appropriate specifications.\u003C\u002Fp>\n\n\u003Cp>Identity testing for each shipment of each lot of components used in drug product manufacturing is required, and you may only rely on COA for other component attributes by validating the suppliers’ test results at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>Glycerin and propylene glycol are ingredients used in some of your drug products, including Keracare® Dry &amp; Itchy Scalp Anti-Dandruff Moisturizing Conditioner and As I Am Dry &amp; Itchy Scalp Care Dandruff Conditioner, and are examples of components with higher risk of DEG or EG contamination compared to other drug components. The identity testing of glycerin and other high-risk components such as propylene glycol may include a limit test per the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for the levels of diethylene glycol (DEG) or ethylene glycol (EG). Because you did not perform the identity testing on each container on each shipment of each high-risk drug component lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of the high-risk components used in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>The use of glycerin or propylene glycol contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at risk for DEG or EG contamination, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Results of tests for DEG and EG in retain samples of all glycerin lots or any other high-risk components (such as propylene glycol) used to manufacture your drug products.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including but not limited to glycerin). Take prompt and appropriate actions to determine the safety of all lots of the ingredient(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures. (21 CFR 211.100(a) and 211.100(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Lack of Process Validation\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to provide data to demonstrate that you adequately validate your manufacturing processes used to manufacture your OTC drug products and demonstrate that your processes are reproducible and controlled to consistently yield drugs of uniform character and quality.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA's guidance for industry, \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Lack of Cleaning Validation\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to provide evidence that you performed cleaning validation for the equipment (e.g., mixing tanks, hoses, filling lines, and packaging lines) used to manufacture your OTC drug products. This is a repeat observation from the 2017 FDA inspection. Additionally, you lacked cleaning and usage logs for production tanks (i.e., kettles), or any holding tanks used in manufacturing your bulk drug products.\u003C\u002Fp>\n\n\u003Cp>You manufacture drug products using the same equipment that you use to manufacture nonpharmaceutical products such as cosmetics. Chemical and microbiological residues on equipment from previous manufacturing activities can adversely impact the purity, quality, and safety of drug products also manufactured on that equipment.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Water System\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm uses water as a component to manufacture your OTC drug products. You failed to provide documentation that you performed a qualification of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water system. You also failed to show that your water system is monitored adequately to ensure it consistently produces water that meets appropriate microbial limits. Routine monitoring of microbial counts and identity of contamination in the system is integral to ensuring oversight of ongoing state of control and suitability of water for use in manufacturing operations. These are repeat observations from the 2017 FDA inspection.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\n\t\u003Cli>A timeline for performing appropriate process performance qualification for each of your marketed drug products.\u003C\u002Fli>\n\t\u003Cli>Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\n\t\u003Cli>Provide a detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\n\t\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\n\t\u003Cli>A comprehensive remediation plan for the design, control, and maintenance of the water system, including a \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\u003C\u002Fli>\n\t\u003Cli>A procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity. (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your OTC drug products. FDA investigators observed multiple documents related to CGMP activities that had not been completed, such as:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>CGMP-related policies\u003C\u002Fli>\n\t\u003Cli>Standard operating procedures (SOPs)\u003C\u002Fli>\n\t\u003Cli>Validation plans\u003C\u002Fli>\n\t\u003Cli>Stability program\u003C\u002Fli>\n\t\u003Cli>Corrective actions and preventive actions (CAPA)\u003C\u002Fli>\n\t\u003Cli>Annual product review (APR)\u003C\u002Fli>\n\t\u003Cli>CGMP training\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003Cbr>\n\u003Cbr>\nIn response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing operations, to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices, to ensure you retain attributable, legible, complete, original, accurate, and contemporaneous records throughout your operation.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Russell K. Riley\u003Cbr>\nCompliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Case Number above (#652903). If you have questions regarding the contents of the letter, please contact Mr. Riley at (630) 277-1908.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Jeffrey D. Meng\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>_______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e. Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Next Day\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. Ali N. Syed\n\nRecipient Title\n\nCo-President\u002FChairman\n\nAvlon Industries, Inc.\n\n1999 N. 15th Avenue\n\nMelrose Park, IL 60160\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nJuly 18, 2023\n\nWARNING LETTER\n\nWL #652903\n\nDear Dr. Syed:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Avlon Industries, Inc., FEI 3007090726, at 1999 N. 15th Avenue, Melrose Park, from January 17 to 24, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your February 13, 2023 response and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYour firm failed to test your incoming components for identity prior to manufacturing your over-the-counter (OTC) drug products (e.g., active ingredients, glycerin, and water as a component). Additionally, you relied on certificates of analysis (COAs) from unqualified suppliers for specifications such as purity, strength, and quality. By not adequately analyzing your components for identity, purity, strength, and quality, you failed to ensure your incoming components meet appropriate specifications.\n\nIdentity testing for each shipment of each lot of components used in drug product manufacturing is required, and you may only rely on COA for other component attributes by validating the suppliers’ test results at appropriate intervals.\n\nGlycerin and propylene glycol are ingredients used in some of your drug products, including Keracare® Dry & Itchy Scalp Anti-Dandruff Moisturizing Conditioner and As I Am Dry & Itchy Scalp Care Dandruff Conditioner, and are examples of components with higher risk of DEG or EG contamination compared to other drug components. The identity testing of glycerin and other high-risk components such as propylene glycol may include a limit test per the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for the levels of diethylene glycol (DEG) or ethylene glycol (EG). Because you did not perform the identity testing on each container on each shipment of each high-risk drug component lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of the high-risk components used in the manufacture of your drug products.\n\nThe use of glycerin or propylene glycol contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at risk for DEG or EG contamination, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn response to this letter, provide:\n\nResults of tests for DEG and EG in retain samples of all glycerin lots or any other high-risk components (such as propylene glycol) used to manufacture your drug products.\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including but not limited to glycerin). Take prompt and appropriate actions to determine the safety of all lots of the ingredient(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures. (21 CFR 211.100(a) and 211.100(b)).\n\nLack of Process Validation\n\nYou failed to provide data to demonstrate that you adequately validate your manufacturing processes used to manufacture your OTC drug products and demonstrate that your processes are reproducible and controlled to consistently yield drugs of uniform character and quality.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nLack of Cleaning Validation\n\nYou failed to provide evidence that you performed cleaning validation for the equipment (e.g., mixing tanks, hoses, filling lines, and packaging lines) used to manufacture your OTC drug products. This is a repeat observation from the 2017 FDA inspection. Additionally, you lacked cleaning and usage logs for production tanks (i.e., kettles), or any holding tanks used in manufacturing your bulk drug products.\n\nYou manufacture drug products using the same equipment that you use to manufacture nonpharmaceutical products such as cosmetics. Chemical and microbiological residues on equipment from previous manufacturing activities can adversely impact the purity, quality, and safety of drug products also manufactured on that equipment.\n\nInadequate Water System\n\nYour firm uses water as a component to manufacture your OTC drug products. You failed to provide documentation that you performed a qualification of your (b)(4) Water system. You also failed to show that your water system is monitored adequately to ensure it consistently produces water that meets appropriate microbial limits. Routine monitoring of microbial counts and identity of contamination in the system is integral to ensuring oversight of ongoing state of control and suitability of water for use in manufacturing operations. These are repeat observations from the 2017 FDA inspection.\n\n(b)(4) water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\n\nIn response to this letter, provide:\n\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\nA timeline for performing appropriate process performance qualification for each of your marketed drug products.\n\nInclude your process performance protocol(s), and written procedures for qualification of equipment and facilities.\n\nProvide a detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Maximum hold times before cleaning\n\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\nA comprehensive remediation plan for the design, control, and maintenance of the water system, including a (b)(4) water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\n\nA procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\n\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) Water system. Ensure that the total count limits for your (b)(4) water are appropriately stringent in view of the intended use of each of the products produced by your firm.\n\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets (b)(4) Water, USP monograph specifications and appropriate microbial limits.\n\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity. (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your OTC drug products. FDA investigators observed multiple documents related to CGMP activities that had not been completed, such as:\n\nCGMP-related policies\n\nStandard operating procedures (SOPs)\n\nValidation plans\n\nStability program\n\nCorrective actions and preventive actions (CAPA)\n\nAnnual product review (APR)\n\nCGMP training\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nA complete assessment of documentation systems used throughout your manufacturing operations, to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices, to ensure you retain attributable, legible, complete, original, accurate, and contemporaneous records throughout your operation.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Russell K. Riley\n\nCompliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations III\n\nYour written notification should refer to the Warning Letter Case Number above (#652903). If you have questions regarding the contents of the letter, please contact Mr. Riley at (630) 277-1908.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Jeffrey D. Meng\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations III\n\n_______________________\n\n1 i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Avlon Industries, Inc.","avlon-industries-inc-652903-07182023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Favlon-industries-inc-652903-07182023","2026-10-26T08:07:59.687766+00:00","2023-08-01","652903","Division of Pharmaceutical Quality Operations III","Dr. Ali N. Syed","2026-08-20T00:49:39.857+00:00","UPS Next Day","2023-07-18",{"id":164,"raw":165,"subject":149,"body_html":169,"body_text":170,"firm_name":171,"letter_id":172,"created_at":42,"fei_number":19,"letter_url":173,"updated_at":174,"action_type":22,"case_status":23,"posted_date":175,"marcs_cms_no":176,"product_type":137,"closeout_date":19,"issuing_office":158,"recipient_name":177,"body_fetched_at":178,"delivery_method":161,"recipient_title":19,"reference_number":19,"action_taken_date":179,"medical_device_id":19,"response_letter_date":19},1549,[166,167,168,148,149,13,13,13],"\u003Ctime datetime=\"2024-03-26T04:00:00Z\">03\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-02-22T05:00:00Z\">02\u002F22\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhigley-industries-inc-669170-02222024\">Higley Industries, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Next Day\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Lance R. Hummel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Higley Industries, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2330 Industrial Parkway SW\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dyersville\u003C\u002Fspan>, \u003Cspan>IA\u003C\u002Fspan> \u003Cspan>52040-8748\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 22, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\n\u003Cstrong>CASE# 669170\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Hummel:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Higley Industries, Inc., FEI 3002984417, at 2330 Industrial Parkway SW, Dyersville, IA 52040-8748, from September 19 to September 21, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your response and subsequent correspondence to our Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately test samples of your incoming components before using the components to manufacture your over-the-counter (OTC) drug products. You also relied on your suppliers’ certificate of analyses (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Ethanol\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately test your incoming ethanol, used as an active ingredient, for methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Glycerin\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately test your incoming components at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin you used in manufacturing your drug products to determine its appropriate identity. Identity testing for glycerin and certain other high-risk drug components include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Water\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm uses water from your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system as a component for manufacturing drug products. Your firm has not demonstrated that the water is suitable for use and meets the USP&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> water monograph.\u003C\u002Fp>\n\n\u003Cp>In your response, you commit to sampling and testing the identity and strength of raw materials as third-party results will be compared to the COA and water quality will be monitored and tested routinely. Your response is inadequate because you failed to specify how you will establish the reliability of your third party’s test results.\u003C\u002Fp>\n\n\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\n\t\u003Cli>The chemical quality control specifications you use to test each incoming lot (including high-risk drug components) to determine acceptability for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\u003C\u002Fli>\n\t\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\n\t\u003Cli>A commitment to provide DEG and EG test results, no later than \u003Cstrong>(b)(4)\u003C\u002Fstrong> calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>A procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately validate your processes and qualify the equipment used to manufacture your PSSI E-SAN Alcohol Antiseptic 80% Topical Solution Hand Sanitizer. During the inspection, you told the investigator that any filling line could be used to manufacture hand sanitizer. However, you were unable to provide documentation of process validation.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledged that you “failed to establish control procedures that monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of the in-process material and the drug product,” and commit to validating the manufacturing process and implement in-process equipment qualification procedures. Your response is inadequate because you did not provide sufficient detail or evidence to demonstrate implementation of adequate corrective actions.\u003C\u002Fp>\n\n\u003Cp>An adequate ongoing program for monitoring process control ensures stable manufacturing operations and consistent drug quality. See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\n\t\u003Cli>A timeline for performing appropriate process performance qualification (PPQ) for each of your marketed drug products.\u003C\u002Fli>\n\t\u003Cli>Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\n\t\u003Cli>Provide a detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Adequate evaluation of product quality before batch release (e.g., Quality Manual designated the Shipping Clerk with final authority to review and approve drug product for release) (21 CFR 211.22(a)).\u003C\u002Fli>\n\t\u003Cli>Adequate batch production and control records that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).\u003C\u002Fli>\n\t\u003Cli>Adequate written procedures for test methods and sampling plans (21 CFR 211.160(b)).\u003C\u002Fli>\n\t\u003Cli>Establishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\u003C\u002Fli>\n\t\u003Cli>Performance of periodic (i.e., at least \u003Cstrong>(b)(4)\u003C\u002Fstrong>) product reviews (21 CFR 211.180(e)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response, you acknowledge that your QU failed to review and approve drug product production and control records for compliance with all procedures before batch release and distribution, and that you updated your QU procedures. Your response is inadequate because you did not provide sufficient detail or evidence to demonstrate implementation of adequate corrective actions.\u003C\u002Fp>\n\n\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective actions and preventive actions (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should refer to Case # 669170. Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Brian Nicholson, Compliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Compliance Officer, Brian Nicholson at (630) 207-9337.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jeffrey D. Meng\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>cc: Project Clean\u003Cbr>\nNormand Frechette, President and CEO\u003Cbr>\n12 James St N, Suite 202\u003Cbr>\nHamilton, ON L8R 2J9,\u003Cbr>\nCanada\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Next Day\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Lance R. Hummel\n\nRecipient Title\n\nPresident\n\nHigley Industries, Inc.\n\n2330 Industrial Parkway SW\n\nDyersville, IA 52040-8748\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nFebruary 22, 2024\n\nWARNING LETTER\n\nCASE# 669170\n\nDear Mr. Hummel:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Higley Industries, Inc., FEI 3002984417, at 2330 Industrial Parkway SW, Dyersville, IA 52040-8748, from September 19 to September 21, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe acknowledge receipt of your response and subsequent correspondence to our Form FDA 483.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYou failed to adequately test samples of your incoming components before using the components to manufacture your over-the-counter (OTC) drug products. You also relied on your suppliers’ certificate of analyses (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\n\nEthanol\n\nYou failed to adequately test your incoming ethanol, used as an active ingredient, for methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\n\nGlycerin\n\nYou failed to adequately test your incoming components at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin you used in manufacturing your drug products to determine its appropriate identity. Identity testing for glycerin and certain other high-risk drug components include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nWater\n\nYour firm uses water from your (b)(4) water system as a component for manufacturing drug products. Your firm has not demonstrated that the water is suitable for use and meets the USP (b)(4) water monograph.\n\nIn your response, you commit to sampling and testing the identity and strength of raw materials as third-party results will be compared to the COA and water quality will be monitored and tested routinely. Your response is inadequate because you failed to specify how you will establish the reliability of your third party’s test results.\n\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\n\nIn response to this letter, provide:\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\n\nThe chemical quality control specifications you use to test each incoming lot (including high-risk drug components) to determine acceptability for use in manufacturing.\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\n\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\nA commitment to provide DEG and EG test results, no later than (b)(4) calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nA procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\n\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) water system. Ensure that the total count limits for your (b)(4) water are appropriately stringent in view of the intended use of each of the products produced by your firm.\n\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets (b)(4) Water, USP monograph specifications and appropriate microbial limits.\n\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYou failed to adequately validate your processes and qualify the equipment used to manufacture your PSSI E-SAN Alcohol Antiseptic 80% Topical Solution Hand Sanitizer. During the inspection, you told the investigator that any filling line could be used to manufacture hand sanitizer. However, you were unable to provide documentation of process validation.\n\nIn your response, you acknowledged that you “failed to establish control procedures that monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of the in-process material and the drug product,” and commit to validating the manufacturing process and implement in-process equipment qualification procedures. Your response is inadequate because you did not provide sufficient detail or evidence to demonstrate implementation of adequate corrective actions.\n\nAn adequate ongoing program for monitoring process control ensures stable manufacturing operations and consistent drug quality. See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nIn response to this letter, provide:\n\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\nA timeline for performing appropriate process performance qualification (PPQ) for each of your marketed drug products.\n\nInclude your process performance protocol(s), and written procedures for qualification of equipment and facilities.\n\nProvide a detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\n\nAdequate evaluation of product quality before batch release (e.g., Quality Manual designated the Shipping Clerk with final authority to review and approve drug product for release) (21 CFR 211.22(a)).\n\nAdequate batch production and control records that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).\n\nAdequate written procedures for test methods and sampling plans (21 CFR 211.160(b)).\n\nEstablishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\n\nPerformance of periodic (i.e., at least (b)(4)) product reviews (21 CFR 211.180(e)).\n\nIn your response, you acknowledge that your QU failed to review and approve drug product production and control records for compliance with all procedures before batch release and distribution, and that you updated your QU procedures. Your response is inadequate because you did not provide sufficient detail or evidence to demonstrate implementation of adequate corrective actions.\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective actions and preventive actions (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive (b)(4)1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour response should refer to Case # 669170. Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Brian Nicholson, Compliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations Division III\n\nIf you have questions regarding the contents of this letter, please contact Compliance Officer, Brian Nicholson at (630) 207-9337.\n\nSincerely,\n\n\u002FS\u002F\n\nJeffrey D. Meng\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations Division III\n\ncc: Project Clean\n\nNormand Frechette, President and CEO\n\n12 James St N, Suite 202\n\nHamilton, ON L8R 2J9,\n\nCanada\n\n_____________________\n\n1 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Higley Industries, Inc.","higley-industries-inc-669170-02222024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhigley-industries-inc-669170-02222024","2026-10-26T08:08:55.005222+00:00","2024-03-26","669170","Mr. Lance R. Hummel","2026-08-20T00:13:10.084+00:00","2024-02-22",{"id":181,"raw":182,"subject":149,"body_html":187,"body_text":188,"firm_name":189,"letter_id":190,"created_at":42,"fei_number":19,"letter_url":191,"updated_at":192,"action_type":22,"case_status":23,"posted_date":162,"marcs_cms_no":193,"product_type":137,"closeout_date":19,"issuing_office":158,"recipient_name":194,"body_fetched_at":195,"delivery_method":161,"recipient_title":19,"reference_number":19,"action_taken_date":196,"medical_device_id":19,"response_letter_date":19},1989,[183,184,185,186,149,13,13,13],"\u003Ctime datetime=\"2023-07-18T13:20:00Z\">07\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-28T04:00:00Z\">06\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffuller-industries-inc-654425-06282023\">Fuller Industries Inc.\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations III ","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Next Day\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Craig Rudin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Fuller Industries Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1 Fuller Way\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Great Bend\u003C\u002Fspan>, \u003Cspan>KS\u003C\u002Fspan> \u003Cspan>67530\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations III \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 28, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nWL 654425\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Rudin:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Fuller Industries Inc., FEI 1922337, at 1 Fuller Way, Great Bend, from February 15 to 17, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drug products do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your March 2, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\nYour firm manufactures over-the-counter (OTC) topical drug products, such as antibacterial hand soaps and hand sanitizers.1 Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Assay testing for the active ingredient, chloroxylenol (PCMX) used in your antibacterial foam hand soap is performed, appropriately documented, and reviewed by your QU for every batch prior to batch release and distribution (21 CFR 211.165(a), 211.160(a), 211.22(c)).\u003C\u002Fli>\n\t\u003Cli>Appropriate procedures for investigating out-of-specification (OOS) and other non-conformances, and accordingly to conduct thorough investigations, including for the pH of your antibacterial foam hand soap. In addition, some PCMX assay results appeared OOS and were not investigated (21 CFR 211.192).\u003C\u002Fli>\n\t\u003Cli>Establishment of an adequate ongoing stability program (21 CFR 211.166(a)).\u003C\u002Fli>\n\t\u003Cli>Establishment of appropriate identification of samples listed on test records. (21 CFR 211.194(a)).\u003C\u002Fli>\n\t\u003Cli>Performance of annual product reviews (21 CFR 211.180(e)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document \u003Cem>Quality Systems approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Stability-indicating methods\u003Cbr>\n&nbsp; &nbsp; o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>\n&nbsp; &nbsp; o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>\n&nbsp; &nbsp; o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>\n&nbsp; &nbsp; o All procedures that describe these and other elements of your remediated stability program\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to perform adequate identity testing of each component lot used in the manufacture of your OTC drug products. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>For example, you failed to adequately test the propylene glycol used in the manufacture of your antibacterial foam hand soap. The identity testing of propylene glycol includes a limit test per the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for the levels of diethylene glycol (DEG) or ethylene glycol (EG). Because you did not adequately perform the identity testing on each shipment of each propylene glycol lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of propylene glycol used in the manufacture of drug products.\u003Cbr>\n\u003Cbr>\nSee FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem>, to help you meet the CGMP requirements when manufacturing drugs containing ingredients at risk for DEG or EG contamination, at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Ftesting-glycerin-propylene-glycol-maltitol-solution-hydrogenated-starch-hydrolysate-sorbitol.\u003C\u002Fp>\n\n\u003Cp>You also failed to appropriately test your incoming ethanol active pharmaceutical ingredient (API) for impurities such as methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document\u003Cem> Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19)\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fpolicy-testing-alcohol-ethanol-and-isopropyl-alcohol-methanol-including-during-public-health.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\n\t\u003Cli>Results of tests for DEG and EG in retain samples of all propylene glycol lots, and tests results for methanol in retain samples of all ethanol lots, used to manufacture your drug products.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that contain propylene glycol and or ethanol that are within expiry in the U.S. market. Take prompt CAPA and detail your future actions to ensure appropriate selection of your suppliers, ongoing scrutiny of their supply chain, and appropriate incoming lot controls.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not ensure that your test methods were appropriate for their intended use. You lacked a scientifically sound procedure for testing your antibacterial foam hand soap drug product for total solids. Your analysts provided our investigator with a non-validated test method from an internet search, which did not appear to be specific for your drug products, nor appropriate for any drug product. Laboratories must establish and validate (or verify, where appropriate) analytical methods and procedures to ensure the robustness and consistency of testing.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\t\u003Cli>A list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Quality Unit Authority\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter indicate that your QU is not able to fully exercise its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit2 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Brian Nicholson, Compliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>Refer to the Unique Identification Number (Case# 654425), and FEI 1922337 when replying. If you have questions regarding the contents of this letter, please contact Mr. Brian Nicholson by phone at (630) 207-3007\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jeffrey Meng\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cstrong>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fstrong> on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (\u003Cstrong>86 Fed Reg at 56960\u003C\u002Fstrong>). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Because Fuller Industries Inc.’s hand sanitizer products are not consistent with the formulations described in these guidances, they do not fall within any temporary Agency policy not to take action against firm’s manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Next Day\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Craig Rudin\n\nRecipient Title\n\nCEO\n\nFuller Industries Inc.\n\n1 Fuller Way\n\nGreat Bend, KS 67530\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nJune 28, 2023\n\nWARNING LETTER\n\nWL 654425\n\nDear Mr. Rudin:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Fuller Industries Inc., FEI 1922337, at 1 Fuller Way, Great Bend, from February 15 to 17, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding drug products do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your March 2, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour firm manufactures over-the-counter (OTC) topical drug products, such as antibacterial hand soaps and hand sanitizers.1 Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\n\nAssay testing for the active ingredient, chloroxylenol (PCMX) used in your antibacterial foam hand soap is performed, appropriately documented, and reviewed by your QU for every batch prior to batch release and distribution (21 CFR 211.165(a), 211.160(a), 211.22(c)).\n\nAppropriate procedures for investigating out-of-specification (OOS) and other non-conformances, and accordingly to conduct thorough investigations, including for the pH of your antibacterial foam hand soap. In addition, some PCMX assay results appeared OOS and were not investigated (21 CFR 211.192).\n\nEstablishment of an adequate ongoing stability program (21 CFR 211.166(a)).\n\nEstablishment of appropriate identification of samples listed on test records. (21 CFR 211.194(a)).\n\nPerformance of annual product reviews (21 CFR 211.180(e)).\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability-indicating methods\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\n\no Detailed definition of the specific attributes to be tested at each station (timepoint)\n\no All procedures that describe these and other elements of your remediated stability program\n\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYou failed to perform adequate identity testing of each component lot used in the manufacture of your OTC drug products. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\n\nFor example, you failed to adequately test the propylene glycol used in the manufacture of your antibacterial foam hand soap. The identity testing of propylene glycol includes a limit test per the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for the levels of diethylene glycol (DEG) or ethylene glycol (EG). Because you did not adequately perform the identity testing on each shipment of each propylene glycol lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of propylene glycol used in the manufacture of drug products.\n\nSee FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol, to help you meet the CGMP requirements when manufacturing drugs containing ingredients at risk for DEG or EG contamination, at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Ftesting-glycerin-propylene-glycol-maltitol-solution-hydrogenated-starch-hydrolysate-sorbitol.\n\nYou also failed to appropriately test your incoming ethanol active pharmaceutical ingredient (API) for impurities such as methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide.\n\nSee FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19) to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fpolicy-testing-alcohol-ethanol-and-isopropyl-alcohol-methanol-including-during-public-health.\n\nIn response to this letter, provide:\n\nA comprehensive review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\nResults of tests for DEG and EG in retain samples of all propylene glycol lots, and tests results for methanol in retain samples of all ethanol lots, used to manufacture your drug products.\n\nA full risk assessment for drug products that contain propylene glycol and or ethanol that are within expiry in the U.S. market. Take prompt CAPA and detail your future actions to ensure appropriate selection of your suppliers, ongoing scrutiny of their supply chain, and appropriate incoming lot controls.\n\n3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\nYou did not ensure that your test methods were appropriate for their intended use. You lacked a scientifically sound procedure for testing your antibacterial foam hand soap drug product for total solids. Your analysts provided our investigator with a non-validated test method from an internet search, which did not appear to be specific for your drug products, nor appropriate for any drug product. Laboratories must establish and validate (or verify, where appropriate) analytical methods and procedures to ensure the robustness and consistency of testing.\n\nIn response to this letter, provide:\n\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nA list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\n\nQuality Unit Authority\n\nSignificant findings in this letter indicate that your QU is not able to fully exercise its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit2 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Brian Nicholson, Compliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations III\n\nRefer to the Unique Identification Number (Case# 654425), and FEI 1922337 when replying. If you have questions regarding the contents of this letter, please contact Mr. Brian Nicholson by phone at (630) 207-3007\n\nSincerely,\n\n\u002FS\u002F\n\nJeffrey Meng\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations III\n\n_________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Because Fuller Industries Inc.’s hand sanitizer products are not consistent with the formulations described in these guidances, they do not fall within any temporary Agency policy not to take action against firm’s manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n2 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Fuller Industries Inc.","fuller-industries-inc-654425-06282023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffuller-industries-inc-654425-06282023","2026-10-26T08:08:44.021073+00:00","654425","Mr. Craig Rudin","2026-08-20T00:52:36.614+00:00","2023-06-28",{"id":198,"raw":199,"subject":149,"body_html":203,"body_text":204,"firm_name":205,"letter_id":206,"created_at":18,"fei_number":19,"letter_url":207,"updated_at":208,"action_type":22,"case_status":23,"posted_date":209,"marcs_cms_no":210,"product_type":137,"closeout_date":19,"issuing_office":126,"recipient_name":211,"body_fetched_at":212,"delivery_method":213,"recipient_title":19,"reference_number":214,"action_taken_date":215,"medical_device_id":19,"response_letter_date":19},137,[200,201,202,126,149,13,13,13],"\u003Ctime datetime=\"2026-06-02T04:00:00Z\">06\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-28T04:00:00Z\">05\u002F28\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedline-inc-724347-05282026\">Medline Inc\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-82\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. James Boyle \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Medline Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3 Lakes Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Northfield\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60093\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-82\u003C\u002Fp>\u003Cp>May 28, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Boyle:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Medline Industries, LP, FEI 3003983334, at 1710 South Lakeside Drive, Waukegan, Illinois, from October 6 to 14, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your November 4, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> is also specifically labeled for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your manufacturing process includes \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and sealed into the respective finished drug product packaging.\u003C\u002Fp>\u003Cp>Between June 2, 2023 and August 27, 2025, your firm isolated objectionable microorganisms (e.g., \u003Cem>Bacillus cereus (B. cereus)\u003C\u002Fem>) from \u003Cstrong>(b)(4)\u003C\u002Fstrong> finished drug product samples on approximately nine occasions. You also recovered \u003Cem>B. cereus\u003C\u002Fem> in at least five samples taken from your manufacturing environment since January 2025. You failed to adequately investigate and implement corrective actions and preventive actions (CAPA) to determine root causes and prevent recurrence of these repeated contamination incidents. This issue was cited on the previous Form FDA 483 issued to your firm in January 2025 and subsequently discussed during the most recent regulatory meeting held with your firm in May 2025.\u003C\u002Fp>\u003Cp>Further, your investigations into contaminated drug product samples identified \u003Cem>B. cereus\u003C\u002Fem> in your manufacturing environment, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> at your facility, as well as on \u003Cstrong>(b)(4)\u003C\u002Fstrong> at another Medline facility (Hartland), which supplies your bulk \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Multiple investigations since 2023 have determined that \u003Cstrong>(b)(4)\u003C\u002Fstrong> are a root cause for the \u003Cem>B. cereus\u003C\u002Fem> contamination in your drug products.\u003C\u002Fp>\u003Cp>In your response, you acknowledge “that the FDA inspection identified gaps in adherence to the corrective actions and cGMP’s.” You suspended \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product production in October 2025. You also committed to verifying corrective actions and their effectiveness before notifying FDA of your intent to resume production. You also refer to several previously initiated CAPA in response to the microbiological contamination incidents, including management controls, deviation investigations, and facility and process improvements.\u003C\u002Fp>\u003Cp>Your response is inadequate because you have not explained why your previous CAPA attempts were not successful. Additionally, your investigations failed to adequately identify the root causes of contamination in your drug products and the source of \u003Cem>B. cereus\u003C\u002Fem> contamination within your manufacturing environment, including from your bulk \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response also states that you have not released any drug product batches with failing microbiological test results. However, finished product microbiological testing cannot be relied upon as sole justification to release drug product batches, as contamination is not uniformly distributed in a system and any given sample may not be representative of the type or level of contamination.\u003C\u002Fp>\u003Cp>Inadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that may pose a patient safety hazard. Your manufacturing processes and cleanroom environments are inadequately designed to assure an ongoing state of control. It is your responsibility to design and control operations to prevent contamination of your \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Microbial contamination of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drugs used for \u003Cstrong>(b)(4)\u003C\u002Fstrong> poses a significant risk of patient harm and adverse \u003Cstrong>(b)(4)\u003C\u002Fstrong> outcomes, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Thus, the use of manufacturing processes that render these drugs sterile is an integral part of ensuring safety of patients due to the vulnerability to \u003Cstrong>(b)(4)\u003C\u002Fstrong> infection.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent risk assessment of all contamination hazards with respect to your manufacturing processes, equipment, and facilities, including, but not limited to:\u003Cbr>o All human interactions within the cleanroom areas (e.g., risk reduction or elimination of manual interventions wherever possible)\u003Cbr>o Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\u003Cbr>o Air quality in the cleanroom area and surrounding room including, but not limited to, air volume and flow\u003Cbr>o Facility layout\u003Cbr>o Personnel Flow and Material Flow (movement throughout all rooms used to conduct and support manufacturing operations, and all material transfers).\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe comprehensive improvements to be made to manufacturing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient manufacturing operations. Include comprehensive changes to the design of both your manufacturing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\u003C\u002Fli>\u003Cli>An independent assessment by qualified experts of the various sterilization options that can be implemented for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> products. Based on this assessment, provide a comprehensive plan and timeline to transition your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drugs to terminal sterilization, or implement aseptic processing of these products. In the event that you are considering continued use of processes that are inherently vulnerable to contamination issues, provide a detailed rationale justifying your scientific and public health basis, with particular attention to the unacceptable patient risks posed by your historical contamination problems.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>An independent, retrospective review of all critical investigations (including each in-process, release, and stability test specification failure) for the last three years as of the date of this letter. Evaluate the adequacy of each investigation, including, but not limited to:\u003Cbr>o Determine whether a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history) was conducted\u003Cbr>o Assess sufficiency of review of past related investigations (deviations, failures) to identify potential associated causes or linkages\u003Cbr>o Evaluate adequacy of scope, rigor, staff competencies, scientific\u002Fanalytical foundation, and CAPA\u003Cbr>o Summary of findings of the assessment for each of the above elements.\u003C\u002Fli>\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program whenever needed, ensures final quality unit decisions, and is fully supported by executive management.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups; failed to perform operations within specifically defined areas of adequate size; and failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.42(c) and 21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm isolated significant opportunistic pathogens, including \u003Cem>B. cereus\u003C\u002Fem>, in numerous samples of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> finished drug products and the manufacturing environment.\u003C\u002Fp>\u003Cp>You failed to establish appropriate design and control of your manufacturing operation to assure your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products \u003Cstrong>(b)(4)\u003C\u002Fstrong> were suitable for their intended use. This issue was cited on the previous Form FDA 483 issued to your firm in January 2025 and subsequently discussed during the most recent regulatory meeting conducted with your firm in May 2025.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Deficient Manufacturing Practices\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your manufacturing operators engaged in practices that pose significant contamination risk to \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products, such as using cleaning tools without suitable gloves and then repeatedly touching the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Investigations by your firm identified objectionable aseptic behaviors as a root cause of \u003Cem>B. cereus\u003C\u002Fem> contamination in your products.\u003C\u002Fp>\u003Cp>Your manufacturing process involves \u003Cstrong>(b)(4)\u003C\u002Fstrong> manipulations including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug components, equipment, and scrap materials. These activities are particularly worrisome if your operations are not conducted and maintained in an aseptic manner (e.g., donning sterile gowning), or the drug product is not sterilized in its final packaging. It is essential that manufacturers establish robust manufacturing design and process control measures to prevent contamination throughout production operations. In addition to appropriate manufacturing facilities and processes, raw materials (e.g., components, containers, and closures) must also be suitable for their intended use.\u003C\u002Fp>\u003Cp>In your response, you acknowledge “that the FDA inspection identified gaps in adherence to the corrective actions and cGMP’s.” As noted above, you also state that you suspended production of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product in October 2025. You commit to verifying your corrective actions as effective prior to notifying FDA of your intent to resume production. You also refer to several previously initiated CAPA in response to the microbiological contamination incidents, including corrections to cleanroom behaviors, cleaning and maintenance procedures, contamination controls, and retraining.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Inadequate Cleaning and Disinfection\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your manufacturing operators have routinely deviated from procedures for cleaning and disinfection of your drug manufacturing equipment, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. For example, numerous deviation investigations have noted operator failures to properly clean and disinfect your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and valves with \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Notably, \u003Cstrong>(b)(4)\u003C\u002Fstrong> have been identified as a root cause for \u003Cem>B. cereus\u003C\u002Fem> contamination in your drug products since 2023.\u003C\u002Fp>\u003Cp>Establishing and following appropriate procedures for cleaning, disinfection, and whenever appropriate, sterilization is essential to ensuring product safety.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your proposed corrections are insufficient to remediate flawed facility and process design. You have unsuccessfully attempted similar corrective actions in the past.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>An independent assessment and associated CAPA plan, following a thorough retrospective review of your cleaning, disinfection, and sterilization program, that includes appropriate remediations and timelines for completion. Provide a detailed summary of vulnerabilities in your processes and procedures relating to equipment cleaning, disinfection, and sterilization. Describe improvements to your program, including enhancements to cleaning and disinfection types and practices; addition or improvement of sterilization methods; and all other needed remediations.\u003C\u002Fli>\u003Cli>Your systematic plan to assure adherence to appropriate aseptic practices, cleanroom behavior, and written procedures, including but not limited to a thorough independent assessment of the following with accompanying CAPA:\u003Cbr>o Suitability of actual practices based on a retrospective review and prospective observation of cleanroom operations\u003Cbr>o Deficiencies in production management oversight, and identification of specific improvements to ensure effective and routine supervisory oversight for all batches\u003Cbr>o Frequency and depth of quality unit oversight (e.g., audit, ad hoc, daily interactions) of aseptic behaviors and its support operations\u003Cbr>o Adequacy of written procedures\u003Cbr>o The risk assessment should also evaluate how poor aseptic technique and cleanroom behavior may have affected the quality of your drugs.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Repeat Observations at Multiple Sites\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA cited similar CGMP observations at other facilities in your company’s network, including inadequate investigations into OOS results at your Hartland, Wisconsin site. These repeated failures at multiple sites demonstrate that management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>Your executive management remains responsible for fully resolving all deficiencies and ensuring ongoing CGMP compliance. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\u003C\u002Fp>\u003Cp>For more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document \u003Cem>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003983334 and ATTN: Philip Kreiter.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Return Receipt Requested\n\nReference #:\n\n320-26-82\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. James Boyle\n\nRecipient Title\n\nChief Executive Officer\n\nMedline Inc\n\n3 Lakes Drive\n\nNorthfield, IL 60093\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-82\nMay 28, 2026\nDear Mr. Boyle:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Medline Industries, LP, FEI 3003983334, at 1710 South Lakeside Drive, Waukegan, Illinois, from October 6 to 14, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your November 4, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm manufactures (b)(4) for (b)(4) is also specifically labeled for (b)(4). Your manufacturing process includes (b)(4), and sealed into the respective finished drug product packaging.\nBetween June 2, 2023 and August 27, 2025, your firm isolated objectionable microorganisms (e.g., Bacillus cereus (B. cereus)) from (b)(4) finished drug product samples on approximately nine occasions. You also recovered B. cereus in at least five samples taken from your manufacturing environment since January 2025. You failed to adequately investigate and implement corrective actions and preventive actions (CAPA) to determine root causes and prevent recurrence of these repeated contamination incidents. This issue was cited on the previous Form FDA 483 issued to your firm in January 2025 and subsequently discussed during the most recent regulatory meeting held with your firm in May 2025.\nFurther, your investigations into contaminated drug product samples identified B. cereus in your manufacturing environment, including (b)(4) at your facility, as well as on (b)(4) at another Medline facility (Hartland), which supplies your bulk (b)(4). Multiple investigations since 2023 have determined that (b)(4) are a root cause for the B. cereus contamination in your drug products.\nIn your response, you acknowledge “that the FDA inspection identified gaps in adherence to the corrective actions and cGMP’s.” You suspended (b)(4) drug product production in October 2025. You also committed to verifying corrective actions and their effectiveness before notifying FDA of your intent to resume production. You also refer to several previously initiated CAPA in response to the microbiological contamination incidents, including management controls, deviation investigations, and facility and process improvements.\nYour response is inadequate because you have not explained why your previous CAPA attempts were not successful. Additionally, your investigations failed to adequately identify the root causes of contamination in your drug products and the source of B. cereus contamination within your manufacturing environment, including from your bulk (b)(4). Your response also states that you have not released any drug product batches with failing microbiological test results. However, finished product microbiological testing cannot be relied upon as sole justification to release drug product batches, as contamination is not uniformly distributed in a system and any given sample may not be representative of the type or level of contamination.\nInadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that may pose a patient safety hazard. Your manufacturing processes and cleanroom environments are inadequately designed to assure an ongoing state of control. It is your responsibility to design and control operations to prevent contamination of your (b)(4).\nMicrobial contamination of (b)(4) drugs used for (b)(4) poses a significant risk of patient harm and adverse (b)(4) outcomes, (b)(4). Thus, the use of manufacturing processes that render these drugs sterile is an integral part of ensuring safety of patients due to the vulnerability to (b)(4) infection.\nIn response to this letter, provide:\nA comprehensive, independent risk assessment of all contamination hazards with respect to your manufacturing processes, equipment, and facilities, including, but not limited to:\no All human interactions within the cleanroom areas (e.g., risk reduction or elimination of manual interventions wherever possible)\no Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\no Air quality in the cleanroom area and surrounding room including, but not limited to, air volume and flow\no Facility layout\no Personnel Flow and Material Flow (movement throughout all rooms used to conduct and support manufacturing operations, and all material transfers).\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe comprehensive improvements to be made to manufacturing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient manufacturing operations. Include comprehensive changes to the design of both your manufacturing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\nAn independent assessment by qualified experts of the various sterilization options that can be implemented for your (b)(4) products. Based on this assessment, provide a comprehensive plan and timeline to transition your (b)(4) drugs to terminal sterilization, or implement aseptic processing of these products. In the event that you are considering continued use of processes that are inherently vulnerable to contamination issues, provide a detailed rationale justifying your scientific and public health basis, with particular attention to the unacceptable patient risks posed by your historical contamination problems.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nAn independent, retrospective review of all critical investigations (including each in-process, release, and stability test specification failure) for the last three years as of the date of this letter. Evaluate the adequacy of each investigation, including, but not limited to:\no Determine whether a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history) was conducted\no Assess sufficiency of review of past related investigations (deviations, failures) to identify potential associated causes or linkages\no Evaluate adequacy of scope, rigor, staff competencies, scientific\u002Fanalytical foundation, and CAPA\no Summary of findings of the assessment for each of the above elements.\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program whenever needed, ensures final quality unit decisions, and is fully supported by executive management.\n2. Your firm failed to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups; failed to perform operations within specifically defined areas of adequate size; and failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.42(c) and 21 CFR 211.67(b)).\nYour firm isolated significant opportunistic pathogens, including B. cereus, in numerous samples of your (b)(4) finished drug products and the manufacturing environment.\nYou failed to establish appropriate design and control of your manufacturing operation to assure your (b)(4) drug products (b)(4) were suitable for their intended use. This issue was cited on the previous Form FDA 483 issued to your firm in January 2025 and subsequently discussed during the most recent regulatory meeting conducted with your firm in May 2025.\nDeficient Manufacturing Practices\nYour manufacturing operators engaged in practices that pose significant contamination risk to (b)(4) drug products, such as using cleaning tools without suitable gloves and then repeatedly touching the (b)(4). Investigations by your firm identified objectionable aseptic behaviors as a root cause of B. cereus contamination in your products.\nYour manufacturing process involves (b)(4) manipulations including the (b)(4) drug components, equipment, and scrap materials. These activities are particularly worrisome if your operations are not conducted and maintained in an aseptic manner (e.g., donning sterile gowning), or the drug product is not sterilized in its final packaging. It is essential that manufacturers establish robust manufacturing design and process control measures to prevent contamination throughout production operations. In addition to appropriate manufacturing facilities and processes, raw materials (e.g., components, containers, and closures) must also be suitable for their intended use.\nIn your response, you acknowledge “that the FDA inspection identified gaps in adherence to the corrective actions and cGMP’s.” As noted above, you also state that you suspended production of the (b)(4) drug product in October 2025. You commit to verifying your corrective actions as effective prior to notifying FDA of your intent to resume production. You also refer to several previously initiated CAPA in response to the microbiological contamination incidents, including corrections to cleanroom behaviors, cleaning and maintenance procedures, contamination controls, and retraining.\nInadequate Cleaning and Disinfection\nYour manufacturing operators have routinely deviated from procedures for cleaning and disinfection of your drug manufacturing equipment, including (b)(4) for (b)(4) drug products. For example, numerous deviation investigations have noted operator failures to properly clean and disinfect your (b)(4) and valves with (b)(4). Notably, (b)(4) have been identified as a root cause for B. cereus contamination in your drug products since 2023.\nEstablishing and following appropriate procedures for cleaning, disinfection, and whenever appropriate, sterilization is essential to ensuring product safety.\nYour response is inadequate. Your proposed corrections are insufficient to remediate flawed facility and process design. You have unsuccessfully attempted similar corrective actions in the past.\nIn response to this letter, provide:\nAn independent assessment and associated CAPA plan, following a thorough retrospective review of your cleaning, disinfection, and sterilization program, that includes appropriate remediations and timelines for completion. Provide a detailed summary of vulnerabilities in your processes and procedures relating to equipment cleaning, disinfection, and sterilization. Describe improvements to your program, including enhancements to cleaning and disinfection types and practices; addition or improvement of sterilization methods; and all other needed remediations.\nYour systematic plan to assure adherence to appropriate aseptic practices, cleanroom behavior, and written procedures, including but not limited to a thorough independent assessment of the following with accompanying CAPA:\no Suitability of actual practices based on a retrospective review and prospective observation of cleanroom operations\no Deficiencies in production management oversight, and identification of specific improvements to ensure effective and routine supervisory oversight for all batches\no Frequency and depth of quality unit oversight (e.g., audit, ad hoc, daily interactions) of aseptic behaviors and its support operations\no Adequacy of written procedures\no The risk assessment should also evaluate how poor aseptic technique and cleanroom behavior may have affected the quality of your drugs.\nRepeat Observations at Multiple Sites\nFDA cited similar CGMP observations at other facilities in your company’s network, including inadequate investigations into OOS results at your Hartland, Wisconsin site. These repeated failures at multiple sites demonstrate that management oversight and control over the manufacture of drugs is inadequate.\nYour executive management remains responsible for fully resolving all deficiencies and ensuring ongoing CGMP compliance. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\nFor more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003983334 and ATTN: Philip Kreiter.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Medline Inc","medline-inc-724347-05282026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedline-inc-724347-05282026","2026-10-26T08:09:23.37043+00:00","2026-06-02","724347","Mr. James Boyle","2026-08-19T04:39:18.457+00:00","Via Electronic Mail - Return Receipt Requested","320-26-82","2026-05-28",{"id":217,"raw":218,"subject":12,"body_html":222,"body_text":223,"firm_name":224,"letter_id":225,"created_at":42,"fei_number":19,"letter_url":226,"updated_at":227,"action_type":22,"case_status":23,"posted_date":228,"marcs_cms_no":229,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":230,"body_fetched_at":231,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":232,"medical_device_id":19,"response_letter_date":19},1505,[219,220,221,11,12,13,13,13],"\u003Ctime datetime=\"2024-04-30T13:20:00Z\">04\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-19T04:00:00Z\">09\u002F19\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpt-sankei-medical-industries-665754-09192023\">P.T. Sankei Medical Industries\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Yoshinori Koyama\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>P.T. Sankei Medical Industries\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>JL. Mordern Inustri III, Komp. BPSP A-12\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kawasan Industri Modern Cikande\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Serang\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Banten\u003C\u002Fspan> \u003Cspan>42186\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Indonesia\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 19, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Koyama:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Banten, Indonesia on May 8, 2023, through May 11, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>We received a response from you dated May 24, 2023, concerning our investigator(s)’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Unapproved Device Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>You currently have a clearance for the Aneroid Sphygmomanometers\u002FMercurial Sphygmomanometers under K942543. Our inspection revealed that your firm made changes to the materials of the cleared device without submission of a new 510(k). As explained in Section C.4.1 of the guidance document \u003Cu>Deciding When to Submit a 510(k) for a Change to an Existing Device\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fu> (“510(k) Modifications Guidance”) in general, changing the material may affect the biocompatibility of the device. Thus, these changes could significantly affect the safety or effectiveness of the device and required the submission of a new 510(k). 21 CFR 807.81(a)(3)(i). Your response did not address this violation.\u003C\u002Fp>\n\n\u003Cp>Accordingly, the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency.21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Quality System Regulations (QSR) Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that this device is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1.&nbsp; Failure to establish and maintain adequate procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).For example:\u003C\u002Fp>\n\n\u003Cp>Your Design and Development Procedure (Document #PS-17, Revision 00) is a process for the development of new systems and products as well as existing ones in order to meet external and internal customer requirements. This procedure was not applied to the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device since design controls have not been conducted for the single use sphygmomanometer.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The response included an updated version of the Design and Development Procedure; however, the supporting documents provided were not in English and could not be reviewed. In response to this Warning Letter, you should provide evidence of the corrective actions. For example, this should include documentation and confirmation the design controls were applied to the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device. Please provide all responses and documentation in English or with English translations.\u003C\u002Fp>\n\n\u003Cp>2.&nbsp; Failure to adequately establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21CFR 820.50. For example:\u003C\u002Fp>\n\n\u003Cp>Your Purchasing Procedure (Document #PS-04, Revision 03) requires samples made by potential suppliers to be checked by Quality Assurance (QA). However, this procedure does not detail the specified requirements, including quality requirements, that potential suppliers and contractors must meet. Further, you do not have an agreement with suppliers and\u002For contractors that requires notification of changes in the product to ensure changes do not affect quality of finished devices.\u003Cbr>\n\u003Cbr>\nWe reviewed your firm’s response and concluded that it is not adequate. The response included an updated version of the Purchasing Procedure; however, the new version did not address the deficiencies noted above. Further, the supporting documents provided were not in English and could not be reviewed.\u003C\u002Fp>\n\n\u003Cp>In response to this Warning Letter, you should provide updated documentation including, but not limited to, an updated Purchasing procedure and documentation of agreements with suppliers and\u002For contractors. You should also provide evidence of the corrective actions. Please provide all responses and documentation in English or with English translations.\u003C\u002Fp>\n\n\u003Cp>3.&nbsp; Failure to adequately ensure Design History Records (DHRs) for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the DMR and the requirements of this part, as required by 21 CFR 820.184 For example:\u003C\u002Fp>\n\n\u003Cp>Your Quality Plan for \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Document #QP-DC-0001A, Revision 2) details the required manufacturing steps for the following procedures\u002Fwork instructions including, but not limited to: \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your firm’s DHRs did not include or refer to the location of the primary identification label and labeling used for each production case. Further, the procedure does not require manufacturing step documentation. Specifically, it does not require technician(s) to document manufacturing\u002Foperation steps in the production record nor utilize any forms to document the manufacturing\u002Foperation steps.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The response included an updated version of the Quality Plan; however, the new version did not address the deficiencies noted above. Further, the supporting documents provided were not in English and could not be reviewed. In response to this Warning Letter, you should provide updated documentation including, but not limited to, updated DHRs for the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device, updates to the DHR procedures and forms. You should also provide evidence of your firm’s corrective actions. Please provide all responses and documentation in English or with English translations.\u003C\u002Fp>\n\n\u003Cp>4.&nbsp; Failure to adequately maintain device master records (DMR's), as required by 21 CFR820.181 For example:\u003C\u002Fp>\n\n\u003Cp>Your Device Master File Procedure (Document #PS-33, Revision 0) requires each DMR to include a Quality Assurance and Reference Documentation section. However, the DMR for the Sphygmomanometer is missing documentation of the Quality Assurance and Reference Document sections. Further, the DMR for the Sphygmomanometer Product has not been reviewed and approved through document controls.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The documents were not provided in English and could not be reviewed. In response to this Warning Letter, you should provide evidence of the corrective actions. For example, this should include updated documentation including, but not limited to, updated DMRs for the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device. Please provide all responses and documentation in English or with English translations.\u003C\u002Fp>\n\n\u003Cp>5.&nbsp; Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198. For example:\u003C\u002Fp>\n\n\u003Cp>Your Customer Claim Handling procedure (Document #PS-15, Revision 01) requires “preventive and corrective actions for the problem must be completed”. However, the procedure does not require review and evaluation of all complaints to determine whether an investigation is necessary, nor does it require the manufacturer to maintain a record that includes the reason no investigation was needed and the name of the individual responsible for the decision not to investigate. Further, it fails to require events meeting the definition of a complaint under 820.3(b) be evaluated to determine whether the complaint represents an event for which reporting is required under 21 CFR part 803, Medical Device Reporting. The procedure states that the Corrective and Preventive Action form is used to document customer claims. The form does not record manufacturer review and evaluation of complaint to determine whether an investigation is necessary.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The response included an updated version of the Customer Claim Handling procedure; however, the new version does not address the deficiencies noted above. Further, the supporting documents provided were not in English and could not be reviewed. In response to this Warning Letter, you should provide evidence of updated documentation including, but not limited to, updates to the Customer Claim Handling procedures and forms as well as evidence of the corrective actions. Please provide all responses and documentation in English or with English translations.\u003C\u002Fp>\n\n\u003Cp>6.&nbsp; Failure to establish procedures for quality audits and conduct such audits to assure that the quality system complies with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR 820.22. For example:\u003C\u002Fp>\n\n\u003Cp>Your Audit Management System Procedure (Document #PS-02, Revision 03) requires audits to be conducted \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, there is no documented evidence to show that the scheduled items\u002Fprocesses of the quality system were audited for 2022 or 2023.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The response included a version of the Audit Management System Procedure; however, the supporting documents provided were not in English and could not be reviewed. In response to this Warning Letter, you should provide an updated documentation including, but not limited to, documentation confirming audit performance and updated Audit Process.\u003C\u002Fp>\n\n\u003Cp>Please provide all responses and documentation in English or with English translations.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Medical Device Reporting (MDR) Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, after reviewing your firm’s MDR procedure titled “Medical Device Adverse Events and Advisory Notice Report”, Document #PS-25, Revision 00, dated 3\u002F2\u002F2023, the following deficiencies were noted:\u003C\u002Fp>\n\n\u003Cp>1.&nbsp; The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, there are no definitions of what your firm will consider to be a reportable event under 21 CFR Part 803. The exclusion of definitions from 21 CFR 803.3 for the terms “become aware,” “caused or contributed,” “malfunction,” “MDR reportable event,” and “serious injury,” and the definition for the term “reasonably suggests,” found in 803.20(c)(1) may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\n\n\u003Cp>2.&nbsp; Your firm’s procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example:\u003Cbr>\n&nbsp; a.&nbsp; There are no instructions for investigating each MDR reportable event and evaluating the cause of the event.\u003Cbr>\n&nbsp; b.&nbsp; The procedure, as written, does not specify who makes the decision for reporting events to FDA.\u003Cbr>\n&nbsp; c.&nbsp; There are no instructions for how the firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\u003C\u002Fp>\n\n\u003Cp>3.&nbsp; Your firm’s procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3).Specifically, the following are not addressed:\u003Cbr>\n&nbsp; a.&nbsp; Instructions for how to obtain and complete the FDA 3500A form.\u003Cbr>\n&nbsp; b.&nbsp; The circumstances under which the firm must submit initial 30 days, supplemental or follow-up, 5-day report and the requirements for such reports.\u003Cbr>\n&nbsp; c.&nbsp; A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21CFR 803.12(a).\u003Cbr>\n&nbsp; d.&nbsp; How your firm will submit all information reasonably known to it for each event. Specifically, which sections of the 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow up within your firm.\u003C\u002Fp>\n\n\u003Cp>4.&nbsp; Your firm’s procedure does not describe how your firm will address documentation and record-keeping requirements, as required by 21 CFR 803.17(b), including:\u003Cbr>\n&nbsp; a.&nbsp; Documentation of medical device reports submitted to FDA.\u003Cbr>\n&nbsp; b.&nbsp; Information that was evaluated to determine if an event related to death, serious injury, or malfunction was reportable.\u003Cbr>\n\u003Cbr>\nWe reviewed your firm’s response and concluded that it is not adequate. Your response included a revised MDR procedure titled “Medical Device Adverse Events and Advisory Notice Report”, Document #PS-25, Revision 01, dated 5\u002F15\u002F2023. However, the revision did not address the deficiencies noted above.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your product is not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. \u003Cstrong>Refer to CMS case # 665754 when replying.\u003C\u002Fstrong> If you have any questions about the contents of this letter, please contact: Stephen Browning at (240) 402-5241 or Stephen.browning@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility.\u003C\u002Fp>\n\n\u003Cp>It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the product into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Bram Zuckerman, M.D.\u003Cbr>\nDirector\u003Cbr>\nOHT 2: Office of Cardiovascular Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nAmy Orrell\u003Cbr>\nUS Agent\u003C\u002Fp>\n\n\u003Cp>Mazza Healthcare, LLC\u003Cbr>\n2101 Waukegan Rd.\u003Cbr>\nSuite 208\u003Cbr>\nBannockburn, IL US 60015\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nYoshinori Koyama\n\nRecipient Title\n\nPresident Director\n\nP.T. Sankei Medical Industries\n\nJL. Mordern Inustri III, Komp. BPSP A-12\n\nKawasan Industri Modern Cikande\n\nSerang\n\nBanten 42186\n\nIndonesia\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nSeptember 19, 2023\n\nDear Mr. Koyama:\n\nDuring an inspection of your firm located in Banten, Indonesia on May 8, 2023, through May 11, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nWe received a response from you dated May 24, 2023, concerning our investigator(s)’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\n\nUnapproved Device Violations\n\nYou currently have a clearance for the Aneroid Sphygmomanometers\u002FMercurial Sphygmomanometers under K942543. Our inspection revealed that your firm made changes to the materials of the cleared device without submission of a new 510(k). As explained in Section C.4.1 of the guidance document Deciding When to Submit a 510(k) for a Change to an Existing Device1 (“510(k) Modifications Guidance”) in general, changing the material may affect the biocompatibility of the device. Thus, these changes could significantly affect the safety or effectiveness of the device and required the submission of a new 510(k). 21 CFR 807.81(a)(3)(i). Your response did not address this violation.\n\nAccordingly, the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency.21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nQuality System Regulations (QSR) Violations\n\nThis inspection also revealed that this device is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nThese violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain adequate procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).For example:\n\nYour Design and Development Procedure (Document #PS-17, Revision 00) is a process for the development of new systems and products as well as existing ones in order to meet external and internal customer requirements. This procedure was not applied to the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device since design controls have not been conducted for the single use sphygmomanometer.\n\nWe reviewed your firm’s response and concluded that it is not adequate. The response included an updated version of the Design and Development Procedure; however, the supporting documents provided were not in English and could not be reviewed. In response to this Warning Letter, you should provide evidence of the corrective actions. For example, this should include documentation and confirmation the design controls were applied to the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device. Please provide all responses and documentation in English or with English translations.\n\n2. Failure to adequately establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21CFR 820.50. For example:\n\nYour Purchasing Procedure (Document #PS-04, Revision 03) requires samples made by potential suppliers to be checked by Quality Assurance (QA). However, this procedure does not detail the specified requirements, including quality requirements, that potential suppliers and contractors must meet. Further, you do not have an agreement with suppliers and\u002For contractors that requires notification of changes in the product to ensure changes do not affect quality of finished devices.\n\nWe reviewed your firm’s response and concluded that it is not adequate. The response included an updated version of the Purchasing Procedure; however, the new version did not address the deficiencies noted above. Further, the supporting documents provided were not in English and could not be reviewed.\n\nIn response to this Warning Letter, you should provide updated documentation including, but not limited to, an updated Purchasing procedure and documentation of agreements with suppliers and\u002For contractors. You should also provide evidence of the corrective actions. Please provide all responses and documentation in English or with English translations.\n\n3. Failure to adequately ensure Design History Records (DHRs) for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the DMR and the requirements of this part, as required by 21 CFR 820.184 For example:\n\nYour Quality Plan for (b)(4) (Document #QP-DC-0001A, Revision 2) details the required manufacturing steps for the following procedures\u002Fwork instructions including, but not limited to: (b)(4), and (b)(4). However, your firm’s DHRs did not include or refer to the location of the primary identification label and labeling used for each production case. Further, the procedure does not require manufacturing step documentation. Specifically, it does not require technician(s) to document manufacturing\u002Foperation steps in the production record nor utilize any forms to document the manufacturing\u002Foperation steps.\n\nWe reviewed your firm’s response and concluded that it is not adequate. The response included an updated version of the Quality Plan; however, the new version did not address the deficiencies noted above. Further, the supporting documents provided were not in English and could not be reviewed. In response to this Warning Letter, you should provide updated documentation including, but not limited to, updated DHRs for the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device, updates to the DHR procedures and forms. You should also provide evidence of your firm’s corrective actions. Please provide all responses and documentation in English or with English translations.\n\n4. Failure to adequately maintain device master records (DMR's), as required by 21 CFR820.181 For example:\n\nYour Device Master File Procedure (Document #PS-33, Revision 0) requires each DMR to include a Quality Assurance and Reference Documentation section. However, the DMR for the Sphygmomanometer is missing documentation of the Quality Assurance and Reference Document sections. Further, the DMR for the Sphygmomanometer Product has not been reviewed and approved through document controls.\n\nWe reviewed your firm’s response and concluded that it is not adequate. The documents were not provided in English and could not be reviewed. In response to this Warning Letter, you should provide evidence of the corrective actions. For example, this should include updated documentation including, but not limited to, updated DMRs for the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device. Please provide all responses and documentation in English or with English translations.\n\n5. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198. For example:\n\nYour Customer Claim Handling procedure (Document #PS-15, Revision 01) requires “preventive and corrective actions for the problem must be completed”. However, the procedure does not require review and evaluation of all complaints to determine whether an investigation is necessary, nor does it require the manufacturer to maintain a record that includes the reason no investigation was needed and the name of the individual responsible for the decision not to investigate. Further, it fails to require events meeting the definition of a complaint under 820.3(b) be evaluated to determine whether the complaint represents an event for which reporting is required under 21 CFR part 803, Medical Device Reporting. The procedure states that the Corrective and Preventive Action form is used to document customer claims. The form does not record manufacturer review and evaluation of complaint to determine whether an investigation is necessary.\n\nWe reviewed your firm’s response and concluded that it is not adequate. The response included an updated version of the Customer Claim Handling procedure; however, the new version does not address the deficiencies noted above. Further, the supporting documents provided were not in English and could not be reviewed. In response to this Warning Letter, you should provide evidence of updated documentation including, but not limited to, updates to the Customer Claim Handling procedures and forms as well as evidence of the corrective actions. Please provide all responses and documentation in English or with English translations.\n\n6. Failure to establish procedures for quality audits and conduct such audits to assure that the quality system complies with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR 820.22. For example:\n\nYour Audit Management System Procedure (Document #PS-02, Revision 03) requires audits to be conducted (b)(4); however, there is no documented evidence to show that the scheduled items\u002Fprocesses of the quality system were audited for 2022 or 2023.\n\nWe reviewed your firm’s response and concluded that it is not adequate. The response included a version of the Audit Management System Procedure; however, the supporting documents provided were not in English and could not be reviewed. In response to this Warning Letter, you should provide an updated documentation including, but not limited to, documentation confirming audit performance and updated Audit Process.\n\nPlease provide all responses and documentation in English or with English translations.\n\nMedical Device Reporting (MDR) Violations\n\nOur inspection also revealed that your firm’s Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\nFailure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, after reviewing your firm’s MDR procedure titled “Medical Device Adverse Events and Advisory Notice Report”, Document #PS-25, Revision 00, dated 3\u002F2\u002F2023, the following deficiencies were noted:\n\n1. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, there are no definitions of what your firm will consider to be a reportable event under 21 CFR Part 803. The exclusion of definitions from 21 CFR 803.3 for the terms “become aware,” “caused or contributed,” “malfunction,” “MDR reportable event,” and “serious injury,” and the definition for the term “reasonably suggests,” found in 803.20(c)(1) may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n\n2. Your firm’s procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example:\n\na. There are no instructions for investigating each MDR reportable event and evaluating the cause of the event.\n\nb. The procedure, as written, does not specify who makes the decision for reporting events to FDA.\n\nc. There are no instructions for how the firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\n\n3. Your firm’s procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3).Specifically, the following are not addressed:\n\na. Instructions for how to obtain and complete the FDA 3500A form.\n\nb. The circumstances under which the firm must submit initial 30 days, supplemental or follow-up, 5-day report and the requirements for such reports.\n\nc. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21CFR 803.12(a).\n\nd. How your firm will submit all information reasonably known to it for each event. Specifically, which sections of the 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow up within your firm.\n\n4. Your firm’s procedure does not describe how your firm will address documentation and record-keeping requirements, as required by 21 CFR 803.17(b), including:\n\na. Documentation of medical device reports submitted to FDA.\n\nb. Information that was evaluated to determine if an event related to death, serious injury, or malfunction was reportable.\n\nWe reviewed your firm’s response and concluded that it is not adequate. Your response included a revised MDR procedure titled “Medical Device Adverse Events and Advisory Notice Report”, Document #PS-25, Revision 01, dated 5\u002F15\u002F2023. However, the revision did not address the deficiencies noted above.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your product is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case # 665754 when replying. If you have any questions about the contents of this letter, please contact: Stephen Browning at (240) 402-5241 or Stephen.browning@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility.\n\nIt is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the product into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBram Zuckerman, M.D.\n\nDirector\n\nOHT 2: Office of Cardiovascular Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nAmy Orrell\n\nUS Agent\n\nMazza Healthcare, LLC\n\n2101 Waukegan Rd.\n\nSuite 208\n\nBannockburn, IL US 60015","P.T. Sankei Medical Industries","pt-sankei-medical-industries-665754-09192023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpt-sankei-medical-industries-665754-09192023","2026-10-26T08:09:45.256579+00:00","2024-04-30","665754","Yoshinori Koyama","2026-08-20T00:09:33.322+00:00","2023-09-19",{"id":234,"raw":235,"subject":149,"body_html":240,"body_text":241,"firm_name":242,"letter_id":243,"created_at":244,"fei_number":19,"letter_url":245,"updated_at":246,"action_type":22,"case_status":23,"posted_date":247,"marcs_cms_no":248,"product_type":137,"closeout_date":19,"issuing_office":239,"recipient_name":249,"body_fetched_at":250,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":251,"medical_device_id":19,"response_letter_date":19},2715,[236,237,238,239,149,13,13,13],"\u003Ctime datetime=\"2022-04-26T13:20:00Z\">04\u002F26\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-04-14T04:00:00Z\">04\u002F14\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcetylite-industries-inc-622823-04142022\">Cetylite Industries, Inc.\u003C\u002Fa>","Division of Pharmaceutical Quality Operations I","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Gary L. Wachman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cetylite Industries, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9051 River Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pennsauken\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08110\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nWL# 622823\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 14, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Wachman:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Cetylite Industries Inc., FEI 2242327, at 9051 River Road, from September 20 to September 24, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your October 14, 2021, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent response. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufacture Cetacaine Mint Gel Topical Anesthetic, a United States Pharmacopeia (USP) article. You utilized a compendial method for the aerosol form instead of using the compendial method for Benzocaine, Butamben, and Tetracaine Hydrochloride Gel to analyze your drug product. You had not appropriately validated that the aerosol method was suitable for testing the gel form of this product. Your firm deviated from the (USP) for testing the potency of your finished aerosol, liquid, and gel topical anesthetic drug products from March 2019 onwards. Additionally, you failed to complete method validation studies for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” method \u003Cstrong>(b)(4)\u003C\u002Fstrong> you used for the release testing of your finished drug products. Therefore, you did not adequately demonstrate that your method is equivalent or better than the current USP compendial method.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you will use your \u003Cstrong>(b)(4)\u003C\u002Fstrong> method to perform the release testing going forward. However, you did not include the validation package in your response demonstrating your method was equal to or better than the USP method. Additionally, data provided in your response demonstrated differing results from your custom test methods (\u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>) for assay versus the USP compendial method for your gel product. We note that your label does not specify that your product does not meet USP specifications therefore the USP monograph for Benzocaine, Butamben, and Tetracaine Hydrochloride Gel is the regulatory test method for your gel drug product.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate, since you have not provided data to demonstrate the methods your firm uses for the determination are equivalent to or better than USP. Additionally, you did not provide a plan for addressing any product quality or patient safety risks should you determine that a batch failed its specification and was previously approved and released.\u003C\u002Fp>\n\n\u003Cp>In response to this letter provide:\u003C\u002Fp>\n\n\u003Cp>• Your commitment to using current USP compendial methods until alternative methods have been demonstrated to be equivalent or better than the USP methods.\u003Cbr>\n• A comprehensive study that determines whether your test methods for your drug products are equivalent to, or better than, the USP method, if you are not using current USP compendial methods. Include all findings and deviations encountered in assessing whether your alternative method is equivalent or superior to the USP compendial method. For FDA’s current thinking regarding analytical test method validation, see\u003Cem> Analytical Procedures and Methods Validation for Drugs and Biologics\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F87801\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F87801\u002Fdownload\u003C\u002Fa>.\u003Cbr>\n• Updated test results using a validated test method (e.g., USP method) of all reserve samples for all drugs released to the market within expiry to ensure that your drug products conform to appropriate standards of identity, strength, quality, and purity.\u003Cbr>\n• Your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including potential customer notifications, recalls, or market withdrawals.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to adequately investigate an out of specification (OOS) test result when you analyzed your gel product utilizing the unvalidated method. Your analysis revealed an OOS for tetracaine HCl for potency of 114.7% and 115.2% (\u003Cstrong>(b)(4)\u003C\u002Fstrong>). During your investigation you retested using the USP compendial method for Benzocaine, Butamben, and Tetracaine Hydrochloride Gel which also resulted in an OOS of 118.9% and 118.3% (\u003Cstrong>(b)(4)\u003C\u002Fstrong>). Drugs that fail compendial test methods are considered adulterated under 501(b) of the Act.\u003C\u002Fp>\n\n\u003Cp>Without adequate scientific justification you again retested the sample using two additional methods \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and obtained passing results. You then released the product without adequate justification to invalidate the OOS test results including an OOS test result using a compendial test method.\u003C\u002Fp>\n\n\u003Cp>In your response you stated that you believe that your OOS investigation was a thorough investigation that supported the quality unit’s decision to release the lot. Your response is inadequate, you repeatedly tested the sample until you achieved a passing result without establishing a scientifically sound justification for the repeated tests including an OOS when you used the compendial method. Well established procedures or protocols for retesting are a part of OOS investigations, however, the procedures must be based on scientifically sound principles and appropriately validated and verified methods.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for US products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>\n&nbsp; o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>\n&nbsp; o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003C\u002Fp>\n\n\u003Cp>• For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements. A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\u003Cbr>\n&nbsp; o Quality unit oversight of laboratory investigations\u003Cbr>\n&nbsp; o Identification of adverse laboratory control trends\u003Cbr>\n&nbsp; o Resolution of causes of laboratory variation\u003Cbr>\n&nbsp; o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>\n&nbsp; o Adequate scoping of each investigation and its CAPA\u003Cbr>\n&nbsp; o Revised OOS investigation procedures with these and other remediations\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility in connection with your product(s). You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to orapharm1_responses@fda.hhs.gov. Please identify your response with FEI 2242327 and refer to WL# 622823. If you have questions regarding the content of this letter, please contact us through ORAPHARM1_RESPONSES@fda.hhs.gov, and cc Compliance Officer Nancy Scheraga, at (Nancy.Scheraga@fda.hhs.gov).\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Craig Swanson\u003Cbr>\nActing Program Division Director\u002FDistrict Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations\u003Cbr>\nDivision I\u002FNew Jersey District\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Gary L. Wachman\n\nRecipient Title\n\nPresident\n\nCetylite Industries, Inc.\n\n9051 River Road\n\nPennsauken, NJ 08110\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWARNING LETTER\n\nWL# 622823\n\nApril 14, 2022\n\nDear Mr. Wachman:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Cetylite Industries Inc., FEI 2242327, at 9051 River Road, from September 20 to September 24, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your October 14, 2021, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent response. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\nYou manufacture Cetacaine Mint Gel Topical Anesthetic, a United States Pharmacopeia (USP) article. You utilized a compendial method for the aerosol form instead of using the compendial method for Benzocaine, Butamben, and Tetracaine Hydrochloride Gel to analyze your drug product. You had not appropriately validated that the aerosol method was suitable for testing the gel form of this product. Your firm deviated from the (USP) for testing the potency of your finished aerosol, liquid, and gel topical anesthetic drug products from March 2019 onwards. Additionally, you failed to complete method validation studies for the “(b)(4)” method (b)(4) you used for the release testing of your finished drug products. Therefore, you did not adequately demonstrate that your method is equivalent or better than the current USP compendial method.\n\nIn your response, you stated that you will use your (b)(4) method to perform the release testing going forward. However, you did not include the validation package in your response demonstrating your method was equal to or better than the USP method. Additionally, data provided in your response demonstrated differing results from your custom test methods ((b)(4), (b)(4)) for assay versus the USP compendial method for your gel product. We note that your label does not specify that your product does not meet USP specifications therefore the USP monograph for Benzocaine, Butamben, and Tetracaine Hydrochloride Gel is the regulatory test method for your gel drug product.\n\nYour response is inadequate, since you have not provided data to demonstrate the methods your firm uses for the determination are equivalent to or better than USP. Additionally, you did not provide a plan for addressing any product quality or patient safety risks should you determine that a batch failed its specification and was previously approved and released.\n\nIn response to this letter provide:\n\n• Your commitment to using current USP compendial methods until alternative methods have been demonstrated to be equivalent or better than the USP methods.\n\n• A comprehensive study that determines whether your test methods for your drug products are equivalent to, or better than, the USP method, if you are not using current USP compendial methods. Include all findings and deviations encountered in assessing whether your alternative method is equivalent or superior to the USP compendial method. For FDA’s current thinking regarding analytical test method validation, see Analytical Procedures and Methods Validation for Drugs and Biologics at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F87801\u002Fdownload.\n\n• Updated test results using a validated test method (e.g., USP method) of all reserve samples for all drugs released to the market within expiry to ensure that your drug products conform to appropriate standards of identity, strength, quality, and purity.\n\n• Your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including potential customer notifications, recalls, or market withdrawals.\n\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYour firm failed to adequately investigate an out of specification (OOS) test result when you analyzed your gel product utilizing the unvalidated method. Your analysis revealed an OOS for tetracaine HCl for potency of 114.7% and 115.2% ((b)(4)). During your investigation you retested using the USP compendial method for Benzocaine, Butamben, and Tetracaine Hydrochloride Gel which also resulted in an OOS of 118.9% and 118.3% ((b)(4)). Drugs that fail compendial test methods are considered adulterated under 501(b) of the Act.\n\nWithout adequate scientific justification you again retested the sample using two additional methods (b)(4) and (b)(4) and obtained passing results. You then released the product without adequate justification to invalidate the OOS test results including an OOS test result using a compendial test method.\n\nIn your response you stated that you believe that your OOS investigation was a thorough investigation that supported the quality unit’s decision to release the lot. Your response is inadequate, you repeatedly tested the sample until you achieved a passing result without establishing a scientifically sound justification for the repeated tests including an OOS when you used the compendial method. Well established procedures or protocols for retesting are a part of OOS investigations, however, the procedures must be based on scientifically sound principles and appropriately validated and verified methods.\n\nIn response to this letter, provide:\n\n• A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for US products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\n\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\n\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\n\n• For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements. A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\n\no Quality unit oversight of laboratory investigations\n\no Identification of adverse laboratory control trends\n\no Resolution of causes of laboratory variation\n\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\n\no Adequate scoping of each investigation and its CAPA\n\no Revised OOS investigation procedures with these and other remediations\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility in connection with your product(s). You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to orapharm1_responses@fda.hhs.gov. Please identify your response with FEI 2242327 and refer to WL# 622823. If you have questions regarding the content of this letter, please contact us through ORAPHARM1_RESPONSES@fda.hhs.gov, and cc Compliance Officer Nancy Scheraga, at (Nancy.Scheraga@fda.hhs.gov).\n\nSincerely,\n\n\u002FS\u002F\n\nCraig Swanson\n\nActing Program Division Director\u002FDistrict Director\n\nOffice of Pharmaceutical Quality Operations\n\nDivision I\u002FNew Jersey District","Cetylite Industries, Inc.","cetylite-industries-inc-622823-04142022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcetylite-industries-inc-622823-04142022","2026-10-26T08:08:13.43372+00:00","2022-04-26","622823","Mr. Gary L. Wachman","2026-08-20T01:58:19.202+00:00","2022-04-14",{"id":253,"raw":254,"subject":80,"body_html":259,"body_text":260,"firm_name":261,"letter_id":262,"created_at":244,"fei_number":19,"letter_url":263,"updated_at":264,"action_type":22,"case_status":111,"posted_date":265,"marcs_cms_no":266,"product_type":90,"closeout_date":267,"issuing_office":79,"recipient_name":268,"body_fetched_at":269,"delivery_method":93,"recipient_title":19,"reference_number":19,"action_taken_date":270,"medical_device_id":19,"response_letter_date":19},2782,[255,256,257,79,80,13,258,13],"\u003Ctime datetime=\"2022-04-05T13:20:00Z\">04\u002F05\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-12-10T05:00:00Z\">12\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fturncoat-industries-inc-623002-12102021\">Turncoat Industries, Inc.\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fturncoat-industries-inc-623002-12012023\">\u003Ctime datetime=\"2024-09-18T04:00:00Z\">09\u002F18\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Khaled Aboabdo\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Turncoat Industries, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9380 7th Street Unit D\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Rancho Cucamonga\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91730\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:cal@shopjohnnyapple.com\"> cal@shopjohnnyapple.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:turncoatlabs@gmail.com\"> turncoatlabs@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 10, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Khaled Aboabdo:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fshopjohnnyapple.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fshopjohnnyapple.com revealed that you manufacture and offer for sale or distribution to customers in the United States the following-liquid products without a marketing authorization order including: Johnny Be Fresh Cowabunga and Johnny Be Fresh Surf’s Up.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with 15 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0001199 on September 07, 2020. However, FDA issued a negative action for STN PM0001199 in the form of a Marketing Denial Order determination on September 15, 2021, which covers 43 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by STN PM0001199 that resulted in a denial determination, are adulterated and misbranded.\u003C\u002Fp>\n\n\u003Cp>All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2101698, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Turncoat Industries, Inc. Attn: Khaled Aboabdo\u003Cbr>\n1235 E Francis St\u003Cbr>\nOntario, CA 91761\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nKhaled Aboabdo\n\nTurncoat Industries, Inc.\n\n9380 7th Street Unit D\n\nRancho Cucamonga, CA 91730\n\nUnited States\n\ncal@shopjohnnyapple.com\n\nturncoatlabs@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nDecember 10, 2021\n\nWARNING LETTER\n\nDear Khaled Aboabdo:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fshopjohnnyapple.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fshopjohnnyapple.com revealed that you manufacture and offer for sale or distribution to customers in the United States the following-liquid products without a marketing authorization order including: Johnny Be Fresh Cowabunga and Johnny Be Fresh Surf’s Up.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with 15 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0001199 on September 07, 2020. However, FDA issued a negative action for STN PM0001199 in the form of a Marketing Denial Order determination on September 15, 2021, which covers 43 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by STN PM0001199 that resulted in a denial determination, are adulterated and misbranded.\n\nAll new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101698, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nTurncoat Industries, Inc. Attn: Khaled Aboabdo\n\n1235 E Francis St\n\nOntario, CA 91761\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nShopify, Inc\n\nabuse@shopify.com","Turncoat Industries, Inc.","turncoat-industries-inc-623002-12102021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fturncoat-industries-inc-623002-12102021","2026-10-26T08:10:15.983577+00:00","2022-04-05","623002","2024-09-18","Khaled Aboabdo","2026-08-20T02:03:26.42+00:00","2021-12-10",{"id":272,"raw":273,"subject":277,"body_html":278,"body_text":279,"firm_name":280,"letter_id":281,"created_at":18,"fei_number":19,"letter_url":282,"updated_at":283,"action_type":22,"case_status":23,"posted_date":284,"marcs_cms_no":285,"product_type":286,"closeout_date":19,"issuing_office":126,"recipient_name":287,"body_fetched_at":288,"delivery_method":289,"recipient_title":19,"reference_number":290,"action_taken_date":291,"medical_device_id":19,"response_letter_date":19},465,[274,275,276,126,277,13,13,13],"\u003Ctime datetime=\"2025-11-18T05:00:00Z\">11\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-27T04:00:00Z\">10\u002F27\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdermarite-industries-llc-710997-10272025\">DermaRite Industries, LLC\u003C\u002Fa>","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-09\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Fabian McCarthy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DermaRite Industries, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7777 West Side Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>North Bergen\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07047\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-09\u003C\u002Fp>\u003Cp>October 27, 2025\u003C\u002Fp>\u003Cp>Dear Mr. McCarthy:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, DermaRite Industries, LLC, FEI 1000526900, at 7777 West Side Avenue, North Bergen, from March 26 to April 8, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL, Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, DermaMed OINTMENT SKIN PROTECTANT, DermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE, and PeriGiene HEALTH CARE ANTISEPTIC are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). In addition, DermaMed OINTMENT SKIN PROTECTANT is misbranded under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1). Furthermore, DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL, Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, DermaMed OINTMENT SKIN PROTECTANT, DermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE, and PeriGiene HEALTH CARE ANTISEPTIC are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>We reviewed your April 28, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>CGMP Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures over-the-counter (OTC) topical drug products for skin and wound care. Your firm failed to adequately investigate several out-of-limit (OOL) and out-of-specification (OOS) laboratory results, as well as unexplained discrepancies. For example, you failed to identify the root cause for the following:\u003C\u002Fp>\u003Cul>\u003Cli>Concerning the initial failing test result for total aerobic microbial count (TAMC) of DermaKleen Lot 40375A, which showed too numerous to count, you failed to scientifically identify the root cause of the contamination. Instead of performing an investigation into the root cause of the failure, you sent a second sample to your third-party contract laboratory, obtained passing results, and subsequently released the drug product batch for distribution. This strategy of using repeated testing until a passing result is obtained, then disregarding the OOS results without scientific justification (“testing into compliance”) is unscientific and objectionable under CGMP.\u003C\u002Fli>\u003Cli>Concerning the initial OOS test result for the assay of the active ingredient chloroxylenol in DermaKleen Lot 9-40545, you failed to scientifically identify the root cause of the OOS. Instead of performing an investigation into the root cause of the failure, you sent a second sample to your contract laboratory. Despite this retest also producing failing results, your firm released the batch for distribution. It is noteworthy that the certificate of analysis did not reflect the actual results.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>You did not thoroughly investigate these unexplained discrepancies or identify failures of a drug product to meet any of its specifications. When an investigation was performed, it was inadequate because you failed to identify the root cause(s), to implement appropriate corrective action and preventive action (CAPA), and to expand the investigation to evaluate the impact on other batches or products.\u003C\u002Fp>\u003Cp>In your response, you indicated that you would perform a retrospective review of all OOS test results from the last two years and determine their impact on product on the market. Your response is inadequate. You did not commit to evaluating your process for investigating unexplained discrepancies or failures of batches to determine a root cause so that you could implement appropriate CAPA. Inadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that compromise the ability to manufacture safe and effective drug products.\u003C\u002Fp>\u003Cp>We acknowledge that you initiated a voluntary recall (https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fdermarite-industries-issues-voluntary-nationwide-recall-dermakleen-dermasarra-kleenfoam-and) on July 17, 2025, for products that initially failed for TAMC and those retains that failed for \u003Cem>Burkholderia cepacia\u003C\u002Fem>. On August 27, 2025, you expanded the voluntary recall to include all lots of all products that contain water (https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fdermarite-industries-expands-voluntary-nationwide-recall-due-potential-burkholderia-cepacia).\u003C\u002Fp>\u003Cp>Microbial contamination may not be a uniformly distributed contamination. A product sample may not be representative of the type or level of contamination within the batch. Further, testing final product for microbial contamination does not ensure that you have appropriate controls in place to ensure product quality. As a manufacturer, you have a responsibility to fully investigate unexplained discrepancies, deviations, and failures to assess their impact on product quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A retrospective, independent review of all invalidated OOS\u002FOOL (including in-process and release\u002Fstability testing) results for U.S. products currently in the U.S. market and within expiry as of the date of this letter, and a report summarizing the findings of the analysis, including the following for each OOS\u002FOOL:\u003Cbr>o Determine whether the scientific justification and evidence relating to the invalidated OOS\u002FOOL result conclusively or inconclusively demonstrate causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>o For all OOS\u002FOOL results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation and include any manufacturing operation improvements.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOS\u002FOOL result investigation systems. The CAPA should include but not be limited to the following:\u003Cbr>o Quality Unit (QU) oversight of laboratory investigations\u003Cbr>o Identification of adverse laboratory control trends\u003Cbr>o Resolution of laboratory variation causes\u003Cbr>o Initiation of thorough investigations of potential manufacturing causes (whenever a laboratory cause cannot be conclusively identified)\u003Cbr>o Adequate scoping of each investigation and its CAPA\u003Cbr>o Revised OOS\u002FOOL investigation procedures with these and other remediations\u003C\u002Fli>\u003Cli>The final investigation, including the root-cause determination, into the batches affected by the voluntary recall.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS\u002FOOL results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include but not be limited to significant improvements in investigation competencies, scope determination, root-cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure that all phases of the investigations are appropriately conducted.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to perform adequate identity testing on each shipment of each lot of incoming components (e.g., ethanol, glycerin) used in the manufacture of your OTC drug products. In addition, you relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of each of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing Ethyl Alcohol\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately test your incoming component ethyl alcohol (ethanol), at risk of methanol contamination, for identity before using it as an active pharmaceutical ingredient (API) in manufacturing your OTC topical drug products. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing Ingredients at Risk for Diethylene Glycol or Ethylene Glycol (DEG or EG) Contamination\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You also failed to adequately test your incoming components at high risk of DEG or EG contamination for identity before using them to manufacture your drug products. This includes but is not limited to testing of propylene glycol and glycerin to determine their appropriate identity, before their use in manufacturing your OTC drug products.\u003C\u002Fp>\u003Cp>Identity testing for propylene glycol, glycerin, and certain other high-risk drug components includes a limit test in the USP to ensure that the component meets the relevant safety limits for DEG or EG levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to ensure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you indicated that you tested all retains of glycerin and propylene glycol for hazardous impurities and will do so for ethanol. In addition, you stated that you have identified all lots of incoming Glycerin \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Propylene Glycol \u003Cstrong>(b)(4)\u003C\u002Fstrong> received from 2023 to present and used in the products manufactured during the same period. Your response is inadequate because you failed to identify and evaluate high-risk drug components that may have been received in 2022 and used in lots manufactured in 2023.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before their use in the manufacture of your drug products. You are responsible for sampling, testing, and examining drug components before use in production to ensure that acceptable quality parameters are met.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A commitment to perform reconciliation of retains tested versus all lots used in production. If retain samples are unavailable, a commitment to test finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products, and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm did not have an adequate stability program to demonstrate that the chemical and microbiological properties of your drug products met established specifications and that they remain acceptable throughout their labeled shelf-life. For example, you failed to place any OTC drug products on stability in 2023 or 2024.\u003C\u002Fp>\u003Cp>Additionally, stability that was conducted in 2022 identified multiple failures during multiple timepoints for chemical and microbiological properties. You lack sufficient data to support your \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiry.\u003C\u002Fp>\u003Cp>In your response, you indicate that you will work with a qualified laboratory to verify that the laboratory test methods are properly validated as stability-indicating methods, and that you will retest retain samples for the marketed product batches within expiry. Your response is inadequate because you failed to address product on the market that lack adequate data to support their shelf life.\u003C\u002Fp>\u003Cp>Without appropriate stability studies, you lack adequate scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system, before distribution is permitted\u003Cbr>o An ongoing program in which representative batches of each product are added each year to determine if the shelf-life claim remains valid\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability.\u003C\u002Fli>\u003Cli>Your action plan to address any product quality or patient safety risks for batches of finished product supported by failing 2022 stability batches that are in U.S. distribution, including potential customer notifications and recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your QU failed to perform adequate oversight for the manufacture and testing of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Performance of annual product reviews (21 CFR 211.180(e))\u003C\u002Fli>\u003Cli>Performance of adequate testing of component (e.g., water) (211.22(d))\u003C\u002Fli>\u003Cli>COA included all data derived from actual testing performed (211.194(a))\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you indicate that you have an SOP in place outlining the responsibilities of your QU and that retraining is occurring. Your response is inadequate because it does not include how you intend to structure the QU to ensure that assigned authorities and responsibilities support the production, quality, and management activities needed to produce quality products.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance with Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate procedures and practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003Cbr>o A description of how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control\u003C\u002Fli>\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL, Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, DermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE, PeriGiene HEALTH CARE ANTISEPTIC, and DermaMed OINTMENT SKIN PROTECTANT, are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from these products’ labeling, including the DermaRite website, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL\u003C\u002Fu>\u003Cbr>“Drug Facts . . . Purpose: Skin Protectant . . . Uses: Dries the oozing and weeping of poison: - Ivy – Oil – Sumac – Or other skin irritations” [from the product label]\u003Cbr>“Also contains menthol to help soothe minor skin irritation and dry\u002Fmanage weeping skin.” [from the DermaRite website https:\u002F\u002Fdermarite.com\u002Fproduct\u002Fdermaseptin-ointment\u002F]\u003C\u002Fp>\u003Cp>\u003Cu>Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT\u003C\u002Fu>\u003Cbr>“Drug Facts . . . Purpose: Skin Protectant . . . Uses: - Helps relieve and prevent rashes and irritation due to wetness from incontinence. Protects chafed skin due to irritation and helps to seal out wetness.” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cu>DermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE\u003C\u002Fu>\u003Cbr>“Drug Facts . . . Purpose: Antifungal . . . Uses: For the treatment and prevention of most – athlete’s foot – jock itch – ringworm….” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cu>PeriGiene HEALTH CARE ANTISEPTIC\u003C\u002Fu>\u003Cbr>“Drug Facts . . . Purpose: Antiseptic . . . Uses: Antiseptic cleanser for use in the perineal area” [from the product label]\u003C\u002Fp>\u003Cp>“PeriGiene is a rinse-free non-drying perineal cleanser…Antimicrobial formula kills bacteria on contact.” [from the DermaRite website https:\u002F\u002Fdermarite.com\u002Fproduct\u002Fperigiene\u002F]\u003C\u002Fp>\u003Cp>\u003Cu>DermaMed OINTMENT SKIN PROTECTANT\u003C\u002Fu>\u003Cbr>“Drug Facts . . . Purpose: Skin protectant . . . Uses: Dries the oozing and weeping of poison: ivy, oak, or sumac, or other skin irritations.” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>OTC Skin protectants\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL, Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, and DermaMed OINTMENT SKIN PROTECTANT are intended for use as skin protectant drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355 are in effect for the drug products identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"over-the-counter (OTC) monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription skin protectant drug products, such as your DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL, Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, and DermaMed OINTMENT SKIN PROTECTANT products, in order to be GRASE and not new drugs, the product must, among other things, conform to the conditions in the applicable OTC monograph, here M016: Skin Protectant Drug Products for Over-the-Counter Human Use (henceforth “M016”).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL, Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, and DermaMed OINTMENT SKIN PROTECTANT do not conform to the conditions specified in M016 for the reasons described below.\u003C\u002Fp>\u003Cp>DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL is formulated with an active ingredient that is not permitted for OTC skin protectant drug products under M016.10. Specifically, your DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL is formulated with the active ingredient menthol. We note that, although you identify this ingredient as an inactive ingredient in Drug Facts on the product label, other statements show that it is an active ingredient because it is intended to furnish pharmacological activity or other direct effect for the treatment of a disease or condition or to affect the structure or any function of the body of humans.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> For example, the product name includes “\u003Cu>COOLING\u003C\u002Fu> MENTHOL” (emphasis added), and the DermaRite website page for DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL states “Also contains menthol to help soothe minor skin irritation and dry\u002Fmanage weeping skin.” Thus, menthol is an active ingredient in your DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL product, but it is not an active ingredient permitted under M016.10.\u003C\u002Fp>\u003Cp>Regarding Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, the Drug Facts panel of this product’s labeling states that the product contains the active ingredient lanolin 50%, while the Uses section of that labeling states that the product “helps relieve and prevent rashes and irritation due to wetness from incontinence” and “Protects chafed skin due to irritation and helps to seal out wetness.” While lanolin up to 50% is permitted as an active ingredient under M016.10(k), these labeled uses are not permitted for products with this active ingredient under M016.50(b).\u003C\u002Fp>\u003Cp>Regarding DermaMed OINTMENT SKIN PROTECTANT, the Drug Facts panel of this product’s labeling states that it contains the active ingredient Aluminum hydroxide gel 2% but includes intended uses that are not permitted for products with this active ingredient in M016. Specifically, the Uses section of that labeling states, “Dries the oozing and weeping of poison: ivy, oak, or sumac, \u003Cu>or other\u003C\u002Fu> \u003Cu>skin irritations\u003C\u002Fu>.” (emphasis added). Claims that suggest DermaMed OINTMENT SKIN PROTECTANT is intended to dry oozing and weeping or otherwise treat skin irritations that are not associated with poison ivy, oak, or sumac go beyond the allowed general intended uses for an OTC skin protectant drug product and do not conform to the uses permitted for a product with the active ingredient Aluminum hydroxide gel\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> as set forth in M016.50(b)(3).\u003C\u002Fp>\u003Cp>Thus, your DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL, Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, and DermaMed OINTMENT SKIN PROTECTANT do not comply with the applicable conditions specified in M016. These products have not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which these products would be legally marketed without an approved application. Because there are no applications in effect for these products, these products are unapproved new drugs.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cem>OTC Topical Antifungals\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Based on its labeling,\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> DermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE is intended for use as a topical antifungal drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355 are in effect for the drug product identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"over-the-counter (OTC) monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription topical antifungal drug products, such as your product mentioned above, in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph, here M005: Topical Antifungal Drug Products for Over-the-Counter Human Use (henceforth “M005”).\u003Cem>\u003Cstrong>\u003Csup>6\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, DermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE does not conform to the conditions specified in M005 for the reason described below.\u003C\u002Fp>\u003Cp>The Uses section of the Drug Facts panel for DermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE states, “…\u003Cu>prevention\u003C\u002Fu> of most – athlete’s foot – jock itch – ringworm.” (emphasis added). While miconazole nitrate 2% is permitted as an active ingredient under M005.10(c), these labeled uses in prevention of athlete’s foot, jock itch, and ringworm are not permitted for products with this active ingredient under M005.50(b). Thus, DermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE does not comply with the applicable conditions specified in M005. This product has not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>7\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which this product would be legally marketed without an approved application. Because there are no applications in effect for this product, this product is an unapproved new drug.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of this unapproved new drug product into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cem>OTC Health Care Antiseptics\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, PeriGiene HEALTH CARE ANTISEPTIC is intended for use as a healthcare topical antiseptic drug product. This product is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that the PeriGiene HEALTH CARE ANTISEPTIC drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application—commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. Under section 505G(a)(3) of the FD&amp;C Act, drugs that (prior to enactment of section 505G) were classified as Category III\u003Cem>\u003Cstrong>\u003Csup>8\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> for safety or effectiveness in the preamble of a tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drugs issued under 21 CFR Part 330—and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredients and indications, and comply with all other applicable requirements.\u003C\u002Fp>\u003Cp>Health care topical antiseptic products, such as your PeriGiene HEALTH CARE ANTISEPTIC product, were addressed in a TFM titled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (hereinafter “1994 TFM”), as amended by “Safety and Effectiveness of Health Care Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 80 FR 25166 (May 1, 2015) (hereinafter “Health Care Topical Antiseptics Proposed Rule”),\u003Cem>\u003Cstrong>\u003Csup>9\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and “Safety and Effectiveness of Health Care Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Final Rule, 82 FR 60474 (December 20, 2017) (hereinafter \"Health Care Topical Antiseptics Final Rule”).\u003Cem>\u003Cstrong>\u003Csup>10\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Over the course of these rulemakings, six active ingredients (benzalkonium chloride, benzethonium chloride, chloroxylenol—the active ingredient in your PeriGiene HEALTH CARE ANTISEPTIC product—ethyl alcohol, isopropyl alcohol, and povidone-iodine) were classified as Category III for use in healthcare OTC antiseptic products. Chloroxylenol was classified as Category III for both safety and effectiveness for use in patient antiseptic skin preparations (i.e., patient preoperative and preinjection skin preparations), health care personnel hand washes, and surgical hand scrubs.\u003Cem>\u003Cstrong>\u003Csup>11\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>However, for the reasons described below, PeriGiene HEALTH CARE ANTISEPTIC product does not meet the conditions under section 505G(a)(3) for legal marketing without an approved application. Specifically, PeriGiene HEALTH CARE ANTISEPTIC does not conform to the conditions applicable to topical antiseptics under the 1994 TFM, as amended by the Healthcare Topical Antiseptics Proposed and Final Rules.\u003C\u002Fp>\u003Cp>The product labeling for PeriGiene HEALTH CARE ANTISEPTIC states that it is an antiseptic cleanser for use in the perineal area. This is not consistent with the 1994 TFM as amended, which provides that a health care antiseptic product with the active ingredient chloroxylenol is Category III for use in patient antiseptic skin preparations (i.e., patient preoperative and preinjection skin preparations), health care personnel hand washes, and surgical hand scrubs. Thus, your PeriGiene HEALTH CARE ANTISEPTIC product does not conform to the conditions for health care topical antiseptic products described in the relevant rulemakings for such products.\u003C\u002Fp>\u003Cp>Accordingly, your PeriGiene HEALTH CARE ANTISEPTIC product does not meet the criteria under section 505G(a)(3) for legal marketing without an approved application and thus cannot be legally marketed as an OTC monograph drug under section 505G of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>DermaMed OINTMENT SKIN PROTECTANT is misbranded under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1), because its labeling does not bear adequate directions for use. Here, the direction set forth in M016.50(d)(4), “children under 6 months: ask a doctor.” is required for a skin protectant containing the active ingredient Aluminum hydroxide gel to be legally marketed under section 505G of the FD&amp;C Act. This monograph labeling also falls within the scope of the directions described in section 502(f)(1) of FD&amp;C Act. Your product’s Directions state, “Apply liberally to affected area as needed \u003Cu>or as\u003C\u002Fu> \u003Cu>directed by a physician\u003C\u002Fu>” (emphasis added) but include no reference to children under 6 months of age.\u003Cem>\u003Cstrong>\u003Csup>12\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> The omission of this monograph direction from your product’s labeling renders it misbranded under section 502(f)(1).\u003C\u002Fp>\u003Cp>Additionally, DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL, Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, DermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE, PeriGiene HEALTH CARE ANTISEPTIC, and DermaMed OINTMENT SKIN PROTECTANT are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section (as described above) and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Test Results Out-of-Specification\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document \u003Cem>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. We note that under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\u003C\u002Fp>\u003Cp>We also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&amp;C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1000526900 and ATTN: Nancy Scheraga.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M016 reflects the conditions set forth in the relevant final order(s) established and in effect under section 505G; see Order ID OTC000005, available at FDA’s website OTC Monographs@FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf]\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 201.66(b)(2), which defines an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans.”\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Aluminum hydroxide gel is an active ingredient identified in M016.10(b).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL, Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, DermaMed OINTMENT SKIN PROTECTANT are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> In addition to labeling cited earlier in this letter, other parts of its labeling indicate in particular that your product is intended for topical application. See, e.g., Warnings: “For external use only” and various Directions in the Drug Facts panel of your product.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> M005 reflects the conditions set forth in the relevant final order(s) established and in effect under section 505G; see Order ID OTC000017, available at FDA’s website OTC Monographs@FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf]\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that DermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE is GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> As used under the OTC monograph system prior to enactment of section 505G, “\u003Cem>[t]he OTC drug procedural regulations in § 330.10 use the terms ‘Category I’ (generally recognized as safe and effective and not misbranded), ‘Category II’ (not generally recognized as safe and effective or misbranded), and ‘Category III’ (available data are insufficient to classify as safe and effective, and further testing is required)\u003C\u002Fem>”, 81 FR 42912, 42915.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem> As stated in the Healthcare Topical Antiseptics Proposed Rule, “\u003Cem>The Food and Drug Administration (FDA) is issuing this proposed rule to amend the 1994 tentative final monograph or proposed rule (the 1994 TFM) for over-the-counter (OTC) antiseptic drug products. In this proposed rule, we are proposing to establish conditions under which OTC antiseptic products intended for use by health care professionals in a hospital setting or other health care situations outside the hospital are generally recognized as safe and effective\u003C\u002Fem>”, 80 FR 25166.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>10\u003C\u002Fstrong>\u003C\u002Fem> As stated in the Health Care Topical Antiseptics Final Rule, “\u003Cem>The Food and Drug Administration (FDA, the Agency, or we) is issuing this final rule establishing that certain active ingredients used in nonprescription (also known as over-the-counter or OTC) antiseptic products intended for use by health care professionals in a hospital setting or other health care situations outside the hospital are not generally recognized as safe and effective (GRAS\u002FGRAE)\u003C\u002Fem>”, 82 FR 60474.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>11\u003C\u002Fstrong>\u003C\u002Fem> 82 FR 60474 at 60478; 80 FR 25166 at 25174-25175.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>12\u003C\u002Fstrong>\u003C\u002Fem> The only reference to seeking physician advice presented in your product’s labeling is “\u003Cstrong>Stop use and ask a doctor if \u003C\u002Fstrong>• condition worsens • symptoms last more than 7 days or clear up and occur again within a few days.” In context, then, the labeling suggests that after one of these events had prompted a user to “stop use and ask a doctor”, use might resume “as directed by a physician”.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-09\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Fabian McCarthy\n\nRecipient Title\n\nCEO\n\nDermaRite Industries, LLC\n\n7777 West Side Avenue\n\nNorth Bergen, NJ 07047\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-09\nOctober 27, 2025\nDear Mr. McCarthy:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, DermaRite Industries, LLC, FEI 1000526900, at 7777 West Side Avenue, North Bergen, from March 26 to April 8, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nIn addition, DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL, Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, DermaMed OINTMENT SKIN PROTECTANT, DermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE, and PeriGiene HEALTH CARE ANTISEPTIC are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). In addition, DermaMed OINTMENT SKIN PROTECTANT is misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1). Furthermore, DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL, Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, DermaMed OINTMENT SKIN PROTECTANT, DermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE, and PeriGiene HEALTH CARE ANTISEPTIC are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). These violations are described in more detail below.\nWe reviewed your April 28, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nCGMP Violations\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192)\nYour firm manufactures over-the-counter (OTC) topical drug products for skin and wound care. Your firm failed to adequately investigate several out-of-limit (OOL) and out-of-specification (OOS) laboratory results, as well as unexplained discrepancies. For example, you failed to identify the root cause for the following:\nConcerning the initial failing test result for total aerobic microbial count (TAMC) of DermaKleen Lot 40375A, which showed too numerous to count, you failed to scientifically identify the root cause of the contamination. Instead of performing an investigation into the root cause of the failure, you sent a second sample to your third-party contract laboratory, obtained passing results, and subsequently released the drug product batch for distribution. This strategy of using repeated testing until a passing result is obtained, then disregarding the OOS results without scientific justification (“testing into compliance”) is unscientific and objectionable under CGMP.\nConcerning the initial OOS test result for the assay of the active ingredient chloroxylenol in DermaKleen Lot 9-40545, you failed to scientifically identify the root cause of the OOS. Instead of performing an investigation into the root cause of the failure, you sent a second sample to your contract laboratory. Despite this retest also producing failing results, your firm released the batch for distribution. It is noteworthy that the certificate of analysis did not reflect the actual results.\nYou did not thoroughly investigate these unexplained discrepancies or identify failures of a drug product to meet any of its specifications. When an investigation was performed, it was inadequate because you failed to identify the root cause(s), to implement appropriate corrective action and preventive action (CAPA), and to expand the investigation to evaluate the impact on other batches or products.\nIn your response, you indicated that you would perform a retrospective review of all OOS test results from the last two years and determine their impact on product on the market. Your response is inadequate. You did not commit to evaluating your process for investigating unexplained discrepancies or failures of batches to determine a root cause so that you could implement appropriate CAPA. Inadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that compromise the ability to manufacture safe and effective drug products.\nWe acknowledge that you initiated a voluntary recall (https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fdermarite-industries-issues-voluntary-nationwide-recall-dermakleen-dermasarra-kleenfoam-and) on July 17, 2025, for products that initially failed for TAMC and those retains that failed for Burkholderia cepacia. On August 27, 2025, you expanded the voluntary recall to include all lots of all products that contain water (https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fdermarite-industries-expands-voluntary-nationwide-recall-due-potential-burkholderia-cepacia).\nMicrobial contamination may not be a uniformly distributed contamination. A product sample may not be representative of the type or level of contamination within the batch. Further, testing final product for microbial contamination does not ensure that you have appropriate controls in place to ensure product quality. As a manufacturer, you have a responsibility to fully investigate unexplained discrepancies, deviations, and failures to assess their impact on product quality.\nIn response to this letter, provide:\nA retrospective, independent review of all invalidated OOS\u002FOOL (including in-process and release\u002Fstability testing) results for U.S. products currently in the U.S. market and within expiry as of the date of this letter, and a report summarizing the findings of the analysis, including the following for each OOS\u002FOOL:\no Determine whether the scientific justification and evidence relating to the invalidated OOS\u002FOOL result conclusively or inconclusively demonstrate causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\no For all OOS\u002FOOL results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation and include any manufacturing operation improvements.\nA comprehensive review and remediation plan for your OOS\u002FOOL result investigation systems. The CAPA should include but not be limited to the following:\no Quality Unit (QU) oversight of laboratory investigations\no Identification of adverse laboratory control trends\no Resolution of laboratory variation causes\no Initiation of thorough investigations of potential manufacturing causes (whenever a laboratory cause cannot be conclusively identified)\no Adequate scoping of each investigation and its CAPA\no Revised OOS\u002FOOL investigation procedures with these and other remediations\nThe final investigation, including the root-cause determination, into the batches affected by the voluntary recall.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS\u002FOOL results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include but not be limited to significant improvements in investigation competencies, scope determination, root-cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure that all phases of the investigations are appropriately conducted.\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYou failed to perform adequate identity testing on each shipment of each lot of incoming components (e.g., ethanol, glycerin) used in the manufacture of your OTC drug products. In addition, you relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of each of your component suppliers’ test analyses at appropriate intervals.\nProducts Containing Ethyl Alcohol\nYou failed to adequately test your incoming component ethyl alcohol (ethanol), at risk of methanol contamination, for identity before using it as an active pharmaceutical ingredient (API) in manufacturing your OTC topical drug products. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\nProducts Containing Ingredients at Risk for Diethylene Glycol or Ethylene Glycol (DEG or EG) Contamination\nYou also failed to adequately test your incoming components at high risk of DEG or EG contamination for identity before using them to manufacture your drug products. This includes but is not limited to testing of propylene glycol and glycerin to determine their appropriate identity, before their use in manufacturing your OTC drug products.\nIdentity testing for propylene glycol, glycerin, and certain other high-risk drug components includes a limit test in the USP to ensure that the component meets the relevant safety limits for DEG or EG levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to ensure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\nIn your response, you indicated that you tested all retains of glycerin and propylene glycol for hazardous impurities and will do so for ethanol. In addition, you stated that you have identified all lots of incoming Glycerin (b)(4) and Propylene Glycol (b)(4) received from 2023 to present and used in the products manufactured during the same period. Your response is inadequate because you failed to identify and evaluate high-risk drug components that may have been received in 2022 and used in lots manufactured in 2023.\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before their use in the manufacture of your drug products. You are responsible for sampling, testing, and examining drug components before use in production to ensure that acceptable quality parameters are met.\nIn response to this letter, provide:\nA commitment to perform reconciliation of retains tested versus all lots used in production. If retain samples are unavailable, a commitment to test finished drug product batches for the presence of DEG and EG.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products, and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\nYour firm did not have an adequate stability program to demonstrate that the chemical and microbiological properties of your drug products met established specifications and that they remain acceptable throughout their labeled shelf-life. For example, you failed to place any OTC drug products on stability in 2023 or 2024.\nAdditionally, stability that was conducted in 2022 identified multiple failures during multiple timepoints for chemical and microbiological properties. You lack sufficient data to support your (b)(4) expiry.\nIn your response, you indicate that you will work with a qualified laboratory to verify that the laboratory test methods are properly validated as stability-indicating methods, and that you will retest retain samples for the marketed product batches within expiry. Your response is inadequate because you failed to address product on the market that lack adequate data to support their shelf life.\nWithout appropriate stability studies, you lack adequate scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\nIn your response to this letter, provide:\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods\no Stability studies for each drug product in its marketed container-closure system, before distribution is permitted\no An ongoing program in which representative batches of each product are added each year to determine if the shelf-life claim remains valid\no Detailed definition of the specific attributes to be tested at each station (timepoint)\nAll procedures that describe these and other elements of your remediated stability.\nYour action plan to address any product quality or patient safety risks for batches of finished product supported by failing 2022 stability batches that are in U.S. distribution, including potential customer notifications and recalls.\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour QU failed to perform adequate oversight for the manufacture and testing of your drug products. For example, your QU failed to ensure the following:\nPerformance of annual product reviews (21 CFR 211.180(e))\nPerformance of adequate testing of component (e.g., water) (211.22(d))\nCOA included all data derived from actual testing performed (211.194(a))\nIn your response, you indicate that you have an SOP in place outlining the responsibilities of your QU and that retraining is occurring. Your response is inadequate because it does not include how you intend to structure the QU to ensure that assigned authorities and responsibilities support the production, quality, and management activities needed to produce quality products.\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance with Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nIn your response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate procedures and practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\no A description of how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\nUnapproved New Drug and Misbranded Drug Violations\nDermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL, Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, DermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE, PeriGiene HEALTH CARE ANTISEPTIC, and DermaMed OINTMENT SKIN PROTECTANT, are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from these products’ labeling, including the DermaRite website, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\nDermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL\n“Drug Facts . . . Purpose: Skin Protectant . . . Uses: Dries the oozing and weeping of poison: - Ivy – Oil – Sumac – Or other skin irritations” [from the product label]\n“Also contains menthol to help soothe minor skin irritation and dry\u002Fmanage weeping skin.” [from the DermaRite website https:\u002F\u002Fdermarite.com\u002Fproduct\u002Fdermaseptin-ointment\u002F]\nLantiseptic Moisture Shield ORIGINALSKIN PROTECTANT\n“Drug Facts . . . Purpose: Skin Protectant . . . Uses: - Helps relieve and prevent rashes and irritation due to wetness from incontinence. Protects chafed skin due to irritation and helps to seal out wetness.” [from the product label]\nDermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE\n“Drug Facts . . . Purpose: Antifungal . . . Uses: For the treatment and prevention of most – athlete’s foot – jock itch – ringworm….” [from the product label]\nPeriGiene HEALTH CARE ANTISEPTIC\n“Drug Facts . . . Purpose: Antiseptic . . . Uses: Antiseptic cleanser for use in the perineal area” [from the product label]\n“PeriGiene is a rinse-free non-drying perineal cleanser…Antimicrobial formula kills bacteria on contact.” [from the DermaRite website https:\u002F\u002Fdermarite.com\u002Fproduct\u002Fperigiene\u002F]\nDermaMed OINTMENT SKIN PROTECTANT\n“Drug Facts . . . Purpose: Skin protectant . . . Uses: Dries the oozing and weeping of poison: ivy, oak, or sumac, or other skin irritations.” [from the product label]\nUnapproved New Drug Violations\nOTC Skin protectants\nBased on the above labeling evidence, DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL, Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, and DermaMed OINTMENT SKIN PROTECTANT are intended for use as skin protectant drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355 are in effect for the drug products identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"over-the-counter (OTC) monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription skin protectant drug products, such as your DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL, Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, and DermaMed OINTMENT SKIN PROTECTANT products, in order to be GRASE and not new drugs, the product must, among other things, conform to the conditions in the applicable OTC monograph, here M016: Skin Protectant Drug Products for Over-the-Counter Human Use (henceforth “M016”).1 However, DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL, Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, and DermaMed OINTMENT SKIN PROTECTANT do not conform to the conditions specified in M016 for the reasons described below.\nDermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL is formulated with an active ingredient that is not permitted for OTC skin protectant drug products under M016.10. Specifically, your DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL is formulated with the active ingredient menthol. We note that, although you identify this ingredient as an inactive ingredient in Drug Facts on the product label, other statements show that it is an active ingredient because it is intended to furnish pharmacological activity or other direct effect for the treatment of a disease or condition or to affect the structure or any function of the body of humans.2 For example, the product name includes “COOLING MENTHOL” (emphasis added), and the DermaRite website page for DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL states “Also contains menthol to help soothe minor skin irritation and dry\u002Fmanage weeping skin.” Thus, menthol is an active ingredient in your DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL product, but it is not an active ingredient permitted under M016.10.\nRegarding Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, the Drug Facts panel of this product’s labeling states that the product contains the active ingredient lanolin 50%, while the Uses section of that labeling states that the product “helps relieve and prevent rashes and irritation due to wetness from incontinence” and “Protects chafed skin due to irritation and helps to seal out wetness.” While lanolin up to 50% is permitted as an active ingredient under M016.10(k), these labeled uses are not permitted for products with this active ingredient under M016.50(b).\nRegarding DermaMed OINTMENT SKIN PROTECTANT, the Drug Facts panel of this product’s labeling states that it contains the active ingredient Aluminum hydroxide gel 2% but includes intended uses that are not permitted for products with this active ingredient in M016. Specifically, the Uses section of that labeling states, “Dries the oozing and weeping of poison: ivy, oak, or sumac, or other skin irritations.” (emphasis added). Claims that suggest DermaMed OINTMENT SKIN PROTECTANT is intended to dry oozing and weeping or otherwise treat skin irritations that are not associated with poison ivy, oak, or sumac go beyond the allowed general intended uses for an OTC skin protectant drug product and do not conform to the uses permitted for a product with the active ingredient Aluminum hydroxide gel3 as set forth in M016.50(b)(3).\nThus, your DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL, Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, and DermaMed OINTMENT SKIN PROTECTANT do not comply with the applicable conditions specified in M016. These products have not otherwise been found GRASE.4 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which these products would be legally marketed without an approved application. Because there are no applications in effect for these products, these products are unapproved new drugs.\nThe introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nOTC Topical Antifungals\nBased on its labeling,5 DermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE is intended for use as a topical antifungal drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355 are in effect for the drug product identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"over-the-counter (OTC) monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription topical antifungal drug products, such as your product mentioned above, in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph, here M005: Topical Antifungal Drug Products for Over-the-Counter Human Use (henceforth “M005”).6 However, DermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE does not conform to the conditions specified in M005 for the reason described below.\nThe Uses section of the Drug Facts panel for DermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE states, “…prevention of most – athlete’s foot – jock itch – ringworm.” (emphasis added). While miconazole nitrate 2% is permitted as an active ingredient under M005.10(c), these labeled uses in prevention of athlete’s foot, jock itch, and ringworm are not permitted for products with this active ingredient under M005.50(b). Thus, DermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE does not comply with the applicable conditions specified in M005. This product has not otherwise been found GRASE.7 Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which this product would be legally marketed without an approved application. Because there are no applications in effect for this product, this product is an unapproved new drug.\nThe introduction or delivery for introduction of this unapproved new drug product into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nOTC Health Care Antiseptics\nBased on the above labeling evidence, PeriGiene HEALTH CARE ANTISEPTIC is intended for use as a healthcare topical antiseptic drug product. This product is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that the PeriGiene HEALTH CARE ANTISEPTIC drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application—commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. Under section 505G(a)(3) of the FD&C Act, drugs that (prior to enactment of section 505G) were classified as Category III8 for safety or effectiveness in the preamble of a tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drugs issued under 21 CFR Part 330—and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredients and indications, and comply with all other applicable requirements.\nHealth care topical antiseptic products, such as your PeriGiene HEALTH CARE ANTISEPTIC product, were addressed in a TFM titled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (hereinafter “1994 TFM”), as amended by “Safety and Effectiveness of Health Care Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 80 FR 25166 (May 1, 2015) (hereinafter “Health Care Topical Antiseptics Proposed Rule”),9 and “Safety and Effectiveness of Health Care Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Final Rule, 82 FR 60474 (December 20, 2017) (hereinafter \"Health Care Topical Antiseptics Final Rule”).10 Over the course of these rulemakings, six active ingredients (benzalkonium chloride, benzethonium chloride, chloroxylenol—the active ingredient in your PeriGiene HEALTH CARE ANTISEPTIC product—ethyl alcohol, isopropyl alcohol, and povidone-iodine) were classified as Category III for use in healthcare OTC antiseptic products. Chloroxylenol was classified as Category III for both safety and effectiveness for use in patient antiseptic skin preparations (i.e., patient preoperative and preinjection skin preparations), health care personnel hand washes, and surgical hand scrubs.11\nHowever, for the reasons described below, PeriGiene HEALTH CARE ANTISEPTIC product does not meet the conditions under section 505G(a)(3) for legal marketing without an approved application. Specifically, PeriGiene HEALTH CARE ANTISEPTIC does not conform to the conditions applicable to topical antiseptics under the 1994 TFM, as amended by the Healthcare Topical Antiseptics Proposed and Final Rules.\nThe product labeling for PeriGiene HEALTH CARE ANTISEPTIC states that it is an antiseptic cleanser for use in the perineal area. This is not consistent with the 1994 TFM as amended, which provides that a health care antiseptic product with the active ingredient chloroxylenol is Category III for use in patient antiseptic skin preparations (i.e., patient preoperative and preinjection skin preparations), health care personnel hand washes, and surgical hand scrubs. Thus, your PeriGiene HEALTH CARE ANTISEPTIC product does not conform to the conditions for health care topical antiseptic products described in the relevant rulemakings for such products.\nAccordingly, your PeriGiene HEALTH CARE ANTISEPTIC product does not meet the criteria under section 505G(a)(3) for legal marketing without an approved application and thus cannot be legally marketed as an OTC monograph drug under section 505G of the FD&C Act.\nThe introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nDermaMed OINTMENT SKIN PROTECTANT is misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1), because its labeling does not bear adequate directions for use. Here, the direction set forth in M016.50(d)(4), “children under 6 months: ask a doctor.” is required for a skin protectant containing the active ingredient Aluminum hydroxide gel to be legally marketed under section 505G of the FD&C Act. This monograph labeling also falls within the scope of the directions described in section 502(f)(1) of FD&C Act. Your product’s Directions state, “Apply liberally to affected area as needed or as directed by a physician” (emphasis added) but include no reference to children under 6 months of age.12 The omission of this monograph direction from your product’s labeling renders it misbranded under section 502(f)(1).\nAdditionally, DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL, Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, DermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE, PeriGiene HEALTH CARE ANTISEPTIC, and DermaMed OINTMENT SKIN PROTECTANT are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section (as described above) and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nTest Results Out-of-Specification\nFor more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nCosmetics Manufactured for Distribution in the United States\nIn addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. We note that under section 301(a) of the FD&C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\nWe also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1000526900 and ATTN: Nancy Scheraga.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_______________________\n1 M016 reflects the conditions set forth in the relevant final order(s) established and in effect under section 505G; see Order ID OTC000005, available at FDA’s website OTC Monographs@FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf]\n2 See 21 CFR 201.66(b)(2), which defines an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans.”\n3 Aluminum hydroxide gel is an active ingredient identified in M016.10(b).\n4 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that DermaSeptin OINTMENT SKIN PROTECTANT with COOLING MENTHOL, Lantiseptic Moisture Shield ORIGINALSKIN PROTECTANT, DermaMed OINTMENT SKIN PROTECTANT are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\n5 In addition to labeling cited earlier in this letter, other parts of its labeling indicate in particular that your product is intended for topical application. See, e.g., Warnings: “For external use only” and various Directions in the Drug Facts panel of your product.\n6 M005 reflects the conditions set forth in the relevant final order(s) established and in effect under section 505G; see Order ID OTC000017, available at FDA’s website OTC Monographs@FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf]\n7 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that DermaFungal ANTIFUNGAL CREAM with 2% MICONAZOLE NITRATE is GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).\n8 As used under the OTC monograph system prior to enactment of section 505G, “[t]he OTC drug procedural regulations in § 330.10 use the terms ‘Category I’ (generally recognized as safe and effective and not misbranded), ‘Category II’ (not generally recognized as safe and effective or misbranded), and ‘Category III’ (available data are insufficient to classify as safe and effective, and further testing is required)”, 81 FR 42912, 42915.\n9 As stated in the Healthcare Topical Antiseptics Proposed Rule, “The Food and Drug Administration (FDA) is issuing this proposed rule to amend the 1994 tentative final monograph or proposed rule (the 1994 TFM) for over-the-counter (OTC) antiseptic drug products. In this proposed rule, we are proposing to establish conditions under which OTC antiseptic products intended for use by health care professionals in a hospital setting or other health care situations outside the hospital are generally recognized as safe and effective”, 80 FR 25166.\n10 As stated in the Health Care Topical Antiseptics Final Rule, “The Food and Drug Administration (FDA, the Agency, or we) is issuing this final rule establishing that certain active ingredients used in nonprescription (also known as over-the-counter or OTC) antiseptic products intended for use by health care professionals in a hospital setting or other health care situations outside the hospital are not generally recognized as safe and effective (GRAS\u002FGRAE)”, 82 FR 60474.\n11 82 FR 60474 at 60478; 80 FR 25166 at 25174-25175.\n12 The only reference to seeking physician advice presented in your product’s labeling is “Stop use and ask a doctor if • condition worsens • symptoms last more than 7 days or clear up and occur again within a few days.” In context, then, the labeling suggests that after one of these events had prompted a user to “stop use and ask a doctor”, use might resume “as directed by a physician”.","DermaRite Industries, LLC","dermarite-industries-llc-710997-10272025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdermarite-industries-llc-710997-10272025","2026-10-26T08:08:23.360348+00:00","2025-11-18","710997","Drugs Over-the-Counter Drugs","Mr. Fabian McCarthy","2026-08-19T14:27:09.367+00:00","VIA UPS","320-26-09","2025-10-27",{"id":293,"raw":294,"subject":298,"body_html":300,"body_text":301,"firm_name":302,"letter_id":303,"created_at":304,"fei_number":19,"letter_url":305,"updated_at":306,"action_type":22,"case_status":111,"posted_date":307,"marcs_cms_no":308,"product_type":26,"closeout_date":309,"issuing_office":11,"recipient_name":310,"body_fetched_at":311,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":307,"medical_device_id":19,"response_letter_date":19},3482,[295,296,297,11,298,13,299,13],"\u003Ctime datetime=\"2021-03-04T21:30:00Z\">03\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-04T05:00:00Z\">03\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fopgal-optronic-industries-ltd-613562-03042021\">Opgal Optronic Industries Ltd.\u003C\u002Fa>","Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fopgal-optronic-industries-ltd-613562-07202023\">\u003Ctime datetime=\"2023-07-25T04:00:00Z\">07\u002F25\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Eran Bluestein\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Opgal Optronic Industries Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>PO Box 462, Industrial Area 5\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Karmiel\u003C\u002Fspan> \u003Cspan>2161401\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Israel\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Opgal Optronic Industries Ltd.\u003Cbr>\nPO Box 462, Industrial Area 5\u003Cbr>\nKarmiel, 2161401\u003Cbr>\nISRAEL\u003C\u002Fp>\n\n\u003Cp>eran.b@opgal.com - Eran Bluestein\u003Cbr>\n&nbsp;\u003Cbr>\nRE:&nbsp;&nbsp;&nbsp;&nbsp; Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>Dear Sir,\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.opgal.com on February 22 and 25, 2021.&nbsp; We have also reviewed your social media pages at https:\u002F\u002Fwww.youtube.com\u002Fchannel\u002FUCDKt9En7lks0xA5W3NtoLqg, https:\u002F\u002Ftwitter.com\u002FOpgalLtd, and https:\u002F\u002Fwww.facebook.com\u002FOpgal\u002F where you direct consumers to your website, https:\u002F\u002Fwww.opgal.com. The FDA has observed that your website offers products for measuring human body temperature, specifically the “Therm-App MD” and “Therm-App MD Pro”, for sale in the United States. Based on our review, these products are intended to mitigate, prevent, treat, diagnose or cure COVID-19\u003Ca id=\"footnoteref1_ffts0bw\" href=\"#footnote1_ffts0bw\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp; in people, and thus are devices under section 201(h) of the Federal, Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>FDA’s review of your website revealed the following statements that establish that the Therm-App MD and Therm-App MD Pro are intended for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, including:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“Have you seen our case study about using thermal cameras to help prevent the spread of COVID-19?” [Published as a pop-up on your Therm-App MD Pro webpage, https:\u002F\u002Fwww.opgal.com\u002Fproducts\u002Ftherm-app-md-pro]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“HELP MINIMIZE THE SPREAD OF THE CORONA VIRUS OUTBREAK.” [Published in your YouTube video titled, “Therm-App MD by Opgal”, https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=2bmmXY8158I]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“The skies are gradually opening up again, and it's time to put the ThermApp MD PRO up to the test... #airportsecurity #airport #covidsolutions #thermalimaging #thermalcameras #feverscreening” [Published your Twitter webpage, https:\u002F\u002Ftwitter.com\u002FOpgalLtd\u002Fstatus\u002F1310828682022453248]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“Elevated body temperature becomes another security concern in this day and age. Opgal's thermal imaging technology has got you covered here as well… #thermalimaging #security #covid19solutions” [Published on your Facebook webpage, https:\u002F\u002Fwww.facebook.com\u002FOpgal\u002Fvideos\u002F721164435451235\u002F?__tn__=-R]\u003C\u002Fp>\n\n\u003Cp>The Therm-App MD and Therm-App MD Pro are offered for sale in the United States without marketing approval, clearance, or authorization from FDA.&nbsp; Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these products into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Ca id=\"footnoteref2_ji77xae\" href=\"#footnote2_ji77xae\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa> In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.\u003Ca id=\"footnoteref3_mloysbp\" href=\"#footnote3_mloysbp\">\u003Csup>3\u003C\u002Fsup>\u003C\u002Fa> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you offer for sale products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such adulterated and misbranded products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Use of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment.&nbsp; These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, \u003Ca href=\"https:\u002F\u002Fwww.opgal.com\u002F\">https:\u002F\u002Fwww.opgal.com\u003C\u002Fa>, includes statements that indicate that the Therm-App MD and Therm-App MD Pro are intended to scan multiple individuals simultaneously, including:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;For the Therm-App MD Pro, “Multiple Hotspot Detection &amp; Tracking” [Published in your Therm-App MD Pro Brochure, https:\u002F\u002Fwww.opgal.com\u002Fwp-content\u002Fuploads\u002F2020\u002F05\u002FTherm-App-MD-Pro-Brochure.pdf]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;For the Therm-App MD Pro, “Up to 20 Simultaneous Scans” and “Scans multiple faces at once” [Published on your Therm-App MD Pro webpage, https:\u002F\u002Fwww.opgal.com\u002Fproducts\u002Ftherm-app-md-pro]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“[T]he Therm-App MD Pro can simultaneously and passively measure multiple people's temperature” [Published in your case study about a hospital in Jerusalem, Israel, https:\u002F\u002Fwww.opgal.com\u002Fwp-content\u002Fuploads\u002F2020\u002F11\u002FShaare-Zedek-Case-Study-4.pdf]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“No individual measurement required.” [Published in your Therm-App MD Brochure, https:\u002F\u002Fwww.opgal.com\u002Fwp-content\u002Fuploads\u002F2020\u002F04\u002FThermAppMD.pdf]\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Enforcement Policy for Telethermographic Systems During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency”\u003Ca id=\"footnoteref4_s5qt9y3\" href=\"#footnote4_s5qt9y3\">\u003Csup>4\u003C\u002Fsup>\u003C\u002Fa> provides information about FDA’s policies intended to help expand the availability of telethermographic systems used for body temperature measurements for triage use during the COVID-19 public health emergency.\u003C\u002Fp>\n\n\u003Cp>You should take action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that misbrand the products in violation of the Act. Within 48 hours, please send an email to \u003Ca href=\"mailto:COVID-19-Task-Force-CDRH@fda.hhs.gov\">COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fa> describing the specific steps you have taken to address these violations, using CMS # 613562 as reference. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address any violations may result in legal action, including, without limitation, seizure and injunction.&nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment,\u003C\u002Fp>\n\n\u003Cp>diagnosis, or cure of COVID-19, and any appropriate correction actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at \u003Ca href=\"mailto:COVID-19-Task-Force-CDRH@fda.hhs.gov\">COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fa>.&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\u003Cbr>\nCourtney H. Lias, Ph.D.\u003Cbr>\nActing Office Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\n&nbsp;&nbsp;&nbsp; General Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\u003Col>\n                  \u003Cli id=\"footnote1_ffts0bw\">\u003Ca href=\"#footnoteref1_ffts0bw\">1\u003C\u002Fa>As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_ji77xae\">\u003Ca href=\"#footnoteref2_ji77xae\">2\u003C\u002Fa>Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\u003C\u002Fli>\n                      \u003Cli id=\"footnote3_mloysbp\">\u003Ca href=\"#footnoteref3_mloysbp\">3\u003C\u002Fa>President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\u003C\u002Fli>\n                      \u003Cli id=\"footnote4_s5qt9y3\">\u003Ca href=\"#footnoteref4_s5qt9y3\">4\u003C\u002Fa>Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F137079\u002Fdownload. \u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nEran Bluestein\n\nOpgal Optronic Industries Ltd.\n\nPO Box 462, Industrial Area 5\n\nKarmiel 2161401\n\nIsrael\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nOpgal Optronic Industries Ltd.\n\nPO Box 462, Industrial Area 5\n\nKarmiel, 2161401\n\nISRAEL\n\neran.b@opgal.com - Eran Bluestein\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nDear Sir,\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.opgal.com on February 22 and 25, 2021. We have also reviewed your social media pages at https:\u002F\u002Fwww.youtube.com\u002Fchannel\u002FUCDKt9En7lks0xA5W3NtoLqg, https:\u002F\u002Ftwitter.com\u002FOpgalLtd, and https:\u002F\u002Fwww.facebook.com\u002FOpgal\u002F where you direct consumers to your website, https:\u002F\u002Fwww.opgal.com. The FDA has observed that your website offers products for measuring human body temperature, specifically the “Therm-App MD” and “Therm-App MD Pro”, for sale in the United States. Based on our review, these products are intended to mitigate, prevent, treat, diagnose or cure COVID-191 in people, and thus are devices under section 201(h) of the Federal, Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nFDA’s review of your website revealed the following statements that establish that the Therm-App MD and Therm-App MD Pro are intended for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, including:\n\n• “Have you seen our case study about using thermal cameras to help prevent the spread of COVID-19?” [Published as a pop-up on your Therm-App MD Pro webpage, https:\u002F\u002Fwww.opgal.com\u002Fproducts\u002Ftherm-app-md-pro]\n\n• “HELP MINIMIZE THE SPREAD OF THE CORONA VIRUS OUTBREAK.” [Published in your YouTube video titled, “Therm-App MD by Opgal”, https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=2bmmXY8158I]\n\n• “The skies are gradually opening up again, and it's time to put the ThermApp MD PRO up to the test... #airportsecurity #airport #covidsolutions #thermalimaging #thermalcameras #feverscreening” [Published your Twitter webpage, https:\u002F\u002Ftwitter.com\u002FOpgalLtd\u002Fstatus\u002F1310828682022453248]\n\n• “Elevated body temperature becomes another security concern in this day and age. Opgal's thermal imaging technology has got you covered here as well… #thermalimaging #security #covid19solutions” [Published on your Facebook webpage, https:\u002F\u002Fwww.facebook.com\u002FOpgal\u002Fvideos\u002F721164435451235\u002F?__tn__=-R]\n\nThe Therm-App MD and Therm-App MD Pro are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these products into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you offer for sale products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such adulterated and misbranded products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nUse of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment. These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, https:\u002F\u002Fwww.opgal.com, includes statements that indicate that the Therm-App MD and Therm-App MD Pro are intended to scan multiple individuals simultaneously, including:\n\n• For the Therm-App MD Pro, “Multiple Hotspot Detection & Tracking” [Published in your Therm-App MD Pro Brochure, https:\u002F\u002Fwww.opgal.com\u002Fwp-content\u002Fuploads\u002F2020\u002F05\u002FTherm-App-MD-Pro-Brochure.pdf]\n\n• For the Therm-App MD Pro, “Up to 20 Simultaneous Scans” and “Scans multiple faces at once” [Published on your Therm-App MD Pro webpage, https:\u002F\u002Fwww.opgal.com\u002Fproducts\u002Ftherm-app-md-pro]\n\n• “[T]he Therm-App MD Pro can simultaneously and passively measure multiple people's temperature” [Published in your case study about a hospital in Jerusalem, Israel, https:\u002F\u002Fwww.opgal.com\u002Fwp-content\u002Fuploads\u002F2020\u002F11\u002FShaare-Zedek-Case-Study-4.pdf]\n\n• “No individual measurement required.” [Published in your Therm-App MD Brochure, https:\u002F\u002Fwww.opgal.com\u002Fwp-content\u002Fuploads\u002F2020\u002F04\u002FThermAppMD.pdf]\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Enforcement Policy for Telethermographic Systems During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency”4 provides information about FDA’s policies intended to help expand the availability of telethermographic systems used for body temperature measurements for triage use during the COVID-19 public health emergency.\n\nYou should take action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations, using CMS # 613562 as reference. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment,\n\ndiagnosis, or cure of COVID-19, and any appropriate correction actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nActing Office Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n1As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n4Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F137079\u002Fdownload.","Opgal Optronic Industries Ltd.","opgal-optronic-industries-ltd-613562-03042021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fopgal-optronic-industries-ltd-613562-03042021","2026-10-26T08:09:38.529712+00:00","2021-03-04","613562","2023-07-25","Eran Bluestein","2026-08-20T03:19:17.641+00:00",{"id":313,"raw":314,"subject":319,"body_html":320,"body_text":321,"firm_name":322,"letter_id":323,"created_at":85,"fei_number":19,"letter_url":324,"updated_at":325,"action_type":22,"case_status":23,"posted_date":326,"marcs_cms_no":327,"product_type":114,"closeout_date":19,"issuing_office":318,"recipient_name":328,"body_fetched_at":329,"delivery_method":330,"recipient_title":19,"reference_number":19,"action_taken_date":331,"medical_device_id":19,"response_letter_date":19},2488,[315,316,317,318,319,13,13,13],"\u003Ctime datetime=\"2022-08-30T04:00:00Z\">08\u002F30\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-18T04:00:00Z\">08\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnational-food-industries-llc-633740-08182022\">National Food Industries LLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition","Food Labeling\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Piyush Mahesh\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>National Food Industries LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Al Quoz – 1, Interchange No. 3, Road No. 8, Behind Time Squares\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Centre P.O. Box 222\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dubai\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United Arab Emirates\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:piyush@nfidubai.com\"> piyush@nfidubai.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:qc@nfidubai.com\"> qc@nfidubai.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 18, 2022\u003C\u002Fp>\u003Cp>RE: 633740, 634411, 638165\u003C\u002Fp>\u003Cp>Dear Mr. Mahesh,\u003C\u002Fp>\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) is taking steps to subject your food products to detention without physical examination (DWPE) when offered for entry into the United States. More information about DWPE is provided in this letter below. This letter describes the reason for the action and the next steps you can take.\u003C\u002Fp>\u003Cp>A representative of the FDA conducted an inspection of your ready-to-eat (RTE) snack food manufacturing facility, National Food Industries LLC, located at National Industries Park, Plot No. Tpo 10422, Dubai, United Arab Emirates on March 14 to 18, 2022. The inspection was conducted to determine your compliance with the Federal Food, Drug, and Cosmetic Act (the Act) and regulations that apply to the food you ship to the United States.\u003C\u002Fp>\u003Cp>During the inspection, our investigator collected three products labels of your Mr. Krisps brand RTE snack foods. Based on our inspection, we found serious violations of the FDA’s Food Labeling regulations found in Title 21, Code of Federal Regulations, Part 101 (21 CFR 101), causing your products to be misbranded within the meaning of section 403 of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 343].\u003C\u002Fp>\u003Cp>You may find the Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranding\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your Mr. Krisps brand Salad Chips, Pizza Flavor, and Cheez Balls products are misbranded within the meaning of section 403 of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 343].\u003C\u002Fp>\u003Cp>Based on our inspectional findings, we are placing your Mr. Krisps Salad Chips and Mr. Krisps Pizza Flavor products on Import Alert #99-22, “Detention Without Physical Examination of Foods Containing Undeclared Major Food Allergens or Foods That Fail to Properly Label Major Food Allergens.” We are also placing your Mr. Krisps brand Salad Chips, Pizza Flavor, and Cheez Balls products on Import Alert #99-39, “Detention Without Physical Examination of Imported Food Products That Appear to be Misbranded.”\u003C\u002Fp>\u003Cp>As a result, when your firm’s products are offered for import into the United States, FDA may take steps to refuse their admission, called Detention Without Physical Examination (DWPE). You may view Import Alert #99-22 at https:\u002F\u002Fwww.accessdata.fda.gov\u002FCMS_IA\u002Fimportalert_561.html and Import Alert #99-39 at https:\u002F\u002Fwww.accessdata.fda.gov\u002FCMS_IA\u002Fimportalert_1144.html.\u003C\u002Fp>\u003Cp>FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. This procedure is generally based on past history or other information, such as an establishment inspection report, indicating that the manufacturing facility or the product may not be in compliance with FDA’s laws and regulations.\u003C\u002Fp>\u003Cp>Your labeling violations related to Import Alert #99-22:\u003C\u002Fp>\u003Cp>1. Your Mr. Krisps Salad Chips and Mr. Krisps Pizza Flavor products are misbranded within the meaning of section 403(w) of the Act [21 U.S.C. 343(w)] in that the finished product labels fail to declare the major food allergen “milk” as required by section 403(w)(1) of the Act. Specifically, the Salad Chips product is manufactured using a \u003Cstrong>(b)(4)\u003C\u002Fstrong> which contains the major food allergen milk, and the Pizza Flavor product is manufactured using “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” which also contains the major food allergen milk.\u003C\u002Fp>\u003Cp>Section 201(qq) of the Act [21 U.S.C. 321(qq)] defines milk, egg, fish, Crustacean shellfish, tree nuts, wheat, peanuts, and soybeans, as well as any food ingredient that contains protein derived from one of these foods, with the exception of highly refined oils, as “major food allergens.” A food is misbranded under section 403(w) of the Act if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\u003C\u002Fp>\u003Cul>\u003Cli>The word “Contains” followed by the name of the food source from which the major food allergen is derived, is printed immediately after or adjacent to the list of ingredients, section 403(w)(1)(A) of the Act [21 U.S.C. 343(w)(1)(A)]; or\u003C\u002Fli>\u003Cli>The common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived [e.g. “Whey”(Milk)], except the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source, or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen), section 403(w)(1)(B) of the Act [21 U.S.C. 343(w)(1)(B)].\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We have reviewed the label proofs provided in your June 7, 2022, email to our CSO, and acknowledge you have revised the ingredient lists on both product label proofs to read “Contains Milk and Milk Products.” However, these appear to be proposed label revisions (label proofs) and are not actual labels, and no evidence was provided that the proposed revisions have been implemented. Additionally, your response did not include information on what steps your firm has taken to address the product that was already distributed without the allergen declaration.\u003C\u002Fp>\u003Cp>Your labeling violations related to Import Alert #99-39:\u003C\u002Fp>\u003Cp>1. Your Mr. Krisps Salad Chips and Mr. Krisps Cheez Balls products are misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. 343(e)(2)] because the labels fail to declare the net quantity of contents on the principal display panel, as required by 21 CFR 101.7.\u003C\u002Fp>\u003Cp>Additionally, your Mr. Krisps Pizza Flavor product is misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. 343(e)(2)] and section 4(a)(2) and (a)(3) of the Fair Packaging and Labeling Act (FPLA) [15 U.S.C. 1453(a)(2) and (a)(3)] because the label fails to declare the net quantity of contents in avoirdupois pound and ounce, as required by 21 CFR 101.7(b)(1).\u003C\u002Fp>\u003Cp>2. Your Mr. Krisps Salad Chips and Mr. Krisps Pizza Flavor products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. 343(i)(2)] in that they are fabricated from two or more ingredients and each ingredient is not declared on the label, as required by 21 CFR 101.4. Specifically:\u003C\u002Fp>\u003Cp>a. The ingredient “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” in your Salad Chips product is not declared by its common or usual name in the ingredient statement. The label declares the ingredient as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” but “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” is not an appropriate ingredient name in the U.S. Additionally, based on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” ingredient list, this ingredient does not meet the definition of either an artificial or natural flavor, per 21 CFR 101.22(a). Therefore, it cannot be declared as a flavor.\u003C\u002Fp>\u003Cp>b. The sub-ingredients in the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” in your Salad Chips product must be declared, as required by 21 CFR 101.4(b)(2). According to 21 CFR 101.4(b)(2), the requirement to list these component ingredients (or “sub-ingredients”) may be met by either parenthetically listing the component ingredients after the common or usual name of the main ingredient, or by listing the component ingredients without listing the ingredient itself. Under the first alternative, the component ingredients must be listed in descending order of predominance within the multi-component ingredient; and under the second alternative, the component ingredients must be listed in descending order of predominance in the finished food.\u003C\u002Fp>\u003Cp>c. The ingredient “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” in your Pizza Flavor product is not declared by its common or usual name in the ingredient statement, as required by 21 CFR 101.4(a)(1). The product label declares “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” which is not an appropriate ingredient name in the U.S. Additionally, based on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” ingredient list, this ingredient does not meet the definition of an artificial or natural flavor, per 21 CFR 101.22(a). Therefore, it cannot be declared as a flavor.\u003C\u002Fp>\u003Cp>d. The sub-ingredients in the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” in the Pizza Flavor product must be declared, as required by 21 CFR 101.4(b)(2). According to 21 CFR 101.4(b)(2), the requirement to list these component ingredients (or “sub-ingredients”) may be met by either parenthetically listing the component ingredients after the common or usual name of the main ingredient, or by listing the component ingredients without listing the ingredient itself. Under the first alternative, the component ingredients must be listed in descending order of predominance within the multi-component ingredient; and under the second alternative, the component ingredients must be listed in descending order of predominance in the finished food.\u003C\u002Fp>\u003Cp>3. Your Mr. Krisps Salad Chips and Mr. Krisps Pizza Flavor products are misbranded within the meaning of section 403(a)(1) of the Act [21 U.S.C. 343(a)(1)] in that the labeling is false and misleading.\u003C\u002Fp>\u003Cp>a. Your Salad Chips ingredient list includes “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”; however, the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” ingredient contains “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” which are artificial colors and an added preservative.\u003C\u002Fp>\u003Cp>b. Your Pizza Flavor ingredient list includes “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”; however, the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” ingredient contains “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” which are artificial colors and an added preservative.\u003C\u002Fp>\u003Cp>4. Your Mr. Krisps Salad Chips and Mr. Krisps Pizza Flavor products are misbranded within the meaning of section 403(k) of the Act [21 U.S.C. 343(k)] because the products contain artificial colorings, but the product labels fail to declare the colors. Specifically, your Salad Chips contain “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and your Pizza Flavor product contains “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\u003Cp>5. Your Mr. Krisps Pizza Flavor product is misbranded within the meaning of section 403(i)(1) of the Act [21 U.S.C. 343(i)(1)] in that the label fails to bear the common or usual name of the food, as required by 21 CFR 101.3(b). Specifically, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” is not an appropriate common or usual name, nor does it appropriately describe a food that has potatoes as the most predominant ingredient [21 CFR 101.3(b)].\u003C\u002Fp>\u003Cp>6. Your Mr. Krisps Salad Chips, Mr. Krisps Pizza Flavor, and Mr. Krisps Cheez Balls products are misbranded within the meaning of section 403(q) of the Act [21 U.S.C. 343(q)] in that the nutrition information (e.g., Nutritional Facts Labels) does not comply with the requirements in 21 CFR 101.9. For example:\u003C\u002Fp>\u003Cp>a. Your Salad Chips, Pizza Flavor, and Cheez Balls product labels do not declare the serving size in a common household measure, as required by 21 CFR 101.9(b)(1). The term serving or serving size means an amount of food customarily consumed per eating occasion by persons 4 years of age or older which is expressed in a common household measure that is appropriate to the food.\u003C\u002Fp>\u003Cp>b. Your Salad Chips, Pizza Flavor, and Cheez Balls product labels list the calories per serving incorrectly; calories must be expressed to the nearest 5-calorie increment up to and including 50 calories, and 10-calorie increments above 50 calories, as required by 21 CFR 101.9(c)(1).\u003C\u002Fp>\u003Cp>c. Your Salad Chips, Pizza Flavor, and Cheez Balls product labels fail to declare polyunsaturated fat and monounsaturated fat, as required by 21 CFR 101.9(c)(2)(iii) and (iv). The product labels bear the claims “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” In accordance with 21 CFR 101.9(c)(2)(iii) and (iv), when a claim about fatty acids or cholesterol is made on the label or in labeling of a food, other than one that meets the criteria in 21 CFR 101.62(b)(1) for a claim for “fat free,” a label declaration of polyunsaturated fat and monounsaturated fat is required.\u003C\u002Fp>\u003Cp>d. Your Salad Chips, Pizza Flavor, and Cheez Balls product labels do not list information on calories and servings per container in accordance with 21 CFR 101.9(d).\u003C\u002Fp>\u003Cp>e. Your Pizza Flavor and Cheez Balls product labels are not in accordance with 21 CFR 101.9(b)(12)(i). Specifically, products that are packaged and sold individually and that contain at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> percent and up to and including \u003Cstrong>(b)(4)\u003C\u002Fstrong> percent of the applicable reference amount must provide an additional column within the Nutrition Facts Label (NFL) that lists the quantitative amounts and percent Daily Values for the entire package, as well as a column listing the quantitative amounts and percent Daily Values for a serving that is less than the entire package (i.e., the serving size derived from the reference amount). The first column would be based on the serving size for the product and the second column would be based on the entire contents of the package. The Pizza Flavor package contains approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>% of the reference amount customarily consumed (RACC) for this product, and the Cheez Balls appear to contain between \u003Cstrong>(b)(4)\u003C\u002Fstrong> percent of the RACC for this product. However, the NFLs fail to include an additional column with nutrition information for the entire package.\u003C\u002Fp>\u003Cp>f. Your Salad Chips product label lists the amount of sodium per serving incorrectly; sodium must be expressed as zero when the serving contains less than 5 milligrams of sodium, to the nearest 5-milligram increment when the serving contains 5 to 140 milligrams, and to the nearest 10-milligram increment when the serving contains more than 140 milligrams, as required by 21 CFR 101.9(c)(4).\u003C\u002Fp>\u003Cp>7. Your Mr. Krisps Salad Chips, Mr. Krisps Pizza Flavor, and Mr. Krisps Cheez Balls products are misbranded within the meaning of section 403(r)(1)(A) of the Act [21 U.S.C. 343(r)(1)(A)] because the labels bear nutrient content claims, but the products do not meet the requirements to bear the claim. Your Mr. Krisps Salad Chips and Mr. Krisps Cheez Balls product labels declare “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and your Mr. Krisps Pizza Flavor product declares “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Under section 403(r)(1)(A) of the Act, a claim that characterizes the level of a nutrient which is of the type required to be in the labeling of the food must be made in accordance with a regulation promulgated by the Secretary (or, by delegation, FDA) authorizing the use of such a claim. Characterizing the level of a nutrient in food labeling of a product without complying with the specific requirements pertaining to nutrient content claims for that nutrient causes the product to be misbranded under section 403(r)(1)(A) of the Act.\u003C\u002Fp>\u003Cp>Specifically, the product labels fail to bear the disclosure statement required by 21 CFR 101.13(h)(1) for total fat, saturated fat, and\u002For sodium. If a food contains more than 13 grams of fat, 4 grams of saturated fat, 60 milligrams of cholesterol, or 480 milligrams of sodium per RACC or per labeled serving, or, for a food with a RACC of 30 grams or less or 2 tablespoons or less, per 50 grams, then that food must bear a statement disclosing that the nutrient exceeding the specified level is present in the food as follows: “See nutrition information for __ content” with the blank filled in with the identity of the nutrient exceeding the specified level (e.g., “See nutrition information for sodium content”).\u003C\u002Fp>\u003Cp>a. Your Salad Chips product contains saturated fat and sodium in excess of the disclosure amount per \u003Cstrong>(b)(4)\u003C\u002Fstrong> grams, but the label fails to bear the required disclosure statement.\u003C\u002Fp>\u003Cp>b. Your Pizza Flavor product contains total fat and saturated fat in excess of the disclosure amount per \u003Cstrong>(b)(4)\u003C\u002Fstrong> grams, but the label fails to bear the required disclosure statement.\u003C\u002Fp>\u003Cp>c. Your Cheez Balls product contains total fat and sodium in excess of the disclosure amount per \u003Cstrong>(b)(4)\u003C\u002Fstrong> grams, but the label fails to bear the required disclosure statement.\u003C\u002Fp>\u003Cp>Your June 7, 2022, email included proposed label revisions (label proofs) for your Mr. Krisps Salad Chips and Mr. Krisps Pizza Flavor products. However, these appear to be proposed revisions for the product labels and not actual product labels and are also not in compliance with the Act. For example, they do not comply with the requirements in 21 CFR 101, Food Labeling regulations. Additionally, you did not indicate whether your firm has reviewed the other product labels for compliance with food labeling regulations, as discussed with you during the inspection. Therefore, the adequacy of your firm’s response cannot be fully determined at this time as you have not provided objective evidence of corrective actions.\u003C\u002Fp>\u003Cp>If you wish to request removal from Import Alerts #99-22 and #99-39, you should address the labeling violations described above. Please provide all necessary documentation to verify that violative conditions no longer exist, e.g., full, and complete copies of your revised product labels and the ingredient statements from the product ingredients. Information supporting the request should be forwarded to the following address:\u003C\u002Fp>\u003Cp>Food and Drug Administration\u003Cbr>Division of Import Operations\u003Cbr>12420 Parklawn Drive, ELEM-3109\u003Cbr>Rockville, MD 20857\u003C\u002Fp>\u003Cp>Or, it may be sent via email to: Importalerts2@fda.hhs.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulteration\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, during the inspection the FDA investigator also found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). At the conclusion of the inspection, FDA issued a Form FDA 483, Inspectional Observations, listing these deviations found at your firm.\u003C\u002Fp>\u003Cp>We have determined that these ready-to-eat (RTE) foods are adulterated within the meaning of section 402(a)(4) of the Act [21 U.S.C. § 342(a)(4)] because they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by Section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP &amp; PC rule through links in FDA's website at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>To date, we have not received a response to the inspectional observations listed on the Form FDA 483, Inspectional Observations, dated March 18, 2022.\u003C\u002Fp>\u003Cp>\u003Cstrong>Hazard Analysis and Risk-Based Preventive Controls (Subpart C):\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>1. Your hazard analysis for RTE corn-based cheese puffs and your hazard analysis for RTE potato chips did not identify and evaluate all known or reasonably foreseeable hazards to determine whether there are any hazards requiring a preventive control, as required by 21 CFR 117.130(a). Specifically:\u003C\u002Fp>\u003Cp>a. Your hazard analysis did not identify and evaluate the hazard of allergens in your ingredients to determine whether allergens are a hazard requiring a preventive control. Further, your hazard evaluation did not consider the effect of allergens in ingredients on the safety of your food, as required by 21 CFR 117.130(c)(2)(iii). Your facility manufactures and labels products which include milk-containing ingredients. Mr. Krisps Cheez Balls (corn-based cheese puffs) contain cheddar cheese, and Mr. Krisps Salad Chips and Mr. Krisps Pizza Flavor (potato chips) contain cheese powder with cheese solids and whey solids. These ingredients contain milk, a major food allergen. Therefore, the presence of allergens in your ingredients is a known or reasonably foreseeable hazard requiring a preventive control (i.e., labeling the finished foods to ensure that that the finished food is not misbranded under section 403(w) of the Act).\u003C\u002Fp>\u003Cp>b. You did not appropriately evaluate contamination with environmental pathogens, such as \u003Cem>Salmonella\u003C\u002Fem> and \u003Cem>Listeria monocytogenes\u003C\u002Fem>, to determine whether it is a hazard requiring a preventive control. Your hazard analysis for RTE corn-based cheese puffs considered post-roasting microorganism contamination at the steps of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your hazard analysis for RTE potato chips considered post-frying microorganism contamination at the steps of \u003Cstrong>(b)(4)\u003C\u002Fstrong> addition, buffer storage\u002Finspection, metal detection, and filling\u002Fsealing. You determined in both hazard analyses that a preventive control was not necessary because the hazard was controlled by “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, your RTE corn-based cheese puffs and RTE potato chips are exposed to the environment at the above steps (after being cooked and until they are packaged). The RTE packaged foods do not receive a treatment or otherwise include a control measure (such as a formulation lethal to the pathogen) that would significantly minimize pathogens. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify environmental pathogens as a hazard requiring preventive controls (i.e., sanitation controls). In addition, when asked during the inspection for a copy of your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” you were unable to provide them. Preventive controls for sanitation include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens (see 21 CFR 117.135(c)(3)).\u003C\u002Fp>\u003Cp>Note that if contamination with environmental pathogens is a hazard requiring a preventive control, the controls must be verified by environmental monitoring (i.e., for an environmental pathogen or an appropriate indicator organism as required by 21 CFR 117.165(a)(3)). Your environmental monitoring tests (Aerobic Plate Count, Total Coliforms, \u003Cem>E. coli, Staphylococcus aureus\u003C\u002Fem>, and Enterobacteriaceae), while reasonable tests for general sanitation, are not appropriate as indicator microorganisms for the presence of environmental pathogens such as \u003Cem>Salmonella\u003C\u002Fem> and \u003Cem>Listeria monocytogenes\u003C\u002Fem>. In addition, your environmental sampling schedule for the year 2022 calls for the collection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> on your corn production line and \u003Cstrong>(b)(4)\u003C\u002Fstrong> on your pellet (potato chip) production line, as well as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, every 6 months. You should consider whether your number of sampling sites is adequate to determine whether preventive controls are effective (see 21 CFR 117.165(b)(3)(iii)) and whether your frequency for collecting and testing samples is adequate to determine whether preventive controls are effective (see 21 CFR 117.165(b)(3)(iv)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Current Good Manufacturing Practice (21 CFR Part 117, Subpart B):\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>2. You did not take effective measures to exclude pests from the manufacturing, processing, packing, and holding areas and to protect against contamination of food on the premises by pests, as required by 21 CFR 117.35(c). Specifically, the following conditions were observed:\u003C\u002Fp>\u003Cp>a. On March 14 and 16, 2022, more than ten flies were observed on the lid of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Blending Machine located in the blending\u002Fmixing room. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> Blender is used to blend RTE ingredients such as cheese powder and seasoning, for flavoring food products.\u003C\u002Fp>\u003Cp>b. On March 14 and 16, 2022, more than six flies were observed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Blender used to blend corn curds prior to baking corn-based cheese puffs.\u003C\u002Fp>\u003Cp>Failure to adequately address these serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117) may lead to regulatory action. For instance, we may take further action to refuse admission of your imported snack food products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). For your information, an example of an Import Alert that conveys information specific to foreign firms where FDA has evidence that a firm's lack of or inadequate preventive controls or inadequate CGMPs has led to adulteration of food products within the meaning of section 402(a)(4) of the Act is Import Alert #99-43. You may view this alert at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. You should take prompt action to correct or implement corrections to the violations cited in this letter.\u003C\u002Fp>\u003Cp>Please respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking or have taken to correct these Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation deviations, including an explanation of how your firm plans to prevent these violations or similar violations from occurring again. More specifically, your response should include documentation of the corrective actions your firm has taken. If you do not believe that your products are in violation of the Act, include your reasoning and any supporting information for our consideration. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed.\u003C\u002Fp>\u003Cp>You should direct your written reply regarding the adulteration violations to Rosemary Sexton, Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-607), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions regarding this letter, you may contact Ms. Sexton via email at Rosemary.Sexton@fda.hhs.gov. Please reference #CMS 633740 on any submissions and on the subject line of any emails to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Thomas Kuntz\u003Cbr>Acting Director\u003Cbr>Division of Enforcement\u003Cbr>Office of Compliance\u003Cbr>Center for Food Safety and Applied Nutrition\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Piyush Mahesh\n\nRecipient Title\n\nOwner\n\nNational Food Industries LLC\n\nAl Quoz – 1, Interchange No. 3, Road No. 8, Behind Time Squares\n\nCentre P.O. Box 222\n\nDubai\n\nUnited Arab Emirates\n\npiyush@nfidubai.com\n\nqc@nfidubai.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition\n\nUnited States\n\nAugust 18, 2022\nRE: 633740, 634411, 638165\nDear Mr. Mahesh,\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) is taking steps to subject your food products to detention without physical examination (DWPE) when offered for entry into the United States. More information about DWPE is provided in this letter below. This letter describes the reason for the action and the next steps you can take.\nA representative of the FDA conducted an inspection of your ready-to-eat (RTE) snack food manufacturing facility, National Food Industries LLC, located at National Industries Park, Plot No. Tpo 10422, Dubai, United Arab Emirates on March 14 to 18, 2022. The inspection was conducted to determine your compliance with the Federal Food, Drug, and Cosmetic Act (the Act) and regulations that apply to the food you ship to the United States.\nDuring the inspection, our investigator collected three products labels of your Mr. Krisps brand RTE snack foods. Based on our inspection, we found serious violations of the FDA’s Food Labeling regulations found in Title 21, Code of Federal Regulations, Part 101 (21 CFR 101), causing your products to be misbranded within the meaning of section 403 of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 343].\nYou may find the Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\nMisbranding\nYour Mr. Krisps brand Salad Chips, Pizza Flavor, and Cheez Balls products are misbranded within the meaning of section 403 of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 343].\nBased on our inspectional findings, we are placing your Mr. Krisps Salad Chips and Mr. Krisps Pizza Flavor products on Import Alert #99-22, “Detention Without Physical Examination of Foods Containing Undeclared Major Food Allergens or Foods That Fail to Properly Label Major Food Allergens.” We are also placing your Mr. Krisps brand Salad Chips, Pizza Flavor, and Cheez Balls products on Import Alert #99-39, “Detention Without Physical Examination of Imported Food Products That Appear to be Misbranded.”\nAs a result, when your firm’s products are offered for import into the United States, FDA may take steps to refuse their admission, called Detention Without Physical Examination (DWPE). You may view Import Alert #99-22 at https:\u002F\u002Fwww.accessdata.fda.gov\u002FCMS_IA\u002Fimportalert_561.html and Import Alert #99-39 at https:\u002F\u002Fwww.accessdata.fda.gov\u002FCMS_IA\u002Fimportalert_1144.html.\nFDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. This procedure is generally based on past history or other information, such as an establishment inspection report, indicating that the manufacturing facility or the product may not be in compliance with FDA’s laws and regulations.\nYour labeling violations related to Import Alert #99-22:\n1. Your Mr. Krisps Salad Chips and Mr. Krisps Pizza Flavor products are misbranded within the meaning of section 403(w) of the Act [21 U.S.C. 343(w)] in that the finished product labels fail to declare the major food allergen “milk” as required by section 403(w)(1) of the Act. Specifically, the Salad Chips product is manufactured using a (b)(4) which contains the major food allergen milk, and the Pizza Flavor product is manufactured using “(b)(4)” which also contains the major food allergen milk.\nSection 201(qq) of the Act [21 U.S.C. 321(qq)] defines milk, egg, fish, Crustacean shellfish, tree nuts, wheat, peanuts, and soybeans, as well as any food ingredient that contains protein derived from one of these foods, with the exception of highly refined oils, as “major food allergens.” A food is misbranded under section 403(w) of the Act if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\nThe word “Contains” followed by the name of the food source from which the major food allergen is derived, is printed immediately after or adjacent to the list of ingredients, section 403(w)(1)(A) of the Act [21 U.S.C. 343(w)(1)(A)]; or\nThe common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived [e.g. “Whey”(Milk)], except the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source, or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen), section 403(w)(1)(B) of the Act [21 U.S.C. 343(w)(1)(B)].\nWe have reviewed the label proofs provided in your June 7, 2022, email to our CSO, and acknowledge you have revised the ingredient lists on both product label proofs to read “Contains Milk and Milk Products.” However, these appear to be proposed label revisions (label proofs) and are not actual labels, and no evidence was provided that the proposed revisions have been implemented. Additionally, your response did not include information on what steps your firm has taken to address the product that was already distributed without the allergen declaration.\nYour labeling violations related to Import Alert #99-39:\n1. Your Mr. Krisps Salad Chips and Mr. Krisps Cheez Balls products are misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. 343(e)(2)] because the labels fail to declare the net quantity of contents on the principal display panel, as required by 21 CFR 101.7.\nAdditionally, your Mr. Krisps Pizza Flavor product is misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. 343(e)(2)] and section 4(a)(2) and (a)(3) of the Fair Packaging and Labeling Act (FPLA) [15 U.S.C. 1453(a)(2) and (a)(3)] because the label fails to declare the net quantity of contents in avoirdupois pound and ounce, as required by 21 CFR 101.7(b)(1).\n2. Your Mr. Krisps Salad Chips and Mr. Krisps Pizza Flavor products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. 343(i)(2)] in that they are fabricated from two or more ingredients and each ingredient is not declared on the label, as required by 21 CFR 101.4. Specifically:\na. The ingredient “(b)(4)” in your Salad Chips product is not declared by its common or usual name in the ingredient statement. The label declares the ingredient as “(b)(4)” but “(b)(4)” is not an appropriate ingredient name in the U.S. Additionally, based on the “(b)(4)” ingredient list, this ingredient does not meet the definition of either an artificial or natural flavor, per 21 CFR 101.22(a). Therefore, it cannot be declared as a flavor.\nb. The sub-ingredients in the “(b)(4)” in your Salad Chips product must be declared, as required by 21 CFR 101.4(b)(2). According to 21 CFR 101.4(b)(2), the requirement to list these component ingredients (or “sub-ingredients”) may be met by either parenthetically listing the component ingredients after the common or usual name of the main ingredient, or by listing the component ingredients without listing the ingredient itself. Under the first alternative, the component ingredients must be listed in descending order of predominance within the multi-component ingredient; and under the second alternative, the component ingredients must be listed in descending order of predominance in the finished food.\nc. The ingredient “(b)(4)” in your Pizza Flavor product is not declared by its common or usual name in the ingredient statement, as required by 21 CFR 101.4(a)(1). The product label declares “(b)(4),” which is not an appropriate ingredient name in the U.S. Additionally, based on the “(b)(4)” ingredient list, this ingredient does not meet the definition of an artificial or natural flavor, per 21 CFR 101.22(a). Therefore, it cannot be declared as a flavor.\nd. The sub-ingredients in the “(b)(4)” in the Pizza Flavor product must be declared, as required by 21 CFR 101.4(b)(2). According to 21 CFR 101.4(b)(2), the requirement to list these component ingredients (or “sub-ingredients”) may be met by either parenthetically listing the component ingredients after the common or usual name of the main ingredient, or by listing the component ingredients without listing the ingredient itself. Under the first alternative, the component ingredients must be listed in descending order of predominance within the multi-component ingredient; and under the second alternative, the component ingredients must be listed in descending order of predominance in the finished food.\n3. Your Mr. Krisps Salad Chips and Mr. Krisps Pizza Flavor products are misbranded within the meaning of section 403(a)(1) of the Act [21 U.S.C. 343(a)(1)] in that the labeling is false and misleading.\na. Your Salad Chips ingredient list includes “(b)(4)”; however, the “(b)(4)” ingredient contains “(b)(4)” and “(b)(4),” which are artificial colors and an added preservative.\nb. Your Pizza Flavor ingredient list includes “(b)(4)”; however, the “(b)(4)” ingredient contains “(b)(4)” and “(b)(4),” which are artificial colors and an added preservative.\n4. Your Mr. Krisps Salad Chips and Mr. Krisps Pizza Flavor products are misbranded within the meaning of section 403(k) of the Act [21 U.S.C. 343(k)] because the products contain artificial colorings, but the product labels fail to declare the colors. Specifically, your Salad Chips contain “(b)(4),” and your Pizza Flavor product contains “(b)(4).”\n5. Your Mr. Krisps Pizza Flavor product is misbranded within the meaning of section 403(i)(1) of the Act [21 U.S.C. 343(i)(1)] in that the label fails to bear the common or usual name of the food, as required by 21 CFR 101.3(b). Specifically, “(b)(4)” is not an appropriate common or usual name, nor does it appropriately describe a food that has potatoes as the most predominant ingredient [21 CFR 101.3(b)].\n6. Your Mr. Krisps Salad Chips, Mr. Krisps Pizza Flavor, and Mr. Krisps Cheez Balls products are misbranded within the meaning of section 403(q) of the Act [21 U.S.C. 343(q)] in that the nutrition information (e.g., Nutritional Facts Labels) does not comply with the requirements in 21 CFR 101.9. For example:\na. Your Salad Chips, Pizza Flavor, and Cheez Balls product labels do not declare the serving size in a common household measure, as required by 21 CFR 101.9(b)(1). The term serving or serving size means an amount of food customarily consumed per eating occasion by persons 4 years of age or older which is expressed in a common household measure that is appropriate to the food.\nb. Your Salad Chips, Pizza Flavor, and Cheez Balls product labels list the calories per serving incorrectly; calories must be expressed to the nearest 5-calorie increment up to and including 50 calories, and 10-calorie increments above 50 calories, as required by 21 CFR 101.9(c)(1).\nc. Your Salad Chips, Pizza Flavor, and Cheez Balls product labels fail to declare polyunsaturated fat and monounsaturated fat, as required by 21 CFR 101.9(c)(2)(iii) and (iv). The product labels bear the claims “(b)(4)” and “(b)(4).” In accordance with 21 CFR 101.9(c)(2)(iii) and (iv), when a claim about fatty acids or cholesterol is made on the label or in labeling of a food, other than one that meets the criteria in 21 CFR 101.62(b)(1) for a claim for “fat free,” a label declaration of polyunsaturated fat and monounsaturated fat is required.\nd. Your Salad Chips, Pizza Flavor, and Cheez Balls product labels do not list information on calories and servings per container in accordance with 21 CFR 101.9(d).\ne. Your Pizza Flavor and Cheez Balls product labels are not in accordance with 21 CFR 101.9(b)(12)(i). Specifically, products that are packaged and sold individually and that contain at least (b)(4) percent and up to and including (b)(4) percent of the applicable reference amount must provide an additional column within the Nutrition Facts Label (NFL) that lists the quantitative amounts and percent Daily Values for the entire package, as well as a column listing the quantitative amounts and percent Daily Values for a serving that is less than the entire package (i.e., the serving size derived from the reference amount). The first column would be based on the serving size for the product and the second column would be based on the entire contents of the package. The Pizza Flavor package contains approximately (b)(4)% of the reference amount customarily consumed (RACC) for this product, and the Cheez Balls appear to contain between (b)(4) percent of the RACC for this product. However, the NFLs fail to include an additional column with nutrition information for the entire package.\nf. Your Salad Chips product label lists the amount of sodium per serving incorrectly; sodium must be expressed as zero when the serving contains less than 5 milligrams of sodium, to the nearest 5-milligram increment when the serving contains 5 to 140 milligrams, and to the nearest 10-milligram increment when the serving contains more than 140 milligrams, as required by 21 CFR 101.9(c)(4).\n7. Your Mr. Krisps Salad Chips, Mr. Krisps Pizza Flavor, and Mr. Krisps Cheez Balls products are misbranded within the meaning of section 403(r)(1)(A) of the Act [21 U.S.C. 343(r)(1)(A)] because the labels bear nutrient content claims, but the products do not meet the requirements to bear the claim. Your Mr. Krisps Salad Chips and Mr. Krisps Cheez Balls product labels declare “(b)(4)” and “(b)(4)” and your Mr. Krisps Pizza Flavor product declares “(b)(4)” and “(b)(4).” Under section 403(r)(1)(A) of the Act, a claim that characterizes the level of a nutrient which is of the type required to be in the labeling of the food must be made in accordance with a regulation promulgated by the Secretary (or, by delegation, FDA) authorizing the use of such a claim. Characterizing the level of a nutrient in food labeling of a product without complying with the specific requirements pertaining to nutrient content claims for that nutrient causes the product to be misbranded under section 403(r)(1)(A) of the Act.\nSpecifically, the product labels fail to bear the disclosure statement required by 21 CFR 101.13(h)(1) for total fat, saturated fat, and\u002For sodium. If a food contains more than 13 grams of fat, 4 grams of saturated fat, 60 milligrams of cholesterol, or 480 milligrams of sodium per RACC or per labeled serving, or, for a food with a RACC of 30 grams or less or 2 tablespoons or less, per 50 grams, then that food must bear a statement disclosing that the nutrient exceeding the specified level is present in the food as follows: “See nutrition information for __ content” with the blank filled in with the identity of the nutrient exceeding the specified level (e.g., “See nutrition information for sodium content”).\na. Your Salad Chips product contains saturated fat and sodium in excess of the disclosure amount per (b)(4) grams, but the label fails to bear the required disclosure statement.\nb. Your Pizza Flavor product contains total fat and saturated fat in excess of the disclosure amount per (b)(4) grams, but the label fails to bear the required disclosure statement.\nc. Your Cheez Balls product contains total fat and sodium in excess of the disclosure amount per (b)(4) grams, but the label fails to bear the required disclosure statement.\nYour June 7, 2022, email included proposed label revisions (label proofs) for your Mr. Krisps Salad Chips and Mr. Krisps Pizza Flavor products. However, these appear to be proposed revisions for the product labels and not actual product labels and are also not in compliance with the Act. For example, they do not comply with the requirements in 21 CFR 101, Food Labeling regulations. Additionally, you did not indicate whether your firm has reviewed the other product labels for compliance with food labeling regulations, as discussed with you during the inspection. Therefore, the adequacy of your firm’s response cannot be fully determined at this time as you have not provided objective evidence of corrective actions.\nIf you wish to request removal from Import Alerts #99-22 and #99-39, you should address the labeling violations described above. Please provide all necessary documentation to verify that violative conditions no longer exist, e.g., full, and complete copies of your revised product labels and the ingredient statements from the product ingredients. Information supporting the request should be forwarded to the following address:\nFood and Drug Administration\nDivision of Import Operations\n12420 Parklawn Drive, ELEM-3109\nRockville, MD 20857\nOr, it may be sent via email to: Importalerts2@fda.hhs.gov.\nAdulteration\nIn addition, during the inspection the FDA investigator also found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). At the conclusion of the inspection, FDA issued a Form FDA 483, Inspectional Observations, listing these deviations found at your firm.\nWe have determined that these ready-to-eat (RTE) foods are adulterated within the meaning of section 402(a)(4) of the Act [21 U.S.C. § 342(a)(4)] because they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by Section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP & PC rule through links in FDA's website at http:\u002F\u002Fwww.fda.gov.\nTo date, we have not received a response to the inspectional observations listed on the Form FDA 483, Inspectional Observations, dated March 18, 2022.\nHazard Analysis and Risk-Based Preventive Controls (Subpart C):\n1. Your hazard analysis for RTE corn-based cheese puffs and your hazard analysis for RTE potato chips did not identify and evaluate all known or reasonably foreseeable hazards to determine whether there are any hazards requiring a preventive control, as required by 21 CFR 117.130(a). Specifically:\na. Your hazard analysis did not identify and evaluate the hazard of allergens in your ingredients to determine whether allergens are a hazard requiring a preventive control. Further, your hazard evaluation did not consider the effect of allergens in ingredients on the safety of your food, as required by 21 CFR 117.130(c)(2)(iii). Your facility manufactures and labels products which include milk-containing ingredients. Mr. Krisps Cheez Balls (corn-based cheese puffs) contain cheddar cheese, and Mr. Krisps Salad Chips and Mr. Krisps Pizza Flavor (potato chips) contain cheese powder with cheese solids and whey solids. These ingredients contain milk, a major food allergen. Therefore, the presence of allergens in your ingredients is a known or reasonably foreseeable hazard requiring a preventive control (i.e., labeling the finished foods to ensure that that the finished food is not misbranded under section 403(w) of the Act).\nb. You did not appropriately evaluate contamination with environmental pathogens, such as Salmonella and Listeria monocytogenes, to determine whether it is a hazard requiring a preventive control. Your hazard analysis for RTE corn-based cheese puffs considered post-roasting microorganism contamination at the steps of (b)(4). Your hazard analysis for RTE potato chips considered post-frying microorganism contamination at the steps of (b)(4) addition, buffer storage\u002Finspection, metal detection, and filling\u002Fsealing. You determined in both hazard analyses that a preventive control was not necessary because the hazard was controlled by “(b)(4).” However, your RTE corn-based cheese puffs and RTE potato chips are exposed to the environment at the above steps (after being cooked and until they are packaged). The RTE packaged foods do not receive a treatment or otherwise include a control measure (such as a formulation lethal to the pathogen) that would significantly minimize pathogens. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify environmental pathogens as a hazard requiring preventive controls (i.e., sanitation controls). In addition, when asked during the inspection for a copy of your “(b)(4),” you were unable to provide them. Preventive controls for sanitation include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens (see 21 CFR 117.135(c)(3)).\nNote that if contamination with environmental pathogens is a hazard requiring a preventive control, the controls must be verified by environmental monitoring (i.e., for an environmental pathogen or an appropriate indicator organism as required by 21 CFR 117.165(a)(3)). Your environmental monitoring tests (Aerobic Plate Count, Total Coliforms, E. coli, Staphylococcus aureus, and Enterobacteriaceae), while reasonable tests for general sanitation, are not appropriate as indicator microorganisms for the presence of environmental pathogens such as Salmonella and Listeria monocytogenes. In addition, your environmental sampling schedule for the year 2022 calls for the collection of (b)(4) on your corn production line and (b)(4) on your pellet (potato chip) production line, as well as (b)(4), every 6 months. You should consider whether your number of sampling sites is adequate to determine whether preventive controls are effective (see 21 CFR 117.165(b)(3)(iii)) and whether your frequency for collecting and testing samples is adequate to determine whether preventive controls are effective (see 21 CFR 117.165(b)(3)(iv)).\nCurrent Good Manufacturing Practice (21 CFR Part 117, Subpart B):\n2. You did not take effective measures to exclude pests from the manufacturing, processing, packing, and holding areas and to protect against contamination of food on the premises by pests, as required by 21 CFR 117.35(c). Specifically, the following conditions were observed:\na. On March 14 and 16, 2022, more than ten flies were observed on the lid of the (b)(4) Blending Machine located in the blending\u002Fmixing room. The (b)(4) Blender is used to blend RTE ingredients such as cheese powder and seasoning, for flavoring food products.\nb. On March 14 and 16, 2022, more than six flies were observed on the (b)(4) Blender used to blend corn curds prior to baking corn-based cheese puffs.\nFailure to adequately address these serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117) may lead to regulatory action. For instance, we may take further action to refuse admission of your imported snack food products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). For your information, an example of an Import Alert that conveys information specific to foreign firms where FDA has evidence that a firm's lack of or inadequate preventive controls or inadequate CGMPs has led to adulteration of food products within the meaning of section 402(a)(4) of the Act is Import Alert #99-43. You may view this alert at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. You should take prompt action to correct or implement corrections to the violations cited in this letter.\nPlease respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking or have taken to correct these Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation deviations, including an explanation of how your firm plans to prevent these violations or similar violations from occurring again. More specifically, your response should include documentation of the corrective actions your firm has taken. If you do not believe that your products are in violation of the Act, include your reasoning and any supporting information for our consideration. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed.\nYou should direct your written reply regarding the adulteration violations to Rosemary Sexton, Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-607), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions regarding this letter, you may contact Ms. Sexton via email at Rosemary.Sexton@fda.hhs.gov. Please reference #CMS 633740 on any submissions and on the subject line of any emails to us.\nSincerely,\n\u002FS\u002F\nThomas Kuntz\nActing Director\nDivision of Enforcement\nOffice of Compliance\nCenter for Food Safety and Applied Nutrition","National Food Industries LLC","national-food-industries-llc-633740-08182022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnational-food-industries-llc-633740-08182022","2026-10-26T08:09:30.134818+00:00","2022-08-30","633740","Mr. Piyush Mahesh","2026-08-20T01:37:47.314+00:00","Via Express Delivery","2022-08-18",{"id":333,"raw":334,"subject":80,"body_html":338,"body_text":339,"firm_name":340,"letter_id":341,"created_at":244,"fei_number":19,"letter_url":342,"updated_at":343,"action_type":22,"case_status":23,"posted_date":344,"marcs_cms_no":345,"product_type":90,"closeout_date":19,"issuing_office":79,"recipient_name":346,"body_fetched_at":347,"delivery_method":93,"recipient_title":19,"reference_number":19,"action_taken_date":344,"medical_device_id":19,"response_letter_date":19},2845,[335,336,337,79,80,13,13,13],"\u003Ctime datetime=\"2022-02-23T20:00:00Z\">02\u002F23\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-23T05:00:00Z\">02\u002F23\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcraving-vapor-industries-llc-627602-02232022\">Craving Vapor Industries, LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joseph K. Williamson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Craving Vapor Industries, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11212 Metric Boulevard, Suite 300\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Austin\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78758\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:joe@cravingvapor.com\"> joe@cravingvapor.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 23, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Williamson:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Craving Vapor Industries, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: Axiom Creamy RY4 3mg 60ml, Axiom Stuffberry 18mg 60ml, and Axiom Strawberry Cloud Rat 3mg 60ml.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 4,600 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0002095, on September 09, 2020. However, FDA issued a negative action for STN PM0002095 in the form of a Refuse To Accept determination on July 6, 2021, which covers 2102 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0002095 that resulted in a Refuse To Accept determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these&nbsp;compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200483, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nJoseph K. Williamson\n\nRecipient Title\n\nManager\n\nCraving Vapor Industries, LLC\n\n11212 Metric Boulevard, Suite 300\n\nAustin, TX 78758\n\nUnited States\n\njoe@cravingvapor.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nFebruary 23, 2022\n\nWARNING LETTER\n\nDear Mr. Williamson:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Craving Vapor Industries, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: Axiom Creamy RY4 3mg 60ml, Axiom Stuffberry 18mg 60ml, and Axiom Strawberry Cloud Rat 3mg 60ml.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 4,600 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0002095, on September 09, 2020. However, FDA issued a negative action for STN PM0002095 in the form of a Refuse To Accept determination on July 6, 2021, which covers 2102 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0002095 that resulted in a Refuse To Accept determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200483, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Craving Vapor Industries, LLC","craving-vapor-industries-llc-627602-02232022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcraving-vapor-industries-llc-627602-02232022","2026-10-26T08:08:19.044895+00:00","2022-02-23","627602","Joseph K. Williamson","2026-08-20T02:09:09.199+00:00",{"id":349,"raw":350,"subject":80,"body_html":353,"body_text":354,"firm_name":340,"letter_id":355,"created_at":244,"fei_number":19,"letter_url":356,"updated_at":357,"action_type":22,"case_status":23,"posted_date":358,"marcs_cms_no":19,"product_type":90,"closeout_date":19,"issuing_office":79,"recipient_name":346,"body_fetched_at":359,"delivery_method":93,"recipient_title":19,"reference_number":19,"action_taken_date":344,"medical_device_id":19,"response_letter_date":19},2812,[351,336,352,79,80,13,13,13],"\u003Ctime datetime=\"2022-03-15T13:20:00Z\">03\u002F15\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcraving-vapor-industries-llc-627602-02232022-0\">Craving Vapor Industries, LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joseph K. Williamson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Craving Vapor Industries, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11212 Metric Boulevard, Suite 300\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Austin\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78758\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:joe@cravingvapor.com\"> joe@cravingvapor.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 23, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Williamson:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Craving Vapor Industries, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: Axiom Creamy RY4 3mg 60ml, Axiom Stuffberry 18mg 60ml, and Axiom Strawberry Cloud Rat 3mg 60ml.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 4,600 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0002095, on September 09, 2020. However, FDA issued a negative action for STN PM0002095 in the form of a Refuse To Accept determination on July 6, 2021, which covers 2102 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0002095 that resulted in a Refuse To Accept determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200483, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nJoseph K. Williamson\n\nRecipient Title\n\nManager\n\nCraving Vapor Industries, LLC\n\n11212 Metric Boulevard, Suite 300\n\nAustin, TX 78758\n\nUnited States\n\njoe@cravingvapor.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nFebruary 23, 2022\n\nWARNING LETTER\n\nDear Mr. Williamson:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Craving Vapor Industries, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: Axiom Creamy RY4 3mg 60ml, Axiom Stuffberry 18mg 60ml, and Axiom Strawberry Cloud Rat 3mg 60ml.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 4,600 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0002095, on September 09, 2020. However, FDA issued a negative action for STN PM0002095 in the form of a Refuse To Accept determination on July 6, 2021, which covers 2102 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0002095 that resulted in a Refuse To Accept determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200483, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","craving-vapor-industries-llc-627602-02232022-0","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcraving-vapor-industries-llc-627602-02232022-0","2026-10-26T08:08:19.08526+00:00","2022-03-15","2026-08-20T02:05:50.575+00:00",{"id":361,"raw":362,"subject":12,"body_html":367,"body_text":368,"firm_name":369,"letter_id":370,"created_at":42,"fei_number":19,"letter_url":371,"updated_at":372,"action_type":22,"case_status":23,"posted_date":373,"marcs_cms_no":374,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":375,"body_fetched_at":376,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":377,"medical_device_id":19,"response_letter_date":19},1747,[363,364,365,11,366,13,13,13],"\u003Ctime datetime=\"2023-11-14T14:20:00Z\">11\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-01T04:00:00Z\">06\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fming-fai-industrial-co-ltd-660075-06012023\">Ming Fai Industrial Co LTD\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Tsz Kin Kent Yim\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Quality Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Ming Fai Industrial Co LTD\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Ming Fai Industrial Estate, Bainikeng, Pinghu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Longgang Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shenzhen Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangdong Sheng\u003C\u002Fspan>, \u003Cspan>518111\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Kent.yim@mingfaigroup.com\"> Kent.yim@mingfaigroup.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 1, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Yim:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, located in Shenzhen, China, on March 06, 2023, through March 10, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures ultrasound gel and probe cover products. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received a response dated March 23, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a). For example, your firm did not maintain documentation of validation for the following processes:\u003C\u002Fp>\n\n\u003Cp>a. Ethylene Oxide (EO) sterilization of the probe cover kit containing the sterile gel pouch\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm’s EO sterilization validation was conducted for a kit containing another device, C-Arm Drape, that is also packaged in a Tyvek pouch.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>However, the C-Arm Drape kit differs from the ultrasound gel probe cover kit, as the probe cover kit contains a sterile gel pouch. Your firm did not maintain documentation with justification that the EO validation conducted on the C-Arm Drapes packaged in a Tyvek pouch is representative for the probe cover kit.\u003C\u002Fp>\n\n\u003Cp>b. Formulation calculation software for mixing of the ultrasound gel\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm did not maintain validation records for the software used to calculate the amounts for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> ingredients to be mixed for the ultrasound gel formulation.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>c. Cleaning of the mixing tank equipment used for ultrasound gel manufacture\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm did not maintain documentation of cleaning validation conducted for the mixing tank equipment used for manufacturing ultrasound gel.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm provided four updates corresponding to the listed examples regarding process validation.\u003C\u002Fp>\n\n\u003Cp>a. Your firm provided a new procedure, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Procedure for Irradiation Sterilization Dose, to document the irradiation validation dose similar to the validation report in Exhibit 22. However, this document does not address the concern of your firm not being able to provide adequate records of the gel lots used during the sterilization validation. Additionally, there is no evidence of procedure effectiveness and documentation of training on the new procedure.\u003C\u002Fp>\n\n\u003Cp>b. Your firm provided a procedure for “Evaluate the Medical Device Family for EO sterilization” under procedure \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The purpose of this procedure is for your firm to evaluate the sterilization methods and parameters of devices to determine how to select a representative model for sterilization of a device family. However, the evaluation has not been completed by your firm and only the procedure to evaluate the representative device has been provided. The response is inadequate because your firm has not provided documentation on training and effectiveness of the new procedure. Therefore, the Agency cannot determine if your firm’s corrections adequately address the requirements of the regulation.\u003C\u002Fp>\n\n\u003Cp>c. Your firm established a procedure “Software Validation for formulation” \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the “validation of formulation systems.” The procedure documents how an Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) should be performed. However, the response is inadequate because of the following:\u003Cbr>\n- There is no specific documentation of the IQ\u002FOQ\u002FPQ protocol and report related to the formulation of the ultrasound gel that include acceptance criteria.\u003Cbr>\n- No CAPA to track and evaluate effectiveness of corrective actions\u003Cbr>\n- No documentation of training on the new procedure\u003Cbr>\n\u003Cbr>\nd. Your firm states that their cleaning validation incorrectly did not list the mixing tank used in the manufacture of ultrasound gel. In your response, your firm provided an equipment list that only lists the mixing tank used for the ultrasound gel manufacturing process. Your firm states that the assigned QA engineer is responsible to review and check the mixer code for each validation report. However, the response is inadequate because of the following:\u003Cbr>\n- There is no documentation of the investigation and evidence to show that the mixing tank was incorrectly listed on the report information.\u003Cbr>\n- No documentation of any updated procedure that instructs the responsible QA engineer to review and check mixer code for each validation report.\u003Cbr>\n- No documentation of training on new procedure.\u003C\u002Fp>\n\n\u003Cp>2. Failure to identify by suitable means the acceptance status of the product, to indicate the conformance or nonconformance of product with acceptance criteria, as required by 21 CFR 820.86. For example, your firm had several pallets of in-process product held next to finished products in an area designated for finished sterile product ready for release. Additionally, the sterility status of product was not identified (e.g., stickers affixed directly to finished product). Only a single loose paper with the lot number and one sterile color identifier (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) was taped to the pallet.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm provided an updated warehouse layout where you proposed storage of sterilized semi-finished products and stated that “labeling on the rack is corrected immediately”. Additionally, your firm has provided a revised procedure for “Finished Device Acceptance, \u003Cstrong>(b)(4)\u003C\u002Fstrong>”. However, the response is inadequate because of the following:\u003C\u002Fp>\n\n\u003Cp>a. No evidence of the labeling on the rack was provided.\u003Cbr>\nb. No documentation was provided demonstrating personnel were trained on the updated layout and procedure.\u003Cbr>\nc. No documentation of a review or evaluation on the effectiveness of the layout change and revised Finished Device Acceptance procedure.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Refer to CMS case #660075 when replying. If you have any questions about the contents of this letter, please contact: Yanna Kang, Ph.D. at +1(301)796-6704.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Robert Ochs, Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT8: Office of Radiological Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>Cc:\u003Cbr>\nDavid Lennarz\u003Cbr>\nU.S. Agent\u003Cbr>\nRegistrar Corp.\u003Cbr>\n144 Research Drive\u003Cbr>\nHampton, Virginia 23666\u003Cbr>\nDavid.Lennarz@registrarcorp.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Tsz Kin Kent Yim\n\nRecipient Title\n\nQuality Director\n\nMing Fai Industrial Co LTD\n\nMing Fai Industrial Estate, Bainikeng, Pinghu\n\nLonggang Qu\n\nShenzhen Shi\n\nGuangdong Sheng, 518111\n\nChina\n\nKent.yim@mingfaigroup.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nJune 1, 2023\n\nWARNING LETTER\n\nDear Mr. Yim:\n\nDuring an inspection of your firm, located in Shenzhen, China, on March 06, 2023, through March 10, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures ultrasound gel and probe cover products. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received a response dated March 23, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a). For example, your firm did not maintain documentation of validation for the following processes:\n\na. Ethylene Oxide (EO) sterilization of the probe cover kit containing the sterile gel pouch\n\nYour firm’s EO sterilization validation was conducted for a kit containing another device, C-Arm Drape, that is also packaged in a Tyvek pouch.\n\nHowever, the C-Arm Drape kit differs from the ultrasound gel probe cover kit, as the probe cover kit contains a sterile gel pouch. Your firm did not maintain documentation with justification that the EO validation conducted on the C-Arm Drapes packaged in a Tyvek pouch is representative for the probe cover kit.\n\nb. Formulation calculation software for mixing of the ultrasound gel\n\nYour firm did not maintain validation records for the software used to calculate the amounts for the (b)(4) ingredients to be mixed for the ultrasound gel formulation.\n\nc. Cleaning of the mixing tank equipment used for ultrasound gel manufacture\n\nYour firm did not maintain documentation of cleaning validation conducted for the mixing tank equipment used for manufacturing ultrasound gel.\n\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm provided four updates corresponding to the listed examples regarding process validation.\n\na. Your firm provided a new procedure, (b)(4) Procedure for Irradiation Sterilization Dose, to document the irradiation validation dose similar to the validation report in Exhibit 22. However, this document does not address the concern of your firm not being able to provide adequate records of the gel lots used during the sterilization validation. Additionally, there is no evidence of procedure effectiveness and documentation of training on the new procedure.\n\nb. Your firm provided a procedure for “Evaluate the Medical Device Family for EO sterilization” under procedure (b)(4). The purpose of this procedure is for your firm to evaluate the sterilization methods and parameters of devices to determine how to select a representative model for sterilization of a device family. However, the evaluation has not been completed by your firm and only the procedure to evaluate the representative device has been provided. The response is inadequate because your firm has not provided documentation on training and effectiveness of the new procedure. Therefore, the Agency cannot determine if your firm’s corrections adequately address the requirements of the regulation.\n\nc. Your firm established a procedure “Software Validation for formulation” (b)(4) for the “validation of formulation systems.” The procedure documents how an Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) should be performed. However, the response is inadequate because of the following:\n\n- There is no specific documentation of the IQ\u002FOQ\u002FPQ protocol and report related to the formulation of the ultrasound gel that include acceptance criteria.\n\n- No CAPA to track and evaluate effectiveness of corrective actions\n\n- No documentation of training on the new procedure\n\nd. Your firm states that their cleaning validation incorrectly did not list the mixing tank used in the manufacture of ultrasound gel. In your response, your firm provided an equipment list that only lists the mixing tank used for the ultrasound gel manufacturing process. Your firm states that the assigned QA engineer is responsible to review and check the mixer code for each validation report. However, the response is inadequate because of the following:\n\n- There is no documentation of the investigation and evidence to show that the mixing tank was incorrectly listed on the report information.\n\n- No documentation of any updated procedure that instructs the responsible QA engineer to review and check mixer code for each validation report.\n\n- No documentation of training on new procedure.\n\n2. Failure to identify by suitable means the acceptance status of the product, to indicate the conformance or nonconformance of product with acceptance criteria, as required by 21 CFR 820.86. For example, your firm had several pallets of in-process product held next to finished products in an area designated for finished sterile product ready for release. Additionally, the sterility status of product was not identified (e.g., stickers affixed directly to finished product). Only a single loose paper with the lot number and one sterile color identifier ((b)(4)) was taped to the pallet.\n\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm provided an updated warehouse layout where you proposed storage of sterilized semi-finished products and stated that “labeling on the rack is corrected immediately”. Additionally, your firm has provided a revised procedure for “Finished Device Acceptance, (b)(4)”. However, the response is inadequate because of the following:\n\na. No evidence of the labeling on the rack was provided.\n\nb. No documentation was provided demonstrating personnel were trained on the updated layout and procedure.\n\nc. No documentation of a review or evaluation on the effectiveness of the layout change and revised Finished Device Acceptance procedure.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov.\n\nRefer to CMS case #660075 when replying. If you have any questions about the contents of this letter, please contact: Yanna Kang, Ph.D. at +1(301)796-6704.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nRobert Ochs, Ph.D.\n\nDirector\n\nOHT8: Office of Radiological Health\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc:\n\nDavid Lennarz\n\nU.S. Agent\n\nRegistrar Corp.\n\n144 Research Drive\n\nHampton, Virginia 23666\n\nDavid.Lennarz@registrarcorp.com","Ming Fai Industrial Co LTD","ming-fai-industrial-co-ltd-660075-06012023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fming-fai-industrial-co-ltd-660075-06012023","2026-10-26T08:09:26.080364+00:00","2023-11-14","660075","Mr. Tsz Kin Kent Yim","2026-08-20T00:31:47.825+00:00","2023-06-01",{"id":379,"raw":380,"subject":149,"body_html":385,"body_text":386,"firm_name":387,"letter_id":388,"created_at":108,"fei_number":19,"letter_url":389,"updated_at":390,"action_type":22,"case_status":23,"posted_date":391,"marcs_cms_no":392,"product_type":137,"closeout_date":19,"issuing_office":384,"recipient_name":393,"body_fetched_at":394,"delivery_method":395,"recipient_title":19,"reference_number":19,"action_taken_date":396,"medical_device_id":19,"response_letter_date":19},1397,[381,382,383,384,149,13,13,13],"\u003Ctime datetime=\"2024-07-02T13:20:00Z\">07\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-06-18T04:00:00Z\">06\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsun-pharmaceutical-industries-limited-677337-06182024\">Sun Pharmaceutical Industries Limited\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Dilip Shanghvi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sun Pharmaceutical Industries Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Sun House, Plot No. 201 B\u002F1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>West Express Highway Goregaon East\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mumbai\u003C\u002Fspan> \u003Cspan>400063\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Maharashtra\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Dilip.Shanghvi@sunpharma.com\"> Dilip.Shanghvi@sunpharma.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-48\u003C\u002Fp>\n\n\u003Cp>June 18, 2024\u003Cbr>\n\u003Cbr>\nDear Mr. Shanghvi:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sun Pharmaceutical Industries Limited, FEI 3004561553, at Survey No. 1012, Dadra-396 193, U.T. of Dadra and Nagar Haveli and Daman and Diu, from December 4 to 15, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your January 9, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately clean and maintain your equipment used for drug product manufacturing. For example, our investigator observed approximately 450 mL of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> stagnant liquid within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your nondedicated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your chemical analysis of the unknown liquid using liquid chromatography mass spectrometry (LC\u002FMS) showed numerous peaks. In addition, the microbiological analysis identified too numerous to count (TNTC) colony forming units for total aerobic microbial count (TAMC) and total yeast and mold count (TYMC) testing. You used this nondedicated \u003Cstrong>(b)(4)\u003C\u002Fstrong> to manufacture over \u003Cstrong>(b)(4)\u003C\u002Fstrong> different drug products.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that a faulty \u003Cstrong>(b)(4)\u003C\u002Fstrong> valve was the root cause for the observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> liquid accumulating in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> valve failed to completely close and seal when you last disassembled it on June 26, 2023. You acknowledge you discovered this equipment malfunction after initiating an investigation as a result of our investigator’s findings. You state that previously manufactured drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> active pharmaceutical ingredient (API) and its degradants, as well as \u003Cstrong>(b)(4)\u003C\u002Fstrong> API, were identified in the liquid. You also identified microorganisms \u003Cem>Sphingomonas paucimobilis, Bordetella bronchiseptica\u003C\u002Fem>, and \u003Cem>Pseudomonas stutzeri\u003C\u002Fem> in the liquid.\u003C\u002Fp>\n\n\u003Cp>We acknowledge you recalled \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches and rejected \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of drug products manufactured on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> between June 2023 and December 2023.\u003C\u002Fp>\n\n\u003Cp>However, your response does not sufficiently address the cross-contamination issue. You failed to provide a full characterization of each unknown peak from your chemical analysis. It remains imperative that your investigations are comprehensive to prevent recurrence of inadequate equipment maintenance. We also understand from your recent correspondence that a third-party consultant identified numerous gaps in your equipment maintenance program, but you conclude no critical or major findings were noted.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure your equipment maintenance program is comprehensive and includes appropriate assessment of equipment failures and their impact to product quality.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include other manufacturing equipment that may have been improperly cleaned, evaluate the identity of any residues, and assess whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\n\t\u003Cli>A corrective action and preventive action (CAPA) plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\n\t\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\u003C\u002Fli>\n\t\u003Cli>Your CAPA plan to comprehensively address any gaps identified by your third-party consultant from the assessment of your equipment maintenance program including, but not limited to, inadequate quality unit (QU) oversight, inadequate trending of preventive maintenance, and lack of detailed procedures.\u003C\u002Fli>\n\t\u003Cli>Your specific activities that are being undertaken to ensure effective remediation of the conditions that caused the specific cross-contamination incidents discussed above. Provide an independent review by your consultant that determines the effectiveness of your CAPA, including but not limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o Enhancements to cleaning and maintenance procedures including determination of specific frequencies and locations to be cleaned in all relevant equipment (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>)\u003Cbr>\no Adequacy of analysis of equipment maintenance and repair history for all \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment\u003Cbr>\no Sufficiency of the evaluation of all significant manufacturing equipment including, but not limited to, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment, to identify other sources of contamination\u003Cbr>\no Whether improvements to your analytical methodology to identify residual carryover were adequate\u003Cbr>\no Whether adequate investigations into other unknown (unidentified) peaks detected in the unknown liquid in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> were performed\u003Cbr>\no Assessment whether the scope of the investigation and its related CAPA were sufficient\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your investigations of out-of-specification (OOS) results were inadequate because they lacked scientific rationale for root cause determinations. For example, you initiated an OOS investigation for an unknown impurity detected during related substances testing of a 12-month stability sample of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets. The specification for any unknown impurity for \u003Cstrong>(b)(4)\u003C\u002Fstrong> is not more than \u003Cstrong>(b)(4)\u003C\u002Fstrong>%, however, your initial test yielded a result of \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. Your investigation concluded, without adequate scientific justification, that dirty glassware was the probable root cause. Upon discussion with our investigator, you reopened your investigation and concluded the root cause to be contamination from another product, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, that was also tested during the same time period. However, this conclusion was not scientifically justified because the retention time of \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not match that of the unknown impurity peak.\u003Cbr>\n\u003Cbr>\nIn your response, you state you performed additional testing of more drug products tested in the same laboratory during the same time period when the OOS result occurred. You identified the root cause as laboratory contamination and the unknown impurity to be \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, you state you have hired a third-party consultant to review invalidated OOS results generated between April 1, 2019, and December 26, 2023, to determine if the decisions made to invalidate those results were scientifically justified.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not explain why root cause determinations in the OOS investigation were accepted by your firm multiple times, although insufficiently justified.\u003C\u002Fp>\n\n\u003Cp>Your quality system failed to ensure appropriate investigations to determine root causes, evaluate the impact of OOS results, and ensure effective CAPA. We recommend that the retrospective review also includes an evaluation of the data associated with pending and approved drug application submissions.\u003C\u002Fp>\n\n\u003Cp>Your OOS investigations conclusions fail to include sufficient rigor and scope in determining root causes and the extent of deviations and drug product impact.\u003C\u002Fp>\n\n\u003Cp>For more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s current guidance document \u003Cem>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOS:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o QU oversight of laboratory investigations\u003Cbr>\no Identification of adverse laboratory control trends\u003Cbr>\no Resolution of causes of laboratory variation\u003Cbr>\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>\no Adequately scoping of each investigation and its CAPA\u003Cbr>\no Revised OOS investigation procedures with these and other remediations\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final QU decisions, and is fully supported by executive management.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Repeat Observation at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On March 29, 2019, your firm was cited for inadequate cleaning and maintenance of manufacturing equipment. On April 13, 2017, your firm was cited for inadequate investigations of laboratory events regarding the recurrence of extraneous unidentified peaks. As a result of your 2017 inspection, you were issued a Response Letter dated September 29, 2017, that stated contaminated glassware should not be a frequent justification for rejecting or discarding aberrant result. Furthermore, the letter stated you should assess and identify additional CAPA to ensure clean laboratory glassware is utilized.\u003C\u002Fp>\n\n\u003Cp>You described specific remediations for these observations in your responses.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Repeat Violations at Multiple Sites\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA also cited a similar CGMP violation at other facilities in your company’s network. Sun Pharmaceutical Industries Ltd., (Halol site), FEI 3002809586, was issued a warning letter dated December 15, 2022 (later amended and dated October 16, 2023), for violation of, among other items, 21 CFR 211.67(a) for inadequate cleaning and maintenance of a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You committed to conduct a comprehensive assessment of your global manufacturing operations across your company’s network to ensure conformance to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>These repeated failures at multiple sites demonstrate that management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>We note the initial steps that you outlined in your written response to this inspection, including changes in key senior leaders at corporate and site levels, and modifications to your corporate structure that are intended to enhance quality oversight.\u003C\u002Fp>\n\n\u003Cp>Your executive management remains responsible for fully resolving all deficiencies and ensuring ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Ineffective Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your QU is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommendation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We strongly recommend that your firm engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Sun Pharmaceutical Industries Ltd., Dadra, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004561553 and ATTN: Christina Alemu-Cruickshank.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Dilip Shanghvi\n\nRecipient Title\n\nManaging Director\n\nSun Pharmaceutical Industries Limited\n\nSun House, Plot No. 201 B\u002F1\n\nWest Express Highway Goregaon East\n\nMumbai 400063\n\nMaharashtra\n\nIndia\n\nDilip.Shanghvi@sunpharma.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-24-48\n\nJune 18, 2024\n\nDear Mr. Shanghvi:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sun Pharmaceutical Industries Limited, FEI 3004561553, at Survey No. 1012, Dadra-396 193, U.T. of Dadra and Nagar Haveli and Daman and Diu, from December 4 to 15, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your January 9, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\n\nYou failed to adequately clean and maintain your equipment used for drug product manufacturing. For example, our investigator observed approximately 450 mL of a (b)(4) stagnant liquid within the (b)(4) of your nondedicated (b)(4). Your chemical analysis of the unknown liquid using liquid chromatography mass spectrometry (LC\u002FMS) showed numerous peaks. In addition, the microbiological analysis identified too numerous to count (TNTC) colony forming units for total aerobic microbial count (TAMC) and total yeast and mold count (TYMC) testing. You used this nondedicated (b)(4) to manufacture over (b)(4) different drug products.\n\nIn your response, you state that a faulty (b)(4) valve was the root cause for the observed (b)(4) liquid accumulating in the (b)(4). The (b)(4) valve failed to completely close and seal when you last disassembled it on June 26, 2023. You acknowledge you discovered this equipment malfunction after initiating an investigation as a result of our investigator’s findings. You state that previously manufactured drug products, including (b)(4) active pharmaceutical ingredient (API) and its degradants, as well as (b)(4) API, were identified in the liquid. You also identified microorganisms Sphingomonas paucimobilis, Bordetella bronchiseptica, and Pseudomonas stutzeri in the liquid.\n\nWe acknowledge you recalled (b)(4) batches and rejected (b)(4) batches of drug products manufactured on the (b)(4) between June 2023 and December 2023.\n\nHowever, your response does not sufficiently address the cross-contamination issue. You failed to provide a full characterization of each unknown peak from your chemical analysis. It remains imperative that your investigations are comprehensive to prevent recurrence of inadequate equipment maintenance. We also understand from your recent correspondence that a third-party consultant identified numerous gaps in your equipment maintenance program, but you conclude no critical or major findings were noted.\n\nIt is your responsibility to ensure your equipment maintenance program is comprehensive and includes appropriate assessment of equipment failures and their impact to product quality.\n\nIn response to this letter, provide:\n\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include other manufacturing equipment that may have been improperly cleaned, evaluate the identity of any residues, and assess whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\nA corrective action and preventive action (CAPA) plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\n\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\n\nYour CAPA plan to comprehensively address any gaps identified by your third-party consultant from the assessment of your equipment maintenance program including, but not limited to, inadequate quality unit (QU) oversight, inadequate trending of preventive maintenance, and lack of detailed procedures.\n\nYour specific activities that are being undertaken to ensure effective remediation of the conditions that caused the specific cross-contamination incidents discussed above. Provide an independent review by your consultant that determines the effectiveness of your CAPA, including but not limited to:\n\no Enhancements to cleaning and maintenance procedures including determination of specific frequencies and locations to be cleaned in all relevant equipment (e.g., (b)(4))\n\no Adequacy of analysis of equipment maintenance and repair history for all (b)(4) equipment\n\no Sufficiency of the evaluation of all significant manufacturing equipment including, but not limited to, the (b)(4) equipment, to identify other sources of contamination\n\no Whether improvements to your analytical methodology to identify residual carryover were adequate\n\no Whether adequate investigations into other unknown (unidentified) peaks detected in the unknown liquid in the (b)(4) were performed\n\no Assessment whether the scope of the investigation and its related CAPA were sufficient\n\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYour investigations of out-of-specification (OOS) results were inadequate because they lacked scientific rationale for root cause determinations. For example, you initiated an OOS investigation for an unknown impurity detected during related substances testing of a 12-month stability sample of (b)(4) and (b)(4) tablets. The specification for any unknown impurity for (b)(4) is not more than (b)(4)%, however, your initial test yielded a result of (b)(4)%. Your investigation concluded, without adequate scientific justification, that dirty glassware was the probable root cause. Upon discussion with our investigator, you reopened your investigation and concluded the root cause to be contamination from another product, (b)(4), that was also tested during the same time period. However, this conclusion was not scientifically justified because the retention time of (b)(4) did not match that of the unknown impurity peak.\n\nIn your response, you state you performed additional testing of more drug products tested in the same laboratory during the same time period when the OOS result occurred. You identified the root cause as laboratory contamination and the unknown impurity to be (b)(4). In addition, you state you have hired a third-party consultant to review invalidated OOS results generated between April 1, 2019, and December 26, 2023, to determine if the decisions made to invalidate those results were scientifically justified.\n\nYour response is inadequate. You did not explain why root cause determinations in the OOS investigation were accepted by your firm multiple times, although insufficiently justified.\n\nYour quality system failed to ensure appropriate investigations to determine root causes, evaluate the impact of OOS results, and ensure effective CAPA. We recommend that the retrospective review also includes an evaluation of the data associated with pending and approved drug application submissions.\n\nYour OOS investigations conclusions fail to include sufficient rigor and scope in determining root causes and the extent of deviations and drug product impact.\n\nFor more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s current guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision.\n\nIn response to this letter, provide:\n\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOS:\n\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\n\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\n\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\n\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\n\no QU oversight of laboratory investigations\n\no Identification of adverse laboratory control trends\n\no Resolution of causes of laboratory variation\n\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\n\no Adequately scoping of each investigation and its CAPA\n\no Revised OOS investigation procedures with these and other remediations\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final QU decisions, and is fully supported by executive management.\n\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nRepeat Observation at Facility\n\nOn March 29, 2019, your firm was cited for inadequate cleaning and maintenance of manufacturing equipment. On April 13, 2017, your firm was cited for inadequate investigations of laboratory events regarding the recurrence of extraneous unidentified peaks. As a result of your 2017 inspection, you were issued a Response Letter dated September 29, 2017, that stated contaminated glassware should not be a frequent justification for rejecting or discarding aberrant result. Furthermore, the letter stated you should assess and identify additional CAPA to ensure clean laboratory glassware is utilized.\n\nYou described specific remediations for these observations in your responses.\n\nRepeat Violations at Multiple Sites\n\nFDA also cited a similar CGMP violation at other facilities in your company’s network. Sun Pharmaceutical Industries Ltd., (Halol site), FEI 3002809586, was issued a warning letter dated December 15, 2022 (later amended and dated October 16, 2023), for violation of, among other items, 21 CFR 211.67(a) for inadequate cleaning and maintenance of a (b)(4). You committed to conduct a comprehensive assessment of your global manufacturing operations across your company’s network to ensure conformance to FDA requirements.\n\nThese repeated failures at multiple sites demonstrate that management oversight and control over the manufacture of drugs is inadequate.\n\nWe note the initial steps that you outlined in your written response to this inspection, including changes in key senior leaders at corporate and site levels, and modifications to your corporate structure that are intended to enhance quality oversight.\n\nYour executive management remains responsible for fully resolving all deficiencies and ensuring ongoing CGMP compliance.\n\nIneffective Quality Systems\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your QU is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\n\nCGMP Consultant Recommendation\n\nWe strongly recommend that your firm engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Sun Pharmaceutical Industries Ltd., Dadra, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004561553 and ATTN: Christina Alemu-Cruickshank.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research","Sun Pharmaceutical Industries Limited","sun-pharmaceutical-industries-limited-677337-06182024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsun-pharmaceutical-industries-limited-677337-06182024","2026-10-26T08:10:07.086028+00:00","2024-07-02","677337","Mr. Dilip Shanghvi","2026-08-20T00:00:11.659+00:00","VIA EMAIL WITH READ RECEIPT","2024-06-18",27,{"510k":399,"classification":400,"enforcement":401,"event":402,"event_backfill":403,"pma":404,"warning_letter":405},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]